,source,target,value,type,source layer,target layer,normalized value
0,KVD20,Initial triggering of complement,0.13341617889045446,0,0,1,0.14041990644578578
1,KVD20,Initial triggering of complement,0.13151090763225828,1,0,1,0.13841461732676957
2,KVD20,Regulation of Complement cascade,0.13341617889045446,0,0,1,0.14041990644578578
3,KVD20,Regulation of Complement cascade,0.13151090763225828,1,0,1,0.13841461732676957
4,KVD20,FCGR activation,0.13341617889045446,0,0,1,0.14041990644578578
5,KVD20,FCGR activation,0.13151090763225828,1,0,1,0.13841461732676957
6,KVD20,Regulation of actin dynamics for phagocytic cup formation,0.13341617889045446,0,0,1,0.14041990644578578
7,KVD20,Regulation of actin dynamics for phagocytic cup formation,0.13151090763225828,1,0,1,0.13841461732676957
8,KVD20,Role of phospholipids in phagocytosis,0.13341617889045446,0,0,1,0.14041990644578578
9,KVD20,Role of phospholipids in phagocytosis,0.13151090763225828,1,0,1,0.13841461732676957
10,KVD20,Role of LAT2/NTAL/LAB on calcium mobilization,0.13341617889045446,0,0,1,0.14041990644578578
11,KVD20,Role of LAT2/NTAL/LAB on calcium mobilization,0.13151090763225828,1,0,1,0.13841461732676957
12,KVD20,FCERI mediated MAPK activation,0.13341617889045446,0,0,1,0.14041990644578578
13,KVD20,FCERI mediated MAPK activation,0.13151090763225828,1,0,1,0.13841461732676957
14,KVD20,FCERI mediated Ca+2 mobilization,0.13341617889045446,0,0,1,0.14041990644578578
15,KVD20,FCERI mediated Ca+2 mobilization,0.13151090763225828,1,0,1,0.13841461732676957
16,KVD20,FCERI mediated NF-kB activation,0.13341617889045446,0,0,1,0.14041990644578578
17,KVD20,FCERI mediated NF-kB activation,0.13151090763225828,1,0,1,0.13841461732676957
18,KVD20,Parasite infection,0.13341617889045446,0,0,1,0.14041990644578578
19,KVD20,Parasite infection,0.13151090763225828,1,0,1,0.13841461732676957
20,KVD20,Leishmania parasite growth and survival,0.13341617889045446,0,0,1,0.14041990644578578
21,KVD20,Leishmania parasite growth and survival,0.13151090763225828,1,0,1,0.13841461732676957
22,KVD20,Potential therapeutics for SARS,0.13341617889045446,0,0,1,0.14041990644578578
23,KVD20,Potential therapeutics for SARS,0.13151090763225828,1,0,1,0.13841461732676957
24,KVD20,CD22 mediated BCR regulation,0.13341617889045446,0,0,1,0.14041990644578578
25,KVD20,CD22 mediated BCR regulation,0.13151090763225828,1,0,1,0.13841461732676957
26,KVD20,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.13341617889045446,0,0,1,0.14041990644578578
27,KVD20,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.13151090763225828,1,0,1,0.13841461732676957
28,KVD20,Cell surface interactions at the vascular wall,0.13341617889045446,0,0,1,0.14041990644578578
29,KVD20,Cell surface interactions at the vascular wall,0.13151090763225828,1,0,1,0.13841461732676957
30,KVD20,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.13341617889045446,0,0,1,0.14041990644578578
31,KVD20,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.13151090763225828,1,0,1,0.13841461732676957
32,KVD20,Scavenging of heme from plasma,0.13341617889045446,0,0,1,0.14041990644578578
33,KVD20,Scavenging of heme from plasma,0.13151090763225828,1,0,1,0.13841461732676957
34,IGLC7,Initial triggering of complement,0.09087685738231285,0,0,1,0.09564746882901767
35,IGLC7,Initial triggering of complement,0.09065911511481169,1,0,1,0.09541829610734265
36,IGLC7,Regulation of Complement cascade,0.09087685738231285,0,0,1,0.09564746882901767
37,IGLC7,Regulation of Complement cascade,0.09065911511481169,1,0,1,0.09541829610734265
38,IGLC7,FCGR activation,0.09087685738231285,0,0,1,0.09564746882901767
39,IGLC7,FCGR activation,0.09065911511481169,1,0,1,0.09541829610734265
40,IGLC7,Regulation of actin dynamics for phagocytic cup formation,0.09087685738231285,0,0,1,0.09564746882901767
41,IGLC7,Regulation of actin dynamics for phagocytic cup formation,0.09065911511481169,1,0,1,0.09541829610734265
42,IGLC7,Role of phospholipids in phagocytosis,0.09087685738231285,0,0,1,0.09564746882901767
43,IGLC7,Role of phospholipids in phagocytosis,0.09065911511481169,1,0,1,0.09541829610734265
44,IGLC7,Role of LAT2/NTAL/LAB on calcium mobilization,0.09087685738231285,0,0,1,0.09564746882901767
45,IGLC7,Role of LAT2/NTAL/LAB on calcium mobilization,0.09065911511481169,1,0,1,0.09541829610734265
46,IGLC7,FCERI mediated MAPK activation,0.09087685738231285,0,0,1,0.09564746882901767
47,IGLC7,FCERI mediated MAPK activation,0.09065911511481169,1,0,1,0.09541829610734265
48,IGLC7,FCERI mediated Ca+2 mobilization,0.09087685738231285,0,0,1,0.09564746882901767
49,IGLC7,FCERI mediated Ca+2 mobilization,0.09065911511481169,1,0,1,0.09541829610734265
50,IGLC7,FCERI mediated NF-kB activation,0.09087685738231285,0,0,1,0.09564746882901767
51,IGLC7,FCERI mediated NF-kB activation,0.09065911511481169,1,0,1,0.09541829610734265
52,IGLC7,Parasite infection,0.09087685738231285,0,0,1,0.09564746882901767
53,IGLC7,Parasite infection,0.09065911511481169,1,0,1,0.09541829610734265
54,IGLC7,Leishmania parasite growth and survival,0.09087685738231285,0,0,1,0.09564746882901767
55,IGLC7,Leishmania parasite growth and survival,0.09065911511481169,1,0,1,0.09541829610734265
56,IGLC7,Potential therapeutics for SARS,0.09087685738231285,0,0,1,0.09564746882901767
57,IGLC7,Potential therapeutics for SARS,0.09065911511481169,1,0,1,0.09541829610734265
58,IGLC7,CD22 mediated BCR regulation,0.09087685738231285,0,0,1,0.09564746882901767
59,IGLC7,CD22 mediated BCR regulation,0.09065911511481169,1,0,1,0.09541829610734265
60,IGLC7,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.09087685738231285,0,0,1,0.09564746882901767
61,IGLC7,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.09065911511481169,1,0,1,0.09541829610734265
62,IGLC7,Cell surface interactions at the vascular wall,0.09087685738231285,0,0,1,0.09564746882901767
63,IGLC7,Cell surface interactions at the vascular wall,0.09065911511481169,1,0,1,0.09541829610734265
64,IGLC7,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.09087685738231285,0,0,1,0.09564746882901767
65,IGLC7,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.09065911511481169,1,0,1,0.09541829610734265
66,IGLC7,Scavenging of heme from plasma,0.09087685738231285,0,0,1,0.09564746882901767
67,IGLC7,Scavenging of heme from plasma,0.09065911511481169,1,0,1,0.09541829610734265
68,FCN3,Initial triggering of complement,0.0012339483703546587,0,0,1,0.001298724908516534
69,FCN3,Initial triggering of complement,0.0011795672140638837,1,0,1,0.0012414889949843814
70,CERU,Metal ion SLC transporters,0.07339267028652577,0,0,1,0.07724544340234961
71,CERU,Metal ion SLC transporters,0.07307245918681197,1,0,1,0.07690842271236542
72,CERU,Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages),0.07339267028652577,0,0,1,0.07724544340234961
73,CERU,Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages),0.07307245918681197,1,0,1,0.07690842271236542
74,CERU,Defective CP causes aceruloplasminemia (ACERULOP),0.07339267028652577,0,0,1,0.07724544340234961
75,CERU,Defective CP causes aceruloplasminemia (ACERULOP),0.07307245918681197,1,0,1,0.07690842271236542
76,CERU,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.07339267028652577,0,0,1,0.07724544340234961
77,CERU,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.07307245918681197,1,0,1,0.07690842271236542
78,CERU,Post-translational protein phosphorylation,0.07339267028652577,0,0,1,0.07724544340234961
79,CERU,Post-translational protein phosphorylation,0.07307245918681197,1,0,1,0.07690842271236542
80,F13A,Interleukin-4 and Interleukin-13 signaling,0.05403863181189098,0,0,1,0.05687540811459188
81,F13A,Interleukin-4 and Interleukin-13 signaling,0.061361788351376706,1,0,1,0.06458299624006773
82,F13A,Platelet degranulation ,0.05403863181189098,0,0,1,0.05687540811459188
83,F13A,Platelet degranulation ,0.061361788351376706,1,0,1,0.06458299624006773
84,F13A,Common Pathway of Fibrin Clot Formation,0.05403863181189098,0,0,1,0.05687540811459188
85,F13A,Common Pathway of Fibrin Clot Formation,0.061361788351376706,1,0,1,0.06458299624006773
86,THRB,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.033807268793706484,0,0,1,0.03558199283384998
87,THRB,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.03469332108658779,1,0,1,0.03651455874232669
88,THRB,Regulation of Complement cascade,0.033807268793706484,0,0,1,0.03558199283384998
89,THRB,Regulation of Complement cascade,0.03469332108658779,1,0,1,0.03651455874232669
90,THRB,Class A/1 (Rhodopsin-like receptors),0.033807268793706484,0,0,1,0.03558199283384998
91,THRB,Class A/1 (Rhodopsin-like receptors),0.03469332108658779,1,0,1,0.03651455874232669
92,THRB,G alpha (q) signalling events,0.033807268793706484,0,0,1,0.03558199283384998
93,THRB,G alpha (q) signalling events,0.03469332108658779,1,0,1,0.03651455874232669
94,THRB,Defective factor XII causes hereditary angioedema,0.033807268793706484,0,0,1,0.03558199283384998
95,THRB,Defective factor XII causes hereditary angioedema,0.03469332108658779,1,0,1,0.03651455874232669
96,THRB,Defective factor VIII causes hemophilia A,0.033807268793706484,0,0,1,0.03558199283384998
97,THRB,Defective factor VIII causes hemophilia A,0.03469332108658779,1,0,1,0.03651455874232669
98,THRB,Cell surface interactions at the vascular wall,0.033807268793706484,0,0,1,0.03558199283384998
99,THRB,Cell surface interactions at the vascular wall,0.03469332108658779,1,0,1,0.03651455874232669
100,THRB,Intrinsic Pathway of Fibrin Clot Formation,0.033807268793706484,0,0,1,0.03558199283384998
101,THRB,Intrinsic Pathway of Fibrin Clot Formation,0.03469332108658779,1,0,1,0.03651455874232669
102,THRB,Common Pathway of Fibrin Clot Formation,0.033807268793706484,0,0,1,0.03558199283384998
103,THRB,Common Pathway of Fibrin Clot Formation,0.03469332108658779,1,0,1,0.03651455874232669
104,THRB,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.033807268793706484,0,0,1,0.03558199283384998
105,THRB,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.03469332108658779,1,0,1,0.03651455874232669
106,THRB,Thrombin signalling through proteinase activated receptors (PARs),0.033807268793706484,0,0,1,0.03558199283384998
107,THRB,Thrombin signalling through proteinase activated receptors (PARs),0.03469332108658779,1,0,1,0.03651455874232669
108,FA9,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.1760710843094354,0,0,1,0.1853139955899899
109,FA9,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.1782890710388344,1,0,1,0.1876484162849187
110,FA9,Defective factor VIII causes hemophilia A,0.1760710843094354,0,0,1,0.1853139955899899
111,FA9,Defective factor VIII causes hemophilia A,0.1782890710388344,1,0,1,0.1876484162849187
112,FA9,Defective factor IX causes hemophilia B,0.1760710843094354,0,0,1,0.1853139955899899
113,FA9,Defective factor IX causes hemophilia B,0.1782890710388344,1,0,1,0.1876484162849187
114,FA9,Defective factor IX causes thrombophilia,0.1760710843094354,0,0,1,0.1853139955899899
115,FA9,Defective factor IX causes thrombophilia,0.1782890710388344,1,0,1,0.1876484162849187
116,FA9,Extrinsic Pathway of Fibrin Clot Formation,0.1760710843094354,0,0,1,0.1853139955899899
117,FA9,Extrinsic Pathway of Fibrin Clot Formation,0.1782890710388344,1,0,1,0.1876484162849187
118,FA9,Intrinsic Pathway of Fibrin Clot Formation,0.1760710843094354,0,0,1,0.1853139955899899
119,FA9,Intrinsic Pathway of Fibrin Clot Formation,0.1782890710388344,1,0,1,0.1876484162849187
120,FA10,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.024519599896404613,0,0,1,0.025806764608123357
121,FA10,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.02472048963397316,1,0,1,0.026018200120591868
122,FA10,Defective factor VIII causes hemophilia A,0.024519599896404613,0,0,1,0.025806764608123357
123,FA10,Defective factor VIII causes hemophilia A,0.02472048963397316,1,0,1,0.026018200120591868
124,FA10,Defective factor IX causes hemophilia B,0.024519599896404613,0,0,1,0.025806764608123357
125,FA10,Defective factor IX causes hemophilia B,0.02472048963397316,1,0,1,0.026018200120591868
126,FA10,Defective factor IX causes thrombophilia,0.024519599896404613,0,0,1,0.025806764608123357
127,FA10,Defective factor IX causes thrombophilia,0.02472048963397316,1,0,1,0.026018200120591868
128,FA10,Extrinsic Pathway of Fibrin Clot Formation,0.024519599896404613,0,0,1,0.025806764608123357
129,FA10,Extrinsic Pathway of Fibrin Clot Formation,0.02472048963397316,1,0,1,0.026018200120591868
130,FA10,Intrinsic Pathway of Fibrin Clot Formation,0.024519599896404613,0,0,1,0.025806764608123357
131,FA10,Intrinsic Pathway of Fibrin Clot Formation,0.02472048963397316,1,0,1,0.026018200120591868
132,FA10,Common Pathway of Fibrin Clot Formation,0.024519599896404613,0,0,1,0.025806764608123357
133,FA10,Common Pathway of Fibrin Clot Formation,0.02472048963397316,1,0,1,0.026018200120591868
134,PLMN,Platelet degranulation ,0.09040330792214847,0,0,1,0.0951490602293505
135,PLMN,Platelet degranulation ,0.09665227343962676,1,0,1,0.10172606731083592
136,PLMN,Dissolution of Fibrin Clot,0.09040330792214847,0,0,1,0.0951490602293505
137,PLMN,Dissolution of Fibrin Clot,0.09665227343962676,1,0,1,0.10172606731083592
138,PLMN,Activation of Matrix Metalloproteinases,0.09040330792214847,0,0,1,0.0951490602293505
139,PLMN,Activation of Matrix Metalloproteinases,0.09665227343962676,1,0,1,0.10172606731083592
140,PLMN,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.09040330792214847,0,0,1,0.0951490602293505
141,PLMN,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.09665227343962676,1,0,1,0.10172606731083592
142,PLMN,Signaling by PDGF,0.09040330792214847,0,0,1,0.0951490602293505
143,PLMN,Signaling by PDGF,0.09665227343962676,1,0,1,0.10172606731083592
144,FA12,Defective factor XII causes hereditary angioedema,0.02038194433112369,0,0,1,0.021451901410769397
145,FA12,Defective factor XII causes hereditary angioedema,0.020310114555053552,1,0,1,0.02137630090624534
146,FA12,Defective SERPING1 causes hereditary angioedema,0.02038194433112369,0,0,1,0.021451901410769397
147,FA12,Defective SERPING1 causes hereditary angioedema,0.020310114555053552,1,0,1,0.02137630090624534
148,FA12,Intrinsic Pathway of Fibrin Clot Formation,0.02038194433112369,0,0,1,0.021451901410769397
149,FA12,Intrinsic Pathway of Fibrin Clot Formation,0.020310114555053552,1,0,1,0.02137630090624534
150,CAH2,Reversible hydration of carbon dioxide,0.04460819240137575,0,0,1,0.046949914589144014
151,CAH2,Reversible hydration of carbon dioxide,0.046056217680446765,1,0,1,0.048473954446298345
152,CAH2,Erythrocytes take up carbon dioxide and release oxygen,0.04460819240137575,0,0,1,0.046949914589144014
153,CAH2,Erythrocytes take up carbon dioxide and release oxygen,0.046056217680446765,1,0,1,0.048473954446298345
154,CAH2,Erythrocytes take up oxygen and release carbon dioxide,0.04460819240137575,0,0,1,0.046949914589144014
155,CAH2,Erythrocytes take up oxygen and release carbon dioxide,0.046056217680446765,1,0,1,0.048473954446298345
156,ANT3,Intrinsic Pathway of Fibrin Clot Formation,0.07613303189113588,0,0,1,0.08012966121871301
157,ANT3,Intrinsic Pathway of Fibrin Clot Formation,0.07736949952959549,1,0,1,0.081431037645168
158,ANT3,Common Pathway of Fibrin Clot Formation,0.07613303189113588,0,0,1,0.08012966121871301
159,ANT3,Common Pathway of Fibrin Clot Formation,0.07736949952959549,1,0,1,0.081431037645168
160,ANT3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.07613303189113588,0,0,1,0.08012966121871301
161,ANT3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.07736949952959549,1,0,1,0.081431037645168
162,ANT3,Post-translational protein phosphorylation,0.07613303189113588,0,0,1,0.08012966121871301
163,ANT3,Post-translational protein phosphorylation,0.07736949952959549,1,0,1,0.081431037645168
164,ANGT,Class A/1 (Rhodopsin-like receptors),0.07690267896424227,0,0,1,0.08093971117592705
165,ANGT,Class A/1 (Rhodopsin-like receptors),0.0678096067457452,1,0,1,0.07136929504765126
166,ANGT,G alpha (q) signalling events,0.07690267896424227,0,0,1,0.08093971117592705
167,ANGT,G alpha (q) signalling events,0.0678096067457452,1,0,1,0.07136929504765126
168,ANGT,G alpha (i) signalling events,0.07690267896424227,0,0,1,0.08093971117592705
169,ANGT,G alpha (i) signalling events,0.0678096067457452,1,0,1,0.07136929504765126
170,ANGT,PPARA activates gene expression,0.07690267896424227,0,0,1,0.08093971117592705
171,ANGT,PPARA activates gene expression,0.0678096067457452,1,0,1,0.07136929504765126
172,ANGT,Metabolism of Angiotensinogen to Angiotensins,0.07690267896424227,0,0,1,0.08093971117592705
173,ANGT,Metabolism of Angiotensinogen to Angiotensins,0.0678096067457452,1,0,1,0.07136929504765126
174,A2MG,Platelet degranulation ,0.1109197841004518,0,0,1,0.11674255578224006
175,A2MG,Platelet degranulation ,0.12199704403396255,1,0,1,0.1284013202325126
176,A2MG,HDL assembly,0.1109197841004518,0,0,1,0.11674255578224006
177,A2MG,HDL assembly,0.12199704403396255,1,0,1,0.1284013202325126
178,A2MG,Intrinsic Pathway of Fibrin Clot Formation,0.1109197841004518,0,0,1,0.11674255578224006
179,A2MG,Intrinsic Pathway of Fibrin Clot Formation,0.12199704403396255,1,0,1,0.1284013202325126
180,CO3,Initial triggering of complement,0.15209520071607696,0,0,1,0.16007948985662776
181,CO3,Initial triggering of complement,0.1533232094373572,1,0,1,0.16137196331217743
182,CO3,Activation of C3 and C5,0.15209520071607696,0,0,1,0.16007948985662776
183,CO3,Activation of C3 and C5,0.1533232094373572,1,0,1,0.16137196331217743
184,CO3,Regulation of Complement cascade,0.15209520071607696,0,0,1,0.16007948985662776
185,CO3,Regulation of Complement cascade,0.1533232094373572,1,0,1,0.16137196331217743
186,CO3,Class A/1 (Rhodopsin-like receptors),0.15209520071607696,0,0,1,0.16007948985662776
187,CO3,Class A/1 (Rhodopsin-like receptors),0.1533232094373572,1,0,1,0.16137196331217743
188,CO3,G alpha (i) signalling events,0.15209520071607696,0,0,1,0.16007948985662776
189,CO3,G alpha (i) signalling events,0.1533232094373572,1,0,1,0.16137196331217743
190,CO3,Cell recruitment (pro-inflammatory response),0.15209520071607696,0,0,1,0.16007948985662776
191,CO3,Cell recruitment (pro-inflammatory response),0.1533232094373572,1,0,1,0.16137196331217743
192,CO3,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.15209520071607696,0,0,1,0.16007948985662776
193,CO3,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.1533232094373572,1,0,1,0.16137196331217743
194,CO3,Neutrophil degranulation,0.15209520071607696,0,0,1,0.16007948985662776
195,CO3,Neutrophil degranulation,0.1533232094373572,1,0,1,0.16137196331217743
196,CO3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.15209520071607696,0,0,1,0.16007948985662776
197,CO3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.1533232094373572,1,0,1,0.16137196331217743
198,CO3,Post-translational protein phosphorylation,0.15209520071607696,0,0,1,0.16007948985662776
199,CO3,Post-translational protein phosphorylation,0.1533232094373572,1,0,1,0.16137196331217743
200,CO5,Terminal pathway of complement,0.06064889144494338,0,0,1,0.06383267556877155
201,CO5,Terminal pathway of complement,0.05662222904972012,1,0,1,0.059594632165577754
202,CO5,Activation of C3 and C5,0.06064889144494338,0,0,1,0.06383267556877155
203,CO5,Activation of C3 and C5,0.05662222904972012,1,0,1,0.059594632165577754
204,CO5,Regulation of Complement cascade,0.06064889144494338,0,0,1,0.06383267556877155
205,CO5,Regulation of Complement cascade,0.05662222904972012,1,0,1,0.059594632165577754
206,CO5,Class A/1 (Rhodopsin-like receptors),0.06064889144494338,0,0,1,0.06383267556877155
207,CO5,Class A/1 (Rhodopsin-like receptors),0.05662222904972012,1,0,1,0.059594632165577754
208,CO5,G alpha (i) signalling events,0.06064889144494338,0,0,1,0.06383267556877155
209,CO5,G alpha (i) signalling events,0.05662222904972012,1,0,1,0.059594632165577754
210,CYTC,Neutrophil degranulation,0.04809132317834138,0,0,1,0.050615893497455745
211,CYTC,Neutrophil degranulation,0.0475600863239449,1,0,1,0.05005676918423316
212,CYTC,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.04809132317834138,0,0,1,0.050615893497455745
213,CYTC,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0475600863239449,1,0,1,0.05005676918423316
214,CYTC,Amyloid fiber formation,0.04809132317834138,0,0,1,0.050615893497455745
215,CYTC,Amyloid fiber formation,0.0475600863239449,1,0,1,0.05005676918423316
216,CYTC,Post-translational protein phosphorylation,0.04809132317834138,0,0,1,0.050615893497455745
217,CYTC,Post-translational protein phosphorylation,0.0475600863239449,1,0,1,0.05005676918423316
218,KNG1,Class A/1 (Rhodopsin-like receptors),0.07784711191619652,0,0,1,0.08193372245597293
219,KNG1,Class A/1 (Rhodopsin-like receptors),0.08000383453200692,1,0,1,0.08420366295689426
220,KNG1,G alpha (q) signalling events,0.07784711191619652,0,0,1,0.08193372245597293
221,KNG1,G alpha (q) signalling events,0.08000383453200692,1,0,1,0.08420366295689426
222,KNG1,G alpha (i) signalling events,0.07784711191619652,0,0,1,0.08193372245597293
223,KNG1,G alpha (i) signalling events,0.08000383453200692,1,0,1,0.08420366295689426
224,KNG1,Platelet degranulation ,0.07784711191619652,0,0,1,0.08193372245597293
225,KNG1,Platelet degranulation ,0.08000383453200692,1,0,1,0.08420366295689426
226,KNG1,Intrinsic Pathway of Fibrin Clot Formation,0.07784711191619652,0,0,1,0.08193372245597293
227,KNG1,Intrinsic Pathway of Fibrin Clot Formation,0.08000383453200692,1,0,1,0.08420366295689426
228,KNG1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.07784711191619652,0,0,1,0.08193372245597293
229,KNG1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.08000383453200692,1,0,1,0.08420366295689426
230,KNG1,Post-translational protein phosphorylation,0.07784711191619652,0,0,1,0.08193372245597293
231,KNG1,Post-translational protein phosphorylation,0.08000383453200692,1,0,1,0.08420366295689426
232,IGJ,Cell surface interactions at the vascular wall,0.007428954854559919,0,0,1,0.007818940358978501
233,IGJ,Cell surface interactions at the vascular wall,0.007304625598663,1,0,1,0.00768808439663038
234,IGJ,Scavenging of heme from plasma,0.007428954854559919,0,0,1,0.007818940358978501
235,IGJ,Scavenging of heme from plasma,0.007304625598663,1,0,1,0.00768808439663038
236,KV117,Initial triggering of complement,0.0755518571038366,0,0,1,0.0795179774638648
237,KV117,Initial triggering of complement,0.07215089552936252,1,0,1,0.07593848125819486
238,KV117,Regulation of Complement cascade,0.0755518571038366,0,0,1,0.0795179774638648
239,KV117,Regulation of Complement cascade,0.07215089552936252,1,0,1,0.07593848125819486
240,KV117,FCGR activation,0.0755518571038366,0,0,1,0.0795179774638648
241,KV117,FCGR activation,0.07215089552936252,1,0,1,0.07593848125819486
242,KV117,Regulation of actin dynamics for phagocytic cup formation,0.0755518571038366,0,0,1,0.0795179774638648
243,KV117,Regulation of actin dynamics for phagocytic cup formation,0.07215089552936252,1,0,1,0.07593848125819486
244,KV117,Role of phospholipids in phagocytosis,0.0755518571038366,0,0,1,0.0795179774638648
245,KV117,Role of phospholipids in phagocytosis,0.07215089552936252,1,0,1,0.07593848125819486
246,KV117,Role of LAT2/NTAL/LAB on calcium mobilization,0.0755518571038366,0,0,1,0.0795179774638648
247,KV117,Role of LAT2/NTAL/LAB on calcium mobilization,0.07215089552936252,1,0,1,0.07593848125819486
248,KV117,FCERI mediated MAPK activation,0.0755518571038366,0,0,1,0.0795179774638648
249,KV117,FCERI mediated MAPK activation,0.07215089552936252,1,0,1,0.07593848125819486
250,KV117,FCERI mediated Ca+2 mobilization,0.0755518571038366,0,0,1,0.0795179774638648
251,KV117,FCERI mediated Ca+2 mobilization,0.07215089552936252,1,0,1,0.07593848125819486
252,KV117,FCERI mediated NF-kB activation,0.0755518571038366,0,0,1,0.0795179774638648
253,KV117,FCERI mediated NF-kB activation,0.07215089552936252,1,0,1,0.07593848125819486
254,KV117,Parasite infection,0.0755518571038366,0,0,1,0.0795179774638648
255,KV117,Parasite infection,0.07215089552936252,1,0,1,0.07593848125819486
256,KV117,Leishmania parasite growth and survival,0.0755518571038366,0,0,1,0.0795179774638648
257,KV117,Leishmania parasite growth and survival,0.07215089552936252,1,0,1,0.07593848125819486
258,KV117,Potential therapeutics for SARS,0.0755518571038366,0,0,1,0.0795179774638648
259,KV117,Potential therapeutics for SARS,0.07215089552936252,1,0,1,0.07593848125819486
260,KV117,CD22 mediated BCR regulation,0.0755518571038366,0,0,1,0.0795179774638648
261,KV117,CD22 mediated BCR regulation,0.07215089552936252,1,0,1,0.07593848125819486
262,KV117,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0755518571038366,0,0,1,0.0795179774638648
263,KV117,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.07215089552936252,1,0,1,0.07593848125819486
264,KV117,Cell surface interactions at the vascular wall,0.0755518571038366,0,0,1,0.0795179774638648
265,KV117,Cell surface interactions at the vascular wall,0.07215089552936252,1,0,1,0.07593848125819486
266,KV117,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0755518571038366,0,0,1,0.0795179774638648
267,KV117,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.07215089552936252,1,0,1,0.07593848125819486
268,KV117,Scavenging of heme from plasma,0.0755518571038366,0,0,1,0.0795179774638648
269,KV117,Scavenging of heme from plasma,0.07215089552936252,1,0,1,0.07593848125819486
270,KVD16,Initial triggering of complement,0.055386921012963074,0,0,1,0.05829447621450995
271,KVD16,Initial triggering of complement,0.05174370146927914,1,0,1,0.054460004625381274
272,KVD16,Regulation of Complement cascade,0.055386921012963074,0,0,1,0.05829447621450995
273,KVD16,Regulation of Complement cascade,0.05174370146927914,1,0,1,0.054460004625381274
274,KVD16,FCGR activation,0.055386921012963074,0,0,1,0.05829447621450995
275,KVD16,FCGR activation,0.05174370146927914,1,0,1,0.054460004625381274
276,KVD16,Regulation of actin dynamics for phagocytic cup formation,0.055386921012963074,0,0,1,0.05829447621450995
277,KVD16,Regulation of actin dynamics for phagocytic cup formation,0.05174370146927914,1,0,1,0.054460004625381274
278,KVD16,Role of phospholipids in phagocytosis,0.055386921012963074,0,0,1,0.05829447621450995
279,KVD16,Role of phospholipids in phagocytosis,0.05174370146927914,1,0,1,0.054460004625381274
280,KVD16,Role of LAT2/NTAL/LAB on calcium mobilization,0.055386921012963074,0,0,1,0.05829447621450995
281,KVD16,Role of LAT2/NTAL/LAB on calcium mobilization,0.05174370146927914,1,0,1,0.054460004625381274
282,KVD16,FCERI mediated MAPK activation,0.055386921012963074,0,0,1,0.05829447621450995
283,KVD16,FCERI mediated MAPK activation,0.05174370146927914,1,0,1,0.054460004625381274
284,KVD16,FCERI mediated Ca+2 mobilization,0.055386921012963074,0,0,1,0.05829447621450995
285,KVD16,FCERI mediated Ca+2 mobilization,0.05174370146927914,1,0,1,0.054460004625381274
286,KVD16,FCERI mediated NF-kB activation,0.055386921012963074,0,0,1,0.05829447621450995
287,KVD16,FCERI mediated NF-kB activation,0.05174370146927914,1,0,1,0.054460004625381274
288,KVD16,Parasite infection,0.055386921012963074,0,0,1,0.05829447621450995
289,KVD16,Parasite infection,0.05174370146927914,1,0,1,0.054460004625381274
290,KVD16,Leishmania parasite growth and survival,0.055386921012963074,0,0,1,0.05829447621450995
291,KVD16,Leishmania parasite growth and survival,0.05174370146927914,1,0,1,0.054460004625381274
292,KVD16,Potential therapeutics for SARS,0.055386921012963074,0,0,1,0.05829447621450995
293,KVD16,Potential therapeutics for SARS,0.05174370146927914,1,0,1,0.054460004625381274
294,KVD16,CD22 mediated BCR regulation,0.055386921012963074,0,0,1,0.05829447621450995
295,KVD16,CD22 mediated BCR regulation,0.05174370146927914,1,0,1,0.054460004625381274
296,KVD16,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.055386921012963074,0,0,1,0.05829447621450995
297,KVD16,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.05174370146927914,1,0,1,0.054460004625381274
298,KVD16,Cell surface interactions at the vascular wall,0.055386921012963074,0,0,1,0.05829447621450995
299,KVD16,Cell surface interactions at the vascular wall,0.05174370146927914,1,0,1,0.054460004625381274
300,KVD16,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.055386921012963074,0,0,1,0.05829447621450995
301,KVD16,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.05174370146927914,1,0,1,0.054460004625381274
302,KVD16,Scavenging of heme from plasma,0.055386921012963074,0,0,1,0.05829447621450995
303,KVD16,Scavenging of heme from plasma,0.05174370146927914,1,0,1,0.054460004625381274
304,KV105,Initial triggering of complement,0.04570250004104784,0,0,1,0.04810166827946543
305,KV105,Initial triggering of complement,0.04454576544666658,1,0,1,0.046884210510276976
306,KV105,Regulation of Complement cascade,0.04570250004104784,0,0,1,0.04810166827946543
307,KV105,Regulation of Complement cascade,0.04454576544666658,1,0,1,0.046884210510276976
308,KV105,FCGR activation,0.04570250004104784,0,0,1,0.04810166827946543
309,KV105,FCGR activation,0.04454576544666658,1,0,1,0.046884210510276976
310,KV105,Regulation of actin dynamics for phagocytic cup formation,0.04570250004104784,0,0,1,0.04810166827946543
311,KV105,Regulation of actin dynamics for phagocytic cup formation,0.04454576544666658,1,0,1,0.046884210510276976
312,KV105,Role of phospholipids in phagocytosis,0.04570250004104784,0,0,1,0.04810166827946543
313,KV105,Role of phospholipids in phagocytosis,0.04454576544666658,1,0,1,0.046884210510276976
314,KV105,Role of LAT2/NTAL/LAB on calcium mobilization,0.04570250004104784,0,0,1,0.04810166827946543
315,KV105,Role of LAT2/NTAL/LAB on calcium mobilization,0.04454576544666658,1,0,1,0.046884210510276976
316,KV105,FCERI mediated MAPK activation,0.04570250004104784,0,0,1,0.04810166827946543
317,KV105,FCERI mediated MAPK activation,0.04454576544666658,1,0,1,0.046884210510276976
318,KV105,FCERI mediated Ca+2 mobilization,0.04570250004104784,0,0,1,0.04810166827946543
319,KV105,FCERI mediated Ca+2 mobilization,0.04454576544666658,1,0,1,0.046884210510276976
320,KV105,FCERI mediated NF-kB activation,0.04570250004104784,0,0,1,0.04810166827946543
321,KV105,FCERI mediated NF-kB activation,0.04454576544666658,1,0,1,0.046884210510276976
322,KV105,Parasite infection,0.04570250004104784,0,0,1,0.04810166827946543
323,KV105,Parasite infection,0.04454576544666658,1,0,1,0.046884210510276976
324,KV105,Leishmania parasite growth and survival,0.04570250004104784,0,0,1,0.04810166827946543
325,KV105,Leishmania parasite growth and survival,0.04454576544666658,1,0,1,0.046884210510276976
326,KV105,Potential therapeutics for SARS,0.04570250004104784,0,0,1,0.04810166827946543
327,KV105,Potential therapeutics for SARS,0.04454576544666658,1,0,1,0.046884210510276976
328,KV105,CD22 mediated BCR regulation,0.04570250004104784,0,0,1,0.04810166827946543
329,KV105,CD22 mediated BCR regulation,0.04454576544666658,1,0,1,0.046884210510276976
330,KV105,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.04570250004104784,0,0,1,0.04810166827946543
331,KV105,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.04454576544666658,1,0,1,0.046884210510276976
332,KV105,Cell surface interactions at the vascular wall,0.04570250004104784,0,0,1,0.04810166827946543
333,KV105,Cell surface interactions at the vascular wall,0.04454576544666658,1,0,1,0.046884210510276976
334,KV105,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.04570250004104784,0,0,1,0.04810166827946543
335,KV105,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.04454576544666658,1,0,1,0.046884210510276976
336,KV105,Scavenging of heme from plasma,0.04570250004104784,0,0,1,0.04810166827946543
337,KV105,Scavenging of heme from plasma,0.04454576544666658,1,0,1,0.046884210510276976
338,KV320,Initial triggering of complement,0.009322441754883087,0,0,1,0.009811826496258839
339,KV320,Initial triggering of complement,0.007382677051500958,1,0,1,0.007770233186954099
340,KV320,Regulation of Complement cascade,0.009322441754883087,0,0,1,0.009811826496258839
341,KV320,Regulation of Complement cascade,0.007382677051500958,1,0,1,0.007770233186954099
342,KV320,FCGR activation,0.009322441754883087,0,0,1,0.009811826496258839
343,KV320,FCGR activation,0.007382677051500958,1,0,1,0.007770233186954099
344,KV320,Regulation of actin dynamics for phagocytic cup formation,0.009322441754883087,0,0,1,0.009811826496258839
345,KV320,Regulation of actin dynamics for phagocytic cup formation,0.007382677051500958,1,0,1,0.007770233186954099
346,KV320,Role of phospholipids in phagocytosis,0.009322441754883087,0,0,1,0.009811826496258839
347,KV320,Role of phospholipids in phagocytosis,0.007382677051500958,1,0,1,0.007770233186954099
348,KV320,Role of LAT2/NTAL/LAB on calcium mobilization,0.009322441754883087,0,0,1,0.009811826496258839
349,KV320,Role of LAT2/NTAL/LAB on calcium mobilization,0.007382677051500958,1,0,1,0.007770233186954099
350,KV320,FCERI mediated MAPK activation,0.009322441754883087,0,0,1,0.009811826496258839
351,KV320,FCERI mediated MAPK activation,0.007382677051500958,1,0,1,0.007770233186954099
352,KV320,FCERI mediated Ca+2 mobilization,0.009322441754883087,0,0,1,0.009811826496258839
353,KV320,FCERI mediated Ca+2 mobilization,0.007382677051500958,1,0,1,0.007770233186954099
354,KV320,FCERI mediated NF-kB activation,0.009322441754883087,0,0,1,0.009811826496258839
355,KV320,FCERI mediated NF-kB activation,0.007382677051500958,1,0,1,0.007770233186954099
356,KV320,Parasite infection,0.009322441754883087,0,0,1,0.009811826496258839
357,KV320,Parasite infection,0.007382677051500958,1,0,1,0.007770233186954099
358,KV320,Leishmania parasite growth and survival,0.009322441754883087,0,0,1,0.009811826496258839
359,KV320,Leishmania parasite growth and survival,0.007382677051500958,1,0,1,0.007770233186954099
360,KV320,Potential therapeutics for SARS,0.009322441754883087,0,0,1,0.009811826496258839
361,KV320,Potential therapeutics for SARS,0.007382677051500958,1,0,1,0.007770233186954099
362,KV320,CD22 mediated BCR regulation,0.009322441754883087,0,0,1,0.009811826496258839
363,KV320,CD22 mediated BCR regulation,0.007382677051500958,1,0,1,0.007770233186954099
364,KV320,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.009322441754883087,0,0,1,0.009811826496258839
365,KV320,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.007382677051500958,1,0,1,0.007770233186954099
366,KV320,Cell surface interactions at the vascular wall,0.009322441754883087,0,0,1,0.009811826496258839
367,KV320,Cell surface interactions at the vascular wall,0.007382677051500958,1,0,1,0.007770233186954099
368,KV320,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.009322441754883087,0,0,1,0.009811826496258839
369,KV320,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.007382677051500958,1,0,1,0.007770233186954099
370,KV320,Scavenging of heme from plasma,0.009322441754883087,0,0,1,0.009811826496258839
371,KV320,Scavenging of heme from plasma,0.007382677051500958,1,0,1,0.007770233186954099
372,LV151,Initial triggering of complement,0.04260109571215881,0,0,1,0.04483745467857425
373,LV151,Initial triggering of complement,0.04643608885423555,1,0,1,0.048873767086178174
374,LV151,Regulation of Complement cascade,0.04260109571215881,0,0,1,0.04483745467857425
375,LV151,Regulation of Complement cascade,0.04643608885423555,1,0,1,0.048873767086178174
376,LV151,FCGR activation,0.04260109571215881,0,0,1,0.04483745467857425
377,LV151,FCGR activation,0.04643608885423555,1,0,1,0.048873767086178174
378,LV151,Regulation of actin dynamics for phagocytic cup formation,0.04260109571215881,0,0,1,0.04483745467857425
379,LV151,Regulation of actin dynamics for phagocytic cup formation,0.04643608885423555,1,0,1,0.048873767086178174
380,LV151,Role of phospholipids in phagocytosis,0.04260109571215881,0,0,1,0.04483745467857425
381,LV151,Role of phospholipids in phagocytosis,0.04643608885423555,1,0,1,0.048873767086178174
382,LV151,Role of LAT2/NTAL/LAB on calcium mobilization,0.04260109571215881,0,0,1,0.04483745467857425
383,LV151,Role of LAT2/NTAL/LAB on calcium mobilization,0.04643608885423555,1,0,1,0.048873767086178174
384,LV151,FCERI mediated MAPK activation,0.04260109571215881,0,0,1,0.04483745467857425
385,LV151,FCERI mediated MAPK activation,0.04643608885423555,1,0,1,0.048873767086178174
386,LV151,FCERI mediated Ca+2 mobilization,0.04260109571215881,0,0,1,0.04483745467857425
387,LV151,FCERI mediated Ca+2 mobilization,0.04643608885423555,1,0,1,0.048873767086178174
388,LV151,FCERI mediated NF-kB activation,0.04260109571215881,0,0,1,0.04483745467857425
389,LV151,FCERI mediated NF-kB activation,0.04643608885423555,1,0,1,0.048873767086178174
390,LV151,Parasite infection,0.04260109571215881,0,0,1,0.04483745467857425
391,LV151,Parasite infection,0.04643608885423555,1,0,1,0.048873767086178174
392,LV151,Leishmania parasite growth and survival,0.04260109571215881,0,0,1,0.04483745467857425
393,LV151,Leishmania parasite growth and survival,0.04643608885423555,1,0,1,0.048873767086178174
394,LV151,Potential therapeutics for SARS,0.04260109571215881,0,0,1,0.04483745467857425
395,LV151,Potential therapeutics for SARS,0.04643608885423555,1,0,1,0.048873767086178174
396,LV151,CD22 mediated BCR regulation,0.04260109571215881,0,0,1,0.04483745467857425
397,LV151,CD22 mediated BCR regulation,0.04643608885423555,1,0,1,0.048873767086178174
398,LV151,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.04260109571215881,0,0,1,0.04483745467857425
399,LV151,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.04643608885423555,1,0,1,0.048873767086178174
400,LV151,Cell surface interactions at the vascular wall,0.04260109571215881,0,0,1,0.04483745467857425
401,LV151,Cell surface interactions at the vascular wall,0.04643608885423555,1,0,1,0.048873767086178174
402,LV151,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.04260109571215881,0,0,1,0.04483745467857425
403,LV151,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.04643608885423555,1,0,1,0.048873767086178174
404,LV151,Scavenging of heme from plasma,0.04260109571215881,0,0,1,0.04483745467857425
405,LV151,Scavenging of heme from plasma,0.04643608885423555,1,0,1,0.048873767086178174
406,LV140,Initial triggering of complement,0.07805963766753814,0,0,1,0.08215740481870357
407,LV140,Initial triggering of complement,0.07377865368495853,1,0,1,0.07765168913017889
408,LV140,Regulation of Complement cascade,0.07805963766753814,0,0,1,0.08215740481870357
409,LV140,Regulation of Complement cascade,0.07377865368495853,1,0,1,0.07765168913017889
410,LV140,FCGR activation,0.07805963766753814,0,0,1,0.08215740481870357
411,LV140,FCGR activation,0.07377865368495853,1,0,1,0.07765168913017889
412,LV140,Regulation of actin dynamics for phagocytic cup formation,0.07805963766753814,0,0,1,0.08215740481870357
413,LV140,Regulation of actin dynamics for phagocytic cup formation,0.07377865368495853,1,0,1,0.07765168913017889
414,LV140,Role of phospholipids in phagocytosis,0.07805963766753814,0,0,1,0.08215740481870357
415,LV140,Role of phospholipids in phagocytosis,0.07377865368495853,1,0,1,0.07765168913017889
416,LV140,Role of LAT2/NTAL/LAB on calcium mobilization,0.07805963766753814,0,0,1,0.08215740481870357
417,LV140,Role of LAT2/NTAL/LAB on calcium mobilization,0.07377865368495853,1,0,1,0.07765168913017889
418,LV140,FCERI mediated MAPK activation,0.07805963766753814,0,0,1,0.08215740481870357
419,LV140,FCERI mediated MAPK activation,0.07377865368495853,1,0,1,0.07765168913017889
420,LV140,FCERI mediated Ca+2 mobilization,0.07805963766753814,0,0,1,0.08215740481870357
421,LV140,FCERI mediated Ca+2 mobilization,0.07377865368495853,1,0,1,0.07765168913017889
422,LV140,FCERI mediated NF-kB activation,0.07805963766753814,0,0,1,0.08215740481870357
423,LV140,FCERI mediated NF-kB activation,0.07377865368495853,1,0,1,0.07765168913017889
424,LV140,Parasite infection,0.07805963766753814,0,0,1,0.08215740481870357
425,LV140,Parasite infection,0.07377865368495853,1,0,1,0.07765168913017889
426,LV140,Leishmania parasite growth and survival,0.07805963766753814,0,0,1,0.08215740481870357
427,LV140,Leishmania parasite growth and survival,0.07377865368495853,1,0,1,0.07765168913017889
428,LV140,Potential therapeutics for SARS,0.07805963766753814,0,0,1,0.08215740481870357
429,LV140,Potential therapeutics for SARS,0.07377865368495853,1,0,1,0.07765168913017889
430,LV140,CD22 mediated BCR regulation,0.07805963766753814,0,0,1,0.08215740481870357
431,LV140,CD22 mediated BCR regulation,0.07377865368495853,1,0,1,0.07765168913017889
432,LV140,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.07805963766753814,0,0,1,0.08215740481870357
433,LV140,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.07377865368495853,1,0,1,0.07765168913017889
434,LV140,Cell surface interactions at the vascular wall,0.07805963766753814,0,0,1,0.08215740481870357
435,LV140,Cell surface interactions at the vascular wall,0.07377865368495853,1,0,1,0.07765168913017889
436,LV140,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.07805963766753814,0,0,1,0.08215740481870357
437,LV140,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.07377865368495853,1,0,1,0.07765168913017889
438,LV140,Scavenging of heme from plasma,0.07805963766753814,0,0,1,0.08215740481870357
439,LV140,Scavenging of heme from plasma,0.07377865368495853,1,0,1,0.07765168913017889
440,LV214,Initial triggering of complement,0.062042245902301035,0,0,1,0.06529917464088655
441,LV214,Initial triggering of complement,0.06124710596665956,1,0,1,0.06446229356467344
442,LV214,Regulation of Complement cascade,0.062042245902301035,0,0,1,0.06529917464088655
443,LV214,Regulation of Complement cascade,0.06124710596665956,1,0,1,0.06446229356467344
444,LV214,FCGR activation,0.062042245902301035,0,0,1,0.06529917464088655
445,LV214,FCGR activation,0.06124710596665956,1,0,1,0.06446229356467344
446,LV214,Regulation of actin dynamics for phagocytic cup formation,0.062042245902301035,0,0,1,0.06529917464088655
447,LV214,Regulation of actin dynamics for phagocytic cup formation,0.06124710596665956,1,0,1,0.06446229356467344
448,LV214,Role of phospholipids in phagocytosis,0.062042245902301035,0,0,1,0.06529917464088655
449,LV214,Role of phospholipids in phagocytosis,0.06124710596665956,1,0,1,0.06446229356467344
450,LV214,Role of LAT2/NTAL/LAB on calcium mobilization,0.062042245902301035,0,0,1,0.06529917464088655
451,LV214,Role of LAT2/NTAL/LAB on calcium mobilization,0.06124710596665956,1,0,1,0.06446229356467344
452,LV214,FCERI mediated MAPK activation,0.062042245902301035,0,0,1,0.06529917464088655
453,LV214,FCERI mediated MAPK activation,0.06124710596665956,1,0,1,0.06446229356467344
454,LV214,FCERI mediated Ca+2 mobilization,0.062042245902301035,0,0,1,0.06529917464088655
455,LV214,FCERI mediated Ca+2 mobilization,0.06124710596665956,1,0,1,0.06446229356467344
456,LV214,FCERI mediated NF-kB activation,0.062042245902301035,0,0,1,0.06529917464088655
457,LV214,FCERI mediated NF-kB activation,0.06124710596665956,1,0,1,0.06446229356467344
458,LV214,Parasite infection,0.062042245902301035,0,0,1,0.06529917464088655
459,LV214,Parasite infection,0.06124710596665956,1,0,1,0.06446229356467344
460,LV214,Leishmania parasite growth and survival,0.062042245902301035,0,0,1,0.06529917464088655
461,LV214,Leishmania parasite growth and survival,0.06124710596665956,1,0,1,0.06446229356467344
462,LV214,Potential therapeutics for SARS,0.062042245902301035,0,0,1,0.06529917464088655
463,LV214,Potential therapeutics for SARS,0.06124710596665956,1,0,1,0.06446229356467344
464,LV214,CD22 mediated BCR regulation,0.062042245902301035,0,0,1,0.06529917464088655
465,LV214,CD22 mediated BCR regulation,0.06124710596665956,1,0,1,0.06446229356467344
466,LV214,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.062042245902301035,0,0,1,0.06529917464088655
467,LV214,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.06124710596665956,1,0,1,0.06446229356467344
468,LV214,Cell surface interactions at the vascular wall,0.062042245902301035,0,0,1,0.06529917464088655
469,LV214,Cell surface interactions at the vascular wall,0.06124710596665956,1,0,1,0.06446229356467344
470,LV214,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.062042245902301035,0,0,1,0.06529917464088655
471,LV214,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.06124710596665956,1,0,1,0.06446229356467344
472,LV214,Scavenging of heme from plasma,0.062042245902301035,0,0,1,0.06529917464088655
473,LV214,Scavenging of heme from plasma,0.06124710596665956,1,0,1,0.06446229356467344
474,LV211,Initial triggering of complement,0.037788082287615335,0,0,1,0.03977178048210646
475,LV211,Initial triggering of complement,0.037458783793960504,1,0,1,0.039425195352354565
476,LV211,Regulation of Complement cascade,0.037788082287615335,0,0,1,0.03977178048210646
477,LV211,Regulation of Complement cascade,0.037458783793960504,1,0,1,0.039425195352354565
478,LV211,FCGR activation,0.037788082287615335,0,0,1,0.03977178048210646
479,LV211,FCGR activation,0.037458783793960504,1,0,1,0.039425195352354565
480,LV211,Regulation of actin dynamics for phagocytic cup formation,0.037788082287615335,0,0,1,0.03977178048210646
481,LV211,Regulation of actin dynamics for phagocytic cup formation,0.037458783793960504,1,0,1,0.039425195352354565
482,LV211,Role of phospholipids in phagocytosis,0.037788082287615335,0,0,1,0.03977178048210646
483,LV211,Role of phospholipids in phagocytosis,0.037458783793960504,1,0,1,0.039425195352354565
484,LV211,Role of LAT2/NTAL/LAB on calcium mobilization,0.037788082287615335,0,0,1,0.03977178048210646
485,LV211,Role of LAT2/NTAL/LAB on calcium mobilization,0.037458783793960504,1,0,1,0.039425195352354565
486,LV211,FCERI mediated MAPK activation,0.037788082287615335,0,0,1,0.03977178048210646
487,LV211,FCERI mediated MAPK activation,0.037458783793960504,1,0,1,0.039425195352354565
488,LV211,FCERI mediated Ca+2 mobilization,0.037788082287615335,0,0,1,0.03977178048210646
489,LV211,FCERI mediated Ca+2 mobilization,0.037458783793960504,1,0,1,0.039425195352354565
490,LV211,FCERI mediated NF-kB activation,0.037788082287615335,0,0,1,0.03977178048210646
491,LV211,FCERI mediated NF-kB activation,0.037458783793960504,1,0,1,0.039425195352354565
492,LV211,Parasite infection,0.037788082287615335,0,0,1,0.03977178048210646
493,LV211,Parasite infection,0.037458783793960504,1,0,1,0.039425195352354565
494,LV211,Leishmania parasite growth and survival,0.037788082287615335,0,0,1,0.03977178048210646
495,LV211,Leishmania parasite growth and survival,0.037458783793960504,1,0,1,0.039425195352354565
496,LV211,Potential therapeutics for SARS,0.037788082287615335,0,0,1,0.03977178048210646
497,LV211,Potential therapeutics for SARS,0.037458783793960504,1,0,1,0.039425195352354565
498,LV211,CD22 mediated BCR regulation,0.037788082287615335,0,0,1,0.03977178048210646
499,LV211,CD22 mediated BCR regulation,0.037458783793960504,1,0,1,0.039425195352354565
500,LV211,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.037788082287615335,0,0,1,0.03977178048210646
501,LV211,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.037458783793960504,1,0,1,0.039425195352354565
502,LV211,Cell surface interactions at the vascular wall,0.037788082287615335,0,0,1,0.03977178048210646
503,LV211,Cell surface interactions at the vascular wall,0.037458783793960504,1,0,1,0.039425195352354565
504,LV211,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.037788082287615335,0,0,1,0.03977178048210646
505,LV211,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.037458783793960504,1,0,1,0.039425195352354565
506,LV211,Scavenging of heme from plasma,0.037788082287615335,0,0,1,0.03977178048210646
507,LV211,Scavenging of heme from plasma,0.037458783793960504,1,0,1,0.039425195352354565
508,LV208,Initial triggering of complement,0.12782289679240938,0,0,1,0.13453300310719396
509,LV208,Initial triggering of complement,0.12617414823119139,1,0,1,0.1327977029311265
510,LV208,Regulation of Complement cascade,0.12782289679240938,0,0,1,0.13453300310719396
511,LV208,Regulation of Complement cascade,0.12617414823119139,1,0,1,0.1327977029311265
512,LV208,FCGR activation,0.12782289679240938,0,0,1,0.13453300310719396
513,LV208,FCGR activation,0.12617414823119139,1,0,1,0.1327977029311265
514,LV208,Regulation of actin dynamics for phagocytic cup formation,0.12782289679240938,0,0,1,0.13453300310719396
515,LV208,Regulation of actin dynamics for phagocytic cup formation,0.12617414823119139,1,0,1,0.1327977029311265
516,LV208,Role of phospholipids in phagocytosis,0.12782289679240938,0,0,1,0.13453300310719396
517,LV208,Role of phospholipids in phagocytosis,0.12617414823119139,1,0,1,0.1327977029311265
518,LV208,Role of LAT2/NTAL/LAB on calcium mobilization,0.12782289679240938,0,0,1,0.13453300310719396
519,LV208,Role of LAT2/NTAL/LAB on calcium mobilization,0.12617414823119139,1,0,1,0.1327977029311265
520,LV208,FCERI mediated MAPK activation,0.12782289679240938,0,0,1,0.13453300310719396
521,LV208,FCERI mediated MAPK activation,0.12617414823119139,1,0,1,0.1327977029311265
522,LV208,FCERI mediated Ca+2 mobilization,0.12782289679240938,0,0,1,0.13453300310719396
523,LV208,FCERI mediated Ca+2 mobilization,0.12617414823119139,1,0,1,0.1327977029311265
524,LV208,FCERI mediated NF-kB activation,0.12782289679240938,0,0,1,0.13453300310719396
525,LV208,FCERI mediated NF-kB activation,0.12617414823119139,1,0,1,0.1327977029311265
526,LV208,Parasite infection,0.12782289679240938,0,0,1,0.13453300310719396
527,LV208,Parasite infection,0.12617414823119139,1,0,1,0.1327977029311265
528,LV208,Leishmania parasite growth and survival,0.12782289679240938,0,0,1,0.13453300310719396
529,LV208,Leishmania parasite growth and survival,0.12617414823119139,1,0,1,0.1327977029311265
530,LV208,Potential therapeutics for SARS,0.12782289679240938,0,0,1,0.13453300310719396
531,LV208,Potential therapeutics for SARS,0.12617414823119139,1,0,1,0.1327977029311265
532,LV208,CD22 mediated BCR regulation,0.12782289679240938,0,0,1,0.13453300310719396
533,LV208,CD22 mediated BCR regulation,0.12617414823119139,1,0,1,0.1327977029311265
534,LV208,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.12782289679240938,0,0,1,0.13453300310719396
535,LV208,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.12617414823119139,1,0,1,0.1327977029311265
536,LV208,Cell surface interactions at the vascular wall,0.12782289679240938,0,0,1,0.13453300310719396
537,LV208,Cell surface interactions at the vascular wall,0.12617414823119139,1,0,1,0.1327977029311265
538,LV208,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.12782289679240938,0,0,1,0.13453300310719396
539,LV208,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.12617414823119139,1,0,1,0.1327977029311265
540,LV208,Scavenging of heme from plasma,0.12782289679240938,0,0,1,0.13453300310719396
541,LV208,Scavenging of heme from plasma,0.12617414823119139,1,0,1,0.1327977029311265
542,LV319,Initial triggering of complement,0.012334105146178246,0,0,1,0.012981588178603955
543,LV319,Initial triggering of complement,0.013801067838621617,1,0,1,0.014525559575067733
544,LV319,Regulation of Complement cascade,0.012334105146178246,0,0,1,0.012981588178603955
545,LV319,Regulation of Complement cascade,0.013801067838621617,1,0,1,0.014525559575067733
546,LV319,FCGR activation,0.012334105146178246,0,0,1,0.012981588178603955
547,LV319,FCGR activation,0.013801067838621617,1,0,1,0.014525559575067733
548,LV319,Regulation of actin dynamics for phagocytic cup formation,0.012334105146178246,0,0,1,0.012981588178603955
549,LV319,Regulation of actin dynamics for phagocytic cup formation,0.013801067838621617,1,0,1,0.014525559575067733
550,LV319,Role of phospholipids in phagocytosis,0.012334105146178246,0,0,1,0.012981588178603955
551,LV319,Role of phospholipids in phagocytosis,0.013801067838621617,1,0,1,0.014525559575067733
552,LV319,Role of LAT2/NTAL/LAB on calcium mobilization,0.012334105146178246,0,0,1,0.012981588178603955
553,LV319,Role of LAT2/NTAL/LAB on calcium mobilization,0.013801067838621617,1,0,1,0.014525559575067733
554,LV319,FCERI mediated MAPK activation,0.012334105146178246,0,0,1,0.012981588178603955
555,LV319,FCERI mediated MAPK activation,0.013801067838621617,1,0,1,0.014525559575067733
556,LV319,FCERI mediated Ca+2 mobilization,0.012334105146178246,0,0,1,0.012981588178603955
557,LV319,FCERI mediated Ca+2 mobilization,0.013801067838621617,1,0,1,0.014525559575067733
558,LV319,FCERI mediated NF-kB activation,0.012334105146178246,0,0,1,0.012981588178603955
559,LV319,FCERI mediated NF-kB activation,0.013801067838621617,1,0,1,0.014525559575067733
560,LV319,Parasite infection,0.012334105146178246,0,0,1,0.012981588178603955
561,LV319,Parasite infection,0.013801067838621617,1,0,1,0.014525559575067733
562,LV319,Leishmania parasite growth and survival,0.012334105146178246,0,0,1,0.012981588178603955
563,LV319,Leishmania parasite growth and survival,0.013801067838621617,1,0,1,0.014525559575067733
564,LV319,Potential therapeutics for SARS,0.012334105146178246,0,0,1,0.012981588178603955
565,LV319,Potential therapeutics for SARS,0.013801067838621617,1,0,1,0.014525559575067733
566,LV319,CD22 mediated BCR regulation,0.012334105146178246,0,0,1,0.012981588178603955
567,LV319,CD22 mediated BCR regulation,0.013801067838621617,1,0,1,0.014525559575067733
568,LV319,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.012334105146178246,0,0,1,0.012981588178603955
569,LV319,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.013801067838621617,1,0,1,0.014525559575067733
570,LV319,Cell surface interactions at the vascular wall,0.012334105146178246,0,0,1,0.012981588178603955
571,LV319,Cell surface interactions at the vascular wall,0.013801067838621617,1,0,1,0.014525559575067733
572,LV319,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.012334105146178246,0,0,1,0.012981588178603955
573,LV319,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.013801067838621617,1,0,1,0.014525559575067733
574,LV319,Scavenging of heme from plasma,0.012334105146178246,0,0,1,0.012981588178603955
575,LV319,Scavenging of heme from plasma,0.013801067838621617,1,0,1,0.014525559575067733
576,LV301,Initial triggering of complement,0.0013672182115855417,0,0,1,0.0014389907952576826
577,LV301,Initial triggering of complement,0.0011988362163460784,1,0,1,0.001261769530075939
578,LV301,Regulation of Complement cascade,0.0013672182115855417,0,0,1,0.0014389907952576826
579,LV301,Regulation of Complement cascade,0.0011988362163460784,1,0,1,0.001261769530075939
580,LV301,FCGR activation,0.0013672182115855417,0,0,1,0.0014389907952576826
581,LV301,FCGR activation,0.0011988362163460784,1,0,1,0.001261769530075939
582,LV301,Regulation of actin dynamics for phagocytic cup formation,0.0013672182115855417,0,0,1,0.0014389907952576826
583,LV301,Regulation of actin dynamics for phagocytic cup formation,0.0011988362163460784,1,0,1,0.001261769530075939
584,LV301,Role of phospholipids in phagocytosis,0.0013672182115855417,0,0,1,0.0014389907952576826
585,LV301,Role of phospholipids in phagocytosis,0.0011988362163460784,1,0,1,0.001261769530075939
586,LV301,Role of LAT2/NTAL/LAB on calcium mobilization,0.0013672182115855417,0,0,1,0.0014389907952576826
587,LV301,Role of LAT2/NTAL/LAB on calcium mobilization,0.0011988362163460784,1,0,1,0.001261769530075939
588,LV301,FCERI mediated MAPK activation,0.0013672182115855417,0,0,1,0.0014389907952576826
589,LV301,FCERI mediated MAPK activation,0.0011988362163460784,1,0,1,0.001261769530075939
590,LV301,FCERI mediated Ca+2 mobilization,0.0013672182115855417,0,0,1,0.0014389907952576826
591,LV301,FCERI mediated Ca+2 mobilization,0.0011988362163460784,1,0,1,0.001261769530075939
592,LV301,FCERI mediated NF-kB activation,0.0013672182115855417,0,0,1,0.0014389907952576826
593,LV301,FCERI mediated NF-kB activation,0.0011988362163460784,1,0,1,0.001261769530075939
594,LV301,Parasite infection,0.0013672182115855417,0,0,1,0.0014389907952576826
595,LV301,Parasite infection,0.0011988362163460784,1,0,1,0.001261769530075939
596,LV301,Leishmania parasite growth and survival,0.0013672182115855417,0,0,1,0.0014389907952576826
597,LV301,Leishmania parasite growth and survival,0.0011988362163460784,1,0,1,0.001261769530075939
598,LV301,Potential therapeutics for SARS,0.0013672182115855417,0,0,1,0.0014389907952576826
599,LV301,Potential therapeutics for SARS,0.0011988362163460784,1,0,1,0.001261769530075939
600,LV301,CD22 mediated BCR regulation,0.0013672182115855417,0,0,1,0.0014389907952576826
601,LV301,CD22 mediated BCR regulation,0.0011988362163460784,1,0,1,0.001261769530075939
602,LV301,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0013672182115855417,0,0,1,0.0014389907952576826
603,LV301,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0011988362163460784,1,0,1,0.001261769530075939
604,LV301,Cell surface interactions at the vascular wall,0.0013672182115855417,0,0,1,0.0014389907952576826
605,LV301,Cell surface interactions at the vascular wall,0.0011988362163460784,1,0,1,0.001261769530075939
606,LV301,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0013672182115855417,0,0,1,0.0014389907952576826
607,LV301,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0011988362163460784,1,0,1,0.001261769530075939
608,LV301,Scavenging of heme from plasma,0.0013672182115855417,0,0,1,0.0014389907952576826
609,LV301,Scavenging of heme from plasma,0.0011988362163460784,1,0,1,0.001261769530075939
610,LV325,Initial triggering of complement,0.07916129561723773,0,0,1,0.08331689467607005
611,LV325,Initial triggering of complement,0.07798995451741865,1,0,1,0.08208406362798742
612,LV325,Regulation of Complement cascade,0.07916129561723773,0,0,1,0.08331689467607005
613,LV325,Regulation of Complement cascade,0.07798995451741865,1,0,1,0.08208406362798742
614,LV325,FCGR activation,0.07916129561723773,0,0,1,0.08331689467607005
615,LV325,FCGR activation,0.07798995451741865,1,0,1,0.08208406362798742
616,LV325,Regulation of actin dynamics for phagocytic cup formation,0.07916129561723773,0,0,1,0.08331689467607005
617,LV325,Regulation of actin dynamics for phagocytic cup formation,0.07798995451741865,1,0,1,0.08208406362798742
618,LV325,Role of phospholipids in phagocytosis,0.07916129561723773,0,0,1,0.08331689467607005
619,LV325,Role of phospholipids in phagocytosis,0.07798995451741865,1,0,1,0.08208406362798742
620,LV325,Role of LAT2/NTAL/LAB on calcium mobilization,0.07916129561723773,0,0,1,0.08331689467607005
621,LV325,Role of LAT2/NTAL/LAB on calcium mobilization,0.07798995451741865,1,0,1,0.08208406362798742
622,LV325,FCERI mediated MAPK activation,0.07916129561723773,0,0,1,0.08331689467607005
623,LV325,FCERI mediated MAPK activation,0.07798995451741865,1,0,1,0.08208406362798742
624,LV325,FCERI mediated Ca+2 mobilization,0.07916129561723773,0,0,1,0.08331689467607005
625,LV325,FCERI mediated Ca+2 mobilization,0.07798995451741865,1,0,1,0.08208406362798742
626,LV325,FCERI mediated NF-kB activation,0.07916129561723773,0,0,1,0.08331689467607005
627,LV325,FCERI mediated NF-kB activation,0.07798995451741865,1,0,1,0.08208406362798742
628,LV325,Parasite infection,0.07916129561723773,0,0,1,0.08331689467607005
629,LV325,Parasite infection,0.07798995451741865,1,0,1,0.08208406362798742
630,LV325,Leishmania parasite growth and survival,0.07916129561723773,0,0,1,0.08331689467607005
631,LV325,Leishmania parasite growth and survival,0.07798995451741865,1,0,1,0.08208406362798742
632,LV325,Potential therapeutics for SARS,0.07916129561723773,0,0,1,0.08331689467607005
633,LV325,Potential therapeutics for SARS,0.07798995451741865,1,0,1,0.08208406362798742
634,LV325,CD22 mediated BCR regulation,0.07916129561723773,0,0,1,0.08331689467607005
635,LV325,CD22 mediated BCR regulation,0.07798995451741865,1,0,1,0.08208406362798742
636,LV325,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.07916129561723773,0,0,1,0.08331689467607005
637,LV325,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.07798995451741865,1,0,1,0.08208406362798742
638,LV325,Cell surface interactions at the vascular wall,0.07916129561723773,0,0,1,0.08331689467607005
639,LV325,Cell surface interactions at the vascular wall,0.07798995451741865,1,0,1,0.08208406362798742
640,LV325,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.07916129561723773,0,0,1,0.08331689467607005
641,LV325,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.07798995451741865,1,0,1,0.08208406362798742
642,LV325,Scavenging of heme from plasma,0.07916129561723773,0,0,1,0.08331689467607005
643,LV325,Scavenging of heme from plasma,0.07798995451741865,1,0,1,0.08208406362798742
644,LV327,Initial triggering of complement,0.07232248227917341,0,0,1,0.07611907551262607
645,LV327,Initial triggering of complement,0.07262667612699063,1,0,1,0.07643923811964352
646,LV327,Regulation of Complement cascade,0.07232248227917341,0,0,1,0.07611907551262607
647,LV327,Regulation of Complement cascade,0.07262667612699063,1,0,1,0.07643923811964352
648,LV327,FCGR activation,0.07232248227917341,0,0,1,0.07611907551262607
649,LV327,FCGR activation,0.07262667612699063,1,0,1,0.07643923811964352
650,LV327,Regulation of actin dynamics for phagocytic cup formation,0.07232248227917341,0,0,1,0.07611907551262607
651,LV327,Regulation of actin dynamics for phagocytic cup formation,0.07262667612699063,1,0,1,0.07643923811964352
652,LV327,Role of phospholipids in phagocytosis,0.07232248227917341,0,0,1,0.07611907551262607
653,LV327,Role of phospholipids in phagocytosis,0.07262667612699063,1,0,1,0.07643923811964352
654,LV327,Role of LAT2/NTAL/LAB on calcium mobilization,0.07232248227917341,0,0,1,0.07611907551262607
655,LV327,Role of LAT2/NTAL/LAB on calcium mobilization,0.07262667612699063,1,0,1,0.07643923811964352
656,LV327,FCERI mediated MAPK activation,0.07232248227917341,0,0,1,0.07611907551262607
657,LV327,FCERI mediated MAPK activation,0.07262667612699063,1,0,1,0.07643923811964352
658,LV327,FCERI mediated Ca+2 mobilization,0.07232248227917341,0,0,1,0.07611907551262607
659,LV327,FCERI mediated Ca+2 mobilization,0.07262667612699063,1,0,1,0.07643923811964352
660,LV327,FCERI mediated NF-kB activation,0.07232248227917341,0,0,1,0.07611907551262607
661,LV327,FCERI mediated NF-kB activation,0.07262667612699063,1,0,1,0.07643923811964352
662,LV327,Parasite infection,0.07232248227917341,0,0,1,0.07611907551262607
663,LV327,Parasite infection,0.07262667612699063,1,0,1,0.07643923811964352
664,LV327,Leishmania parasite growth and survival,0.07232248227917341,0,0,1,0.07611907551262607
665,LV327,Leishmania parasite growth and survival,0.07262667612699063,1,0,1,0.07643923811964352
666,LV327,Potential therapeutics for SARS,0.07232248227917341,0,0,1,0.07611907551262607
667,LV327,Potential therapeutics for SARS,0.07262667612699063,1,0,1,0.07643923811964352
668,LV327,CD22 mediated BCR regulation,0.07232248227917341,0,0,1,0.07611907551262607
669,LV327,CD22 mediated BCR regulation,0.07262667612699063,1,0,1,0.07643923811964352
670,LV327,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.07232248227917341,0,0,1,0.07611907551262607
671,LV327,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.07262667612699063,1,0,1,0.07643923811964352
672,LV327,Cell surface interactions at the vascular wall,0.07232248227917341,0,0,1,0.07611907551262607
673,LV327,Cell surface interactions at the vascular wall,0.07262667612699063,1,0,1,0.07643923811964352
674,LV327,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.07232248227917341,0,0,1,0.07611907551262607
675,LV327,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.07262667612699063,1,0,1,0.07643923811964352
676,LV327,Scavenging of heme from plasma,0.07232248227917341,0,0,1,0.07611907551262607
677,LV327,Scavenging of heme from plasma,0.07262667612699063,1,0,1,0.07643923811964352
678,LV657,Initial triggering of complement,0.16304156331768357,0,0,1,0.17160048547516757
679,LV657,Initial triggering of complement,0.1603339868395225,1,0,1,0.1687507738515843
680,LV657,Regulation of Complement cascade,0.16304156331768357,0,0,1,0.17160048547516757
681,LV657,Regulation of Complement cascade,0.1603339868395225,1,0,1,0.1687507738515843
682,LV657,FCGR activation,0.16304156331768357,0,0,1,0.17160048547516757
683,LV657,FCGR activation,0.1603339868395225,1,0,1,0.1687507738515843
684,LV657,Regulation of actin dynamics for phagocytic cup formation,0.16304156331768357,0,0,1,0.17160048547516757
685,LV657,Regulation of actin dynamics for phagocytic cup formation,0.1603339868395225,1,0,1,0.1687507738515843
686,LV657,Role of phospholipids in phagocytosis,0.16304156331768357,0,0,1,0.17160048547516757
687,LV657,Role of phospholipids in phagocytosis,0.1603339868395225,1,0,1,0.1687507738515843
688,LV657,Role of LAT2/NTAL/LAB on calcium mobilization,0.16304156331768357,0,0,1,0.17160048547516757
689,LV657,Role of LAT2/NTAL/LAB on calcium mobilization,0.1603339868395225,1,0,1,0.1687507738515843
690,LV657,FCERI mediated MAPK activation,0.16304156331768357,0,0,1,0.17160048547516757
691,LV657,FCERI mediated MAPK activation,0.1603339868395225,1,0,1,0.1687507738515843
692,LV657,FCERI mediated Ca+2 mobilization,0.16304156331768357,0,0,1,0.17160048547516757
693,LV657,FCERI mediated Ca+2 mobilization,0.1603339868395225,1,0,1,0.1687507738515843
694,LV657,FCERI mediated NF-kB activation,0.16304156331768357,0,0,1,0.17160048547516757
695,LV657,FCERI mediated NF-kB activation,0.1603339868395225,1,0,1,0.1687507738515843
696,LV657,Parasite infection,0.16304156331768357,0,0,1,0.17160048547516757
697,LV657,Parasite infection,0.1603339868395225,1,0,1,0.1687507738515843
698,LV657,Leishmania parasite growth and survival,0.16304156331768357,0,0,1,0.17160048547516757
699,LV657,Leishmania parasite growth and survival,0.1603339868395225,1,0,1,0.1687507738515843
700,LV657,Potential therapeutics for SARS,0.16304156331768357,0,0,1,0.17160048547516757
701,LV657,Potential therapeutics for SARS,0.1603339868395225,1,0,1,0.1687507738515843
702,LV657,CD22 mediated BCR regulation,0.16304156331768357,0,0,1,0.17160048547516757
703,LV657,CD22 mediated BCR regulation,0.1603339868395225,1,0,1,0.1687507738515843
704,LV657,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.16304156331768357,0,0,1,0.17160048547516757
705,LV657,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.1603339868395225,1,0,1,0.1687507738515843
706,LV657,Cell surface interactions at the vascular wall,0.16304156331768357,0,0,1,0.17160048547516757
707,LV657,Cell surface interactions at the vascular wall,0.1603339868395225,1,0,1,0.1687507738515843
708,LV657,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.16304156331768357,0,0,1,0.17160048547516757
709,LV657,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.1603339868395225,1,0,1,0.1687507738515843
710,LV657,Scavenging of heme from plasma,0.16304156331768357,0,0,1,0.17160048547516757
711,LV657,Scavenging of heme from plasma,0.1603339868395225,1,0,1,0.1687507738515843
712,HV169,Initial triggering of complement,0.03219592418899289,0,0,1,0.033886060147668144
713,HV169,Initial triggering of complement,0.033101051365361935,1,0,1,0.03483870228211001
714,HV169,Regulation of Complement cascade,0.03219592418899289,0,0,1,0.033886060147668144
715,HV169,Regulation of Complement cascade,0.033101051365361935,1,0,1,0.03483870228211001
716,HV169,FCGR activation,0.03219592418899289,0,0,1,0.033886060147668144
717,HV169,FCGR activation,0.033101051365361935,1,0,1,0.03483870228211001
718,HV169,Regulation of actin dynamics for phagocytic cup formation,0.03219592418899289,0,0,1,0.033886060147668144
719,HV169,Regulation of actin dynamics for phagocytic cup formation,0.033101051365361935,1,0,1,0.03483870228211001
720,HV169,Role of phospholipids in phagocytosis,0.03219592418899289,0,0,1,0.033886060147668144
721,HV169,Role of phospholipids in phagocytosis,0.033101051365361935,1,0,1,0.03483870228211001
722,HV169,Role of LAT2/NTAL/LAB on calcium mobilization,0.03219592418899289,0,0,1,0.033886060147668144
723,HV169,Role of LAT2/NTAL/LAB on calcium mobilization,0.033101051365361935,1,0,1,0.03483870228211001
724,HV169,FCERI mediated MAPK activation,0.03219592418899289,0,0,1,0.033886060147668144
725,HV169,FCERI mediated MAPK activation,0.033101051365361935,1,0,1,0.03483870228211001
726,HV169,FCERI mediated Ca+2 mobilization,0.03219592418899289,0,0,1,0.033886060147668144
727,HV169,FCERI mediated Ca+2 mobilization,0.033101051365361935,1,0,1,0.03483870228211001
728,HV169,FCERI mediated NF-kB activation,0.03219592418899289,0,0,1,0.033886060147668144
729,HV169,FCERI mediated NF-kB activation,0.033101051365361935,1,0,1,0.03483870228211001
730,HV169,Parasite infection,0.03219592418899289,0,0,1,0.033886060147668144
731,HV169,Parasite infection,0.033101051365361935,1,0,1,0.03483870228211001
732,HV169,Leishmania parasite growth and survival,0.03219592418899289,0,0,1,0.033886060147668144
733,HV169,Leishmania parasite growth and survival,0.033101051365361935,1,0,1,0.03483870228211001
734,HV169,Potential therapeutics for SARS,0.03219592418899289,0,0,1,0.033886060147668144
735,HV169,Potential therapeutics for SARS,0.033101051365361935,1,0,1,0.03483870228211001
736,HV169,CD22 mediated BCR regulation,0.03219592418899289,0,0,1,0.033886060147668144
737,HV169,CD22 mediated BCR regulation,0.033101051365361935,1,0,1,0.03483870228211001
738,HV169,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.03219592418899289,0,0,1,0.033886060147668144
739,HV169,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.033101051365361935,1,0,1,0.03483870228211001
740,HV169,Cell surface interactions at the vascular wall,0.03219592418899289,0,0,1,0.033886060147668144
741,HV169,Cell surface interactions at the vascular wall,0.033101051365361935,1,0,1,0.03483870228211001
742,HV169,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.03219592418899289,0,0,1,0.033886060147668144
743,HV169,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.033101051365361935,1,0,1,0.03483870228211001
744,HV169,Scavenging of heme from plasma,0.03219592418899289,0,0,1,0.033886060147668144
745,HV169,Scavenging of heme from plasma,0.033101051365361935,1,0,1,0.03483870228211001
746,HV146,Initial triggering of complement,0.08430450123392837,0,0,1,0.08873009461578749
747,HV146,Initial triggering of complement,0.08084641856586804,1,0,1,0.08509047872535241
748,HV146,Regulation of Complement cascade,0.08430450123392837,0,0,1,0.08873009461578749
749,HV146,Regulation of Complement cascade,0.08084641856586804,1,0,1,0.08509047872535241
750,HV146,FCGR activation,0.08430450123392837,0,0,1,0.08873009461578749
751,HV146,FCGR activation,0.08084641856586804,1,0,1,0.08509047872535241
752,HV146,Regulation of actin dynamics for phagocytic cup formation,0.08430450123392837,0,0,1,0.08873009461578749
753,HV146,Regulation of actin dynamics for phagocytic cup formation,0.08084641856586804,1,0,1,0.08509047872535241
754,HV146,Role of phospholipids in phagocytosis,0.08430450123392837,0,0,1,0.08873009461578749
755,HV146,Role of phospholipids in phagocytosis,0.08084641856586804,1,0,1,0.08509047872535241
756,HV146,Role of LAT2/NTAL/LAB on calcium mobilization,0.08430450123392837,0,0,1,0.08873009461578749
757,HV146,Role of LAT2/NTAL/LAB on calcium mobilization,0.08084641856586804,1,0,1,0.08509047872535241
758,HV146,FCERI mediated MAPK activation,0.08430450123392837,0,0,1,0.08873009461578749
759,HV146,FCERI mediated MAPK activation,0.08084641856586804,1,0,1,0.08509047872535241
760,HV146,FCERI mediated Ca+2 mobilization,0.08430450123392837,0,0,1,0.08873009461578749
761,HV146,FCERI mediated Ca+2 mobilization,0.08084641856586804,1,0,1,0.08509047872535241
762,HV146,FCERI mediated NF-kB activation,0.08430450123392837,0,0,1,0.08873009461578749
763,HV146,FCERI mediated NF-kB activation,0.08084641856586804,1,0,1,0.08509047872535241
764,HV146,Parasite infection,0.08430450123392837,0,0,1,0.08873009461578749
765,HV146,Parasite infection,0.08084641856586804,1,0,1,0.08509047872535241
766,HV146,Leishmania parasite growth and survival,0.08430450123392837,0,0,1,0.08873009461578749
767,HV146,Leishmania parasite growth and survival,0.08084641856586804,1,0,1,0.08509047872535241
768,HV146,Potential therapeutics for SARS,0.08430450123392837,0,0,1,0.08873009461578749
769,HV146,Potential therapeutics for SARS,0.08084641856586804,1,0,1,0.08509047872535241
770,HV146,CD22 mediated BCR regulation,0.08430450123392837,0,0,1,0.08873009461578749
771,HV146,CD22 mediated BCR regulation,0.08084641856586804,1,0,1,0.08509047872535241
772,HV146,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.08430450123392837,0,0,1,0.08873009461578749
773,HV146,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.08084641856586804,1,0,1,0.08509047872535241
774,HV146,Cell surface interactions at the vascular wall,0.08430450123392837,0,0,1,0.08873009461578749
775,HV146,Cell surface interactions at the vascular wall,0.08084641856586804,1,0,1,0.08509047872535241
776,HV146,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.08430450123392837,0,0,1,0.08873009461578749
777,HV146,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.08084641856586804,1,0,1,0.08509047872535241
778,HV146,Scavenging of heme from plasma,0.08430450123392837,0,0,1,0.08873009461578749
779,HV146,Scavenging of heme from plasma,0.08084641856586804,1,0,1,0.08509047872535241
780,HV348,Initial triggering of complement,0.008101769832102357,0,0,1,0.008527074986933973
781,HV348,Initial triggering of complement,0.007810312204888531,1,0,1,0.008220317192739612
782,HV348,Regulation of Complement cascade,0.008101769832102357,0,0,1,0.008527074986933973
783,HV348,Regulation of Complement cascade,0.007810312204888531,1,0,1,0.008220317192739612
784,HV348,FCGR activation,0.008101769832102357,0,0,1,0.008527074986933973
785,HV348,FCGR activation,0.007810312204888531,1,0,1,0.008220317192739612
786,HV348,Regulation of actin dynamics for phagocytic cup formation,0.008101769832102357,0,0,1,0.008527074986933973
787,HV348,Regulation of actin dynamics for phagocytic cup formation,0.007810312204888531,1,0,1,0.008220317192739612
788,HV348,Role of phospholipids in phagocytosis,0.008101769832102357,0,0,1,0.008527074986933973
789,HV348,Role of phospholipids in phagocytosis,0.007810312204888531,1,0,1,0.008220317192739612
790,HV348,Role of LAT2/NTAL/LAB on calcium mobilization,0.008101769832102357,0,0,1,0.008527074986933973
791,HV348,Role of LAT2/NTAL/LAB on calcium mobilization,0.007810312204888531,1,0,1,0.008220317192739612
792,HV348,FCERI mediated MAPK activation,0.008101769832102357,0,0,1,0.008527074986933973
793,HV348,FCERI mediated MAPK activation,0.007810312204888531,1,0,1,0.008220317192739612
794,HV348,FCERI mediated Ca+2 mobilization,0.008101769832102357,0,0,1,0.008527074986933973
795,HV348,FCERI mediated Ca+2 mobilization,0.007810312204888531,1,0,1,0.008220317192739612
796,HV348,FCERI mediated NF-kB activation,0.008101769832102357,0,0,1,0.008527074986933973
797,HV348,FCERI mediated NF-kB activation,0.007810312204888531,1,0,1,0.008220317192739612
798,HV348,Parasite infection,0.008101769832102357,0,0,1,0.008527074986933973
799,HV348,Parasite infection,0.007810312204888531,1,0,1,0.008220317192739612
800,HV348,Leishmania parasite growth and survival,0.008101769832102357,0,0,1,0.008527074986933973
801,HV348,Leishmania parasite growth and survival,0.007810312204888531,1,0,1,0.008220317192739612
802,HV348,Potential therapeutics for SARS,0.008101769832102357,0,0,1,0.008527074986933973
803,HV348,Potential therapeutics for SARS,0.007810312204888531,1,0,1,0.008220317192739612
804,HV348,CD22 mediated BCR regulation,0.008101769832102357,0,0,1,0.008527074986933973
805,HV348,CD22 mediated BCR regulation,0.007810312204888531,1,0,1,0.008220317192739612
806,HV348,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.008101769832102357,0,0,1,0.008527074986933973
807,HV348,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.007810312204888531,1,0,1,0.008220317192739612
808,HV348,Cell surface interactions at the vascular wall,0.008101769832102357,0,0,1,0.008527074986933973
809,HV348,Cell surface interactions at the vascular wall,0.007810312204888531,1,0,1,0.008220317192739612
810,HV348,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.008101769832102357,0,0,1,0.008527074986933973
811,HV348,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.007810312204888531,1,0,1,0.008220317192739612
812,HV348,Scavenging of heme from plasma,0.008101769832102357,0,0,1,0.008527074986933973
813,HV348,Scavenging of heme from plasma,0.007810312204888531,1,0,1,0.008220317192739612
814,HV323,Initial triggering of complement,0.05812919247447815,0,0,1,0.061180704146364215
815,HV323,Initial triggering of complement,0.05664684711972359,1,0,1,0.05962054256951461
816,HV323,Regulation of Complement cascade,0.05812919247447815,0,0,1,0.061180704146364215
817,HV323,Regulation of Complement cascade,0.05664684711972359,1,0,1,0.05962054256951461
818,HV323,FCGR activation,0.05812919247447815,0,0,1,0.061180704146364215
819,HV323,FCGR activation,0.05664684711972359,1,0,1,0.05962054256951461
820,HV323,Regulation of actin dynamics for phagocytic cup formation,0.05812919247447815,0,0,1,0.061180704146364215
821,HV323,Regulation of actin dynamics for phagocytic cup formation,0.05664684711972359,1,0,1,0.05962054256951461
822,HV323,Role of phospholipids in phagocytosis,0.05812919247447815,0,0,1,0.061180704146364215
823,HV323,Role of phospholipids in phagocytosis,0.05664684711972359,1,0,1,0.05962054256951461
824,HV323,Role of LAT2/NTAL/LAB on calcium mobilization,0.05812919247447815,0,0,1,0.061180704146364215
825,HV323,Role of LAT2/NTAL/LAB on calcium mobilization,0.05664684711972359,1,0,1,0.05962054256951461
826,HV323,FCERI mediated MAPK activation,0.05812919247447815,0,0,1,0.061180704146364215
827,HV323,FCERI mediated MAPK activation,0.05664684711972359,1,0,1,0.05962054256951461
828,HV323,FCERI mediated Ca+2 mobilization,0.05812919247447815,0,0,1,0.061180704146364215
829,HV323,FCERI mediated Ca+2 mobilization,0.05664684711972359,1,0,1,0.05962054256951461
830,HV323,FCERI mediated NF-kB activation,0.05812919247447815,0,0,1,0.061180704146364215
831,HV323,FCERI mediated NF-kB activation,0.05664684711972359,1,0,1,0.05962054256951461
832,HV323,Parasite infection,0.05812919247447815,0,0,1,0.061180704146364215
833,HV323,Parasite infection,0.05664684711972359,1,0,1,0.05962054256951461
834,HV323,Leishmania parasite growth and survival,0.05812919247447815,0,0,1,0.061180704146364215
835,HV323,Leishmania parasite growth and survival,0.05664684711972359,1,0,1,0.05962054256951461
836,HV323,Potential therapeutics for SARS,0.05812919247447815,0,0,1,0.061180704146364215
837,HV323,Potential therapeutics for SARS,0.05664684711972359,1,0,1,0.05962054256951461
838,HV323,CD22 mediated BCR regulation,0.05812919247447815,0,0,1,0.061180704146364215
839,HV323,CD22 mediated BCR regulation,0.05664684711972359,1,0,1,0.05962054256951461
840,HV323,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.05812919247447815,0,0,1,0.061180704146364215
841,HV323,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.05664684711972359,1,0,1,0.05962054256951461
842,HV323,Cell surface interactions at the vascular wall,0.05812919247447815,0,0,1,0.061180704146364215
843,HV323,Cell surface interactions at the vascular wall,0.05664684711972359,1,0,1,0.05962054256951461
844,HV323,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.05812919247447815,0,0,1,0.061180704146364215
845,HV323,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.05664684711972359,1,0,1,0.05962054256951461
846,HV323,Scavenging of heme from plasma,0.05812919247447815,0,0,1,0.061180704146364215
847,HV323,Scavenging of heme from plasma,0.05664684711972359,1,0,1,0.05962054256951461
848,HV313,Initial triggering of complement,0.03401970656182678,0,0,1,0.03580558259465026
849,HV313,Initial triggering of complement,0.032960849093269906,1,0,1,0.03469114004419871
850,HV313,Regulation of Complement cascade,0.03401970656182678,0,0,1,0.03580558259465026
851,HV313,Regulation of Complement cascade,0.032960849093269906,1,0,1,0.03469114004419871
852,HV313,FCGR activation,0.03401970656182678,0,0,1,0.03580558259465026
853,HV313,FCGR activation,0.032960849093269906,1,0,1,0.03469114004419871
854,HV313,Regulation of actin dynamics for phagocytic cup formation,0.03401970656182678,0,0,1,0.03580558259465026
855,HV313,Regulation of actin dynamics for phagocytic cup formation,0.032960849093269906,1,0,1,0.03469114004419871
856,HV313,Role of phospholipids in phagocytosis,0.03401970656182678,0,0,1,0.03580558259465026
857,HV313,Role of phospholipids in phagocytosis,0.032960849093269906,1,0,1,0.03469114004419871
858,HV313,Role of LAT2/NTAL/LAB on calcium mobilization,0.03401970656182678,0,0,1,0.03580558259465026
859,HV313,Role of LAT2/NTAL/LAB on calcium mobilization,0.032960849093269906,1,0,1,0.03469114004419871
860,HV313,FCERI mediated MAPK activation,0.03401970656182678,0,0,1,0.03580558259465026
861,HV313,FCERI mediated MAPK activation,0.032960849093269906,1,0,1,0.03469114004419871
862,HV313,FCERI mediated Ca+2 mobilization,0.03401970656182678,0,0,1,0.03580558259465026
863,HV313,FCERI mediated Ca+2 mobilization,0.032960849093269906,1,0,1,0.03469114004419871
864,HV313,FCERI mediated NF-kB activation,0.03401970656182678,0,0,1,0.03580558259465026
865,HV313,FCERI mediated NF-kB activation,0.032960849093269906,1,0,1,0.03469114004419871
866,HV313,Parasite infection,0.03401970656182678,0,0,1,0.03580558259465026
867,HV313,Parasite infection,0.032960849093269906,1,0,1,0.03469114004419871
868,HV313,Leishmania parasite growth and survival,0.03401970656182678,0,0,1,0.03580558259465026
869,HV313,Leishmania parasite growth and survival,0.032960849093269906,1,0,1,0.03469114004419871
870,HV313,Potential therapeutics for SARS,0.03401970656182678,0,0,1,0.03580558259465026
871,HV313,Potential therapeutics for SARS,0.032960849093269906,1,0,1,0.03469114004419871
872,HV313,CD22 mediated BCR regulation,0.03401970656182678,0,0,1,0.03580558259465026
873,HV313,CD22 mediated BCR regulation,0.032960849093269906,1,0,1,0.03469114004419871
874,HV313,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.03401970656182678,0,0,1,0.03580558259465026
875,HV313,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.032960849093269906,1,0,1,0.03469114004419871
876,HV313,Cell surface interactions at the vascular wall,0.03401970656182678,0,0,1,0.03580558259465026
877,HV313,Cell surface interactions at the vascular wall,0.032960849093269906,1,0,1,0.03469114004419871
878,HV313,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.03401970656182678,0,0,1,0.03580558259465026
879,HV313,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.032960849093269906,1,0,1,0.03469114004419871
880,HV313,Scavenging of heme from plasma,0.03401970656182678,0,0,1,0.03580558259465026
881,HV313,Scavenging of heme from plasma,0.032960849093269906,1,0,1,0.03469114004419871
882,HV353,Initial triggering of complement,0.02788314875215292,0,0,1,0.029346884101710494
883,HV353,Initial triggering of complement,0.027869845178104254,1,0,1,0.0293328821520306
884,HV353,Regulation of Complement cascade,0.02788314875215292,0,0,1,0.029346884101710494
885,HV353,Regulation of Complement cascade,0.027869845178104254,1,0,1,0.0293328821520306
886,HV353,FCGR activation,0.02788314875215292,0,0,1,0.029346884101710494
887,HV353,FCGR activation,0.027869845178104254,1,0,1,0.0293328821520306
888,HV353,Regulation of actin dynamics for phagocytic cup formation,0.02788314875215292,0,0,1,0.029346884101710494
889,HV353,Regulation of actin dynamics for phagocytic cup formation,0.027869845178104254,1,0,1,0.0293328821520306
890,HV353,Role of phospholipids in phagocytosis,0.02788314875215292,0,0,1,0.029346884101710494
891,HV353,Role of phospholipids in phagocytosis,0.027869845178104254,1,0,1,0.0293328821520306
892,HV353,Role of LAT2/NTAL/LAB on calcium mobilization,0.02788314875215292,0,0,1,0.029346884101710494
893,HV353,Role of LAT2/NTAL/LAB on calcium mobilization,0.027869845178104254,1,0,1,0.0293328821520306
894,HV353,FCERI mediated MAPK activation,0.02788314875215292,0,0,1,0.029346884101710494
895,HV353,FCERI mediated MAPK activation,0.027869845178104254,1,0,1,0.0293328821520306
896,HV353,FCERI mediated Ca+2 mobilization,0.02788314875215292,0,0,1,0.029346884101710494
897,HV353,FCERI mediated Ca+2 mobilization,0.027869845178104254,1,0,1,0.0293328821520306
898,HV353,FCERI mediated NF-kB activation,0.02788314875215292,0,0,1,0.029346884101710494
899,HV353,FCERI mediated NF-kB activation,0.027869845178104254,1,0,1,0.0293328821520306
900,HV353,Parasite infection,0.02788314875215292,0,0,1,0.029346884101710494
901,HV353,Parasite infection,0.027869845178104254,1,0,1,0.0293328821520306
902,HV353,Leishmania parasite growth and survival,0.02788314875215292,0,0,1,0.029346884101710494
903,HV353,Leishmania parasite growth and survival,0.027869845178104254,1,0,1,0.0293328821520306
904,HV353,Potential therapeutics for SARS,0.02788314875215292,0,0,1,0.029346884101710494
905,HV353,Potential therapeutics for SARS,0.027869845178104254,1,0,1,0.0293328821520306
906,HV353,CD22 mediated BCR regulation,0.02788314875215292,0,0,1,0.029346884101710494
907,HV353,CD22 mediated BCR regulation,0.027869845178104254,1,0,1,0.0293328821520306
908,HV353,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.02788314875215292,0,0,1,0.029346884101710494
909,HV353,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.027869845178104254,1,0,1,0.0293328821520306
910,HV353,Cell surface interactions at the vascular wall,0.02788314875215292,0,0,1,0.029346884101710494
911,HV353,Cell surface interactions at the vascular wall,0.027869845178104254,1,0,1,0.0293328821520306
912,HV353,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.02788314875215292,0,0,1,0.029346884101710494
913,HV353,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.027869845178104254,1,0,1,0.0293328821520306
914,HV353,Scavenging of heme from plasma,0.02788314875215292,0,0,1,0.029346884101710494
915,HV353,Scavenging of heme from plasma,0.027869845178104254,1,0,1,0.0293328821520306
916,HV307,Initial triggering of complement,0.07567565653114332,0,0,1,0.07964827578409119
917,HV307,Initial triggering of complement,0.07574399990920463,1,0,1,0.07972020687096064
918,HV307,Regulation of Complement cascade,0.07567565653114332,0,0,1,0.07964827578409119
919,HV307,Regulation of Complement cascade,0.07574399990920463,1,0,1,0.07972020687096064
920,HV307,FCGR activation,0.07567565653114332,0,0,1,0.07964827578409119
921,HV307,FCGR activation,0.07574399990920463,1,0,1,0.07972020687096064
922,HV307,Regulation of actin dynamics for phagocytic cup formation,0.07567565653114332,0,0,1,0.07964827578409119
923,HV307,Regulation of actin dynamics for phagocytic cup formation,0.07574399990920463,1,0,1,0.07972020687096064
924,HV307,Role of phospholipids in phagocytosis,0.07567565653114332,0,0,1,0.07964827578409119
925,HV307,Role of phospholipids in phagocytosis,0.07574399990920463,1,0,1,0.07972020687096064
926,HV307,Role of LAT2/NTAL/LAB on calcium mobilization,0.07567565653114332,0,0,1,0.07964827578409119
927,HV307,Role of LAT2/NTAL/LAB on calcium mobilization,0.07574399990920463,1,0,1,0.07972020687096064
928,HV307,FCERI mediated MAPK activation,0.07567565653114332,0,0,1,0.07964827578409119
929,HV307,FCERI mediated MAPK activation,0.07574399990920463,1,0,1,0.07972020687096064
930,HV307,FCERI mediated Ca+2 mobilization,0.07567565653114332,0,0,1,0.07964827578409119
931,HV307,FCERI mediated Ca+2 mobilization,0.07574399990920463,1,0,1,0.07972020687096064
932,HV307,FCERI mediated NF-kB activation,0.07567565653114332,0,0,1,0.07964827578409119
933,HV307,FCERI mediated NF-kB activation,0.07574399990920463,1,0,1,0.07972020687096064
934,HV307,Parasite infection,0.07567565653114332,0,0,1,0.07964827578409119
935,HV307,Parasite infection,0.07574399990920463,1,0,1,0.07972020687096064
936,HV307,Leishmania parasite growth and survival,0.07567565653114332,0,0,1,0.07964827578409119
937,HV307,Leishmania parasite growth and survival,0.07574399990920463,1,0,1,0.07972020687096064
938,HV307,Potential therapeutics for SARS,0.07567565653114332,0,0,1,0.07964827578409119
939,HV307,Potential therapeutics for SARS,0.07574399990920463,1,0,1,0.07972020687096064
940,HV307,CD22 mediated BCR regulation,0.07567565653114332,0,0,1,0.07964827578409119
941,HV307,CD22 mediated BCR regulation,0.07574399990920463,1,0,1,0.07972020687096064
942,HV307,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.07567565653114332,0,0,1,0.07964827578409119
943,HV307,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.07574399990920463,1,0,1,0.07972020687096064
944,HV307,Cell surface interactions at the vascular wall,0.07567565653114332,0,0,1,0.07964827578409119
945,HV307,Cell surface interactions at the vascular wall,0.07574399990920463,1,0,1,0.07972020687096064
946,HV307,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.07567565653114332,0,0,1,0.07964827578409119
947,HV307,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.07574399990920463,1,0,1,0.07972020687096064
948,HV307,Scavenging of heme from plasma,0.07567565653114332,0,0,1,0.07964827578409119
949,HV307,Scavenging of heme from plasma,0.07574399990920463,1,0,1,0.07972020687096064
950,HV205,Initial triggering of complement,0.031666244533146926,0,0,1,0.03332857477866207
951,HV205,Initial triggering of complement,0.03064135130908754,1,0,1,0.032249879437240954
952,HV205,Regulation of Complement cascade,0.031666244533146926,0,0,1,0.03332857477866207
953,HV205,Regulation of Complement cascade,0.03064135130908754,1,0,1,0.032249879437240954
954,HV205,FCGR activation,0.031666244533146926,0,0,1,0.03332857477866207
955,HV205,FCGR activation,0.03064135130908754,1,0,1,0.032249879437240954
956,HV205,Regulation of actin dynamics for phagocytic cup formation,0.031666244533146926,0,0,1,0.03332857477866207
957,HV205,Regulation of actin dynamics for phagocytic cup formation,0.03064135130908754,1,0,1,0.032249879437240954
958,HV205,Role of phospholipids in phagocytosis,0.031666244533146926,0,0,1,0.03332857477866207
959,HV205,Role of phospholipids in phagocytosis,0.03064135130908754,1,0,1,0.032249879437240954
960,HV205,Role of LAT2/NTAL/LAB on calcium mobilization,0.031666244533146926,0,0,1,0.03332857477866207
961,HV205,Role of LAT2/NTAL/LAB on calcium mobilization,0.03064135130908754,1,0,1,0.032249879437240954
962,HV205,FCERI mediated MAPK activation,0.031666244533146926,0,0,1,0.03332857477866207
963,HV205,FCERI mediated MAPK activation,0.03064135130908754,1,0,1,0.032249879437240954
964,HV205,FCERI mediated Ca+2 mobilization,0.031666244533146926,0,0,1,0.03332857477866207
965,HV205,FCERI mediated Ca+2 mobilization,0.03064135130908754,1,0,1,0.032249879437240954
966,HV205,FCERI mediated NF-kB activation,0.031666244533146926,0,0,1,0.03332857477866207
967,HV205,FCERI mediated NF-kB activation,0.03064135130908754,1,0,1,0.032249879437240954
968,HV205,Parasite infection,0.031666244533146926,0,0,1,0.03332857477866207
969,HV205,Parasite infection,0.03064135130908754,1,0,1,0.032249879437240954
970,HV205,Leishmania parasite growth and survival,0.031666244533146926,0,0,1,0.03332857477866207
971,HV205,Leishmania parasite growth and survival,0.03064135130908754,1,0,1,0.032249879437240954
972,HV205,Potential therapeutics for SARS,0.031666244533146926,0,0,1,0.03332857477866207
973,HV205,Potential therapeutics for SARS,0.03064135130908754,1,0,1,0.032249879437240954
974,HV205,CD22 mediated BCR regulation,0.031666244533146926,0,0,1,0.03332857477866207
975,HV205,CD22 mediated BCR regulation,0.03064135130908754,1,0,1,0.032249879437240954
976,HV205,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.031666244533146926,0,0,1,0.03332857477866207
977,HV205,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.03064135130908754,1,0,1,0.032249879437240954
978,HV205,Cell surface interactions at the vascular wall,0.031666244533146926,0,0,1,0.03332857477866207
979,HV205,Cell surface interactions at the vascular wall,0.03064135130908754,1,0,1,0.032249879437240954
980,HV205,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.031666244533146926,0,0,1,0.03332857477866207
981,HV205,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.03064135130908754,1,0,1,0.032249879437240954
982,HV205,Scavenging of heme from plasma,0.031666244533146926,0,0,1,0.03332857477866207
983,HV205,Scavenging of heme from plasma,0.03064135130908754,1,0,1,0.032249879437240954
984,PIGR,Neutrophil degranulation,0.038080613857491175,0,0,1,0.040079668595947075
985,PIGR,Neutrophil degranulation,0.036666530358042626,1,0,1,0.03859135230364692
986,IGKC,Initial triggering of complement,0.15052975547400974,0,0,1,0.15843186603569992
987,IGKC,Initial triggering of complement,0.14896303139416645,1,0,1,0.1567828962439733
988,IGKC,Regulation of Complement cascade,0.15052975547400974,0,0,1,0.15843186603569992
989,IGKC,Regulation of Complement cascade,0.14896303139416645,1,0,1,0.1567828962439733
990,IGKC,FCGR activation,0.15052975547400974,0,0,1,0.15843186603569992
991,IGKC,FCGR activation,0.14896303139416645,1,0,1,0.1567828962439733
992,IGKC,Regulation of actin dynamics for phagocytic cup formation,0.15052975547400974,0,0,1,0.15843186603569992
993,IGKC,Regulation of actin dynamics for phagocytic cup formation,0.14896303139416645,1,0,1,0.1567828962439733
994,IGKC,Role of phospholipids in phagocytosis,0.15052975547400974,0,0,1,0.15843186603569992
995,IGKC,Role of phospholipids in phagocytosis,0.14896303139416645,1,0,1,0.1567828962439733
996,IGKC,Role of LAT2/NTAL/LAB on calcium mobilization,0.15052975547400974,0,0,1,0.15843186603569992
997,IGKC,Role of LAT2/NTAL/LAB on calcium mobilization,0.14896303139416645,1,0,1,0.1567828962439733
998,IGKC,FCERI mediated MAPK activation,0.15052975547400974,0,0,1,0.15843186603569992
999,IGKC,FCERI mediated MAPK activation,0.14896303139416645,1,0,1,0.1567828962439733
1000,IGKC,FCERI mediated Ca+2 mobilization,0.15052975547400974,0,0,1,0.15843186603569992
1001,IGKC,FCERI mediated Ca+2 mobilization,0.14896303139416645,1,0,1,0.1567828962439733
1002,IGKC,FCERI mediated NF-kB activation,0.15052975547400974,0,0,1,0.15843186603569992
1003,IGKC,FCERI mediated NF-kB activation,0.14896303139416645,1,0,1,0.1567828962439733
1004,IGKC,Parasite infection,0.15052975547400974,0,0,1,0.15843186603569992
1005,IGKC,Parasite infection,0.14896303139416645,1,0,1,0.1567828962439733
1006,IGKC,Leishmania parasite growth and survival,0.15052975547400974,0,0,1,0.15843186603569992
1007,IGKC,Leishmania parasite growth and survival,0.14896303139416645,1,0,1,0.1567828962439733
1008,IGKC,Potential therapeutics for SARS,0.15052975547400974,0,0,1,0.15843186603569992
1009,IGKC,Potential therapeutics for SARS,0.14896303139416645,1,0,1,0.1567828962439733
1010,IGKC,CD22 mediated BCR regulation,0.15052975547400974,0,0,1,0.15843186603569992
1011,IGKC,CD22 mediated BCR regulation,0.14896303139416645,1,0,1,0.1567828962439733
1012,IGKC,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.15052975547400974,0,0,1,0.15843186603569992
1013,IGKC,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.14896303139416645,1,0,1,0.1567828962439733
1014,IGKC,Cell surface interactions at the vascular wall,0.15052975547400974,0,0,1,0.15843186603569992
1015,IGKC,Cell surface interactions at the vascular wall,0.14896303139416645,1,0,1,0.1567828962439733
1016,IGKC,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.15052975547400974,0,0,1,0.15843186603569992
1017,IGKC,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.14896303139416645,1,0,1,0.1567828962439733
1018,IGKC,Scavenging of heme from plasma,0.15052975547400974,0,0,1,0.15843186603569992
1019,IGKC,Scavenging of heme from plasma,0.14896303139416645,1,0,1,0.1567828962439733
1020,IGHM,Potential therapeutics for SARS,0.022041930613973502,0,0,1,0.023199029236476716
1021,IGHM,Potential therapeutics for SARS,0.0215580868851617,1,0,1,0.022689785967038467
1022,IGHM,CD22 mediated BCR regulation,0.022041930613973502,0,0,1,0.023199029236476716
1023,IGHM,CD22 mediated BCR regulation,0.0215580868851617,1,0,1,0.022689785967038467
1024,IGHM,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.022041930613973502,0,0,1,0.023199029236476716
1025,IGHM,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0215580868851617,1,0,1,0.022689785967038467
1026,IGHM,Cell surface interactions at the vascular wall,0.022041930613973502,0,0,1,0.023199029236476716
1027,IGHM,Cell surface interactions at the vascular wall,0.0215580868851617,1,0,1,0.022689785967038467
1028,IGHD,Potential therapeutics for SARS,0.019295304482898356,0,0,1,0.020308218035207055
1029,IGHD,Potential therapeutics for SARS,0.018717912638336106,1,0,1,0.019700515809957735
1030,IGHD,CD22 mediated BCR regulation,0.019295304482898356,0,0,1,0.020308218035207055
1031,IGHD,CD22 mediated BCR regulation,0.018717912638336106,1,0,1,0.019700515809957735
1032,IGHD,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.019295304482898356,0,0,1,0.020308218035207055
1033,IGHD,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.018717912638336106,1,0,1,0.019700515809957735
1034,HBD,Factors involved in megakaryocyte development and platelet production,0.00037526399773512003,0,0,1,0.00039496360855682745
1035,HBD,Factors involved in megakaryocyte development and platelet production,9.889836464611762e-05,1,0,1,0.0001040900678369124
1036,APOA1,PPARA activates gene expression,0.03523976432533112,0,0,1,0.037089687704199244
1037,APOA1,PPARA activates gene expression,0.03192113630510451,1,0,1,0.033596847180628185
1038,APOA1,Defective ABCA1 causes TGD,0.03523976432533112,0,0,1,0.037089687704199244
1039,APOA1,Defective ABCA1 causes TGD,0.03192113630510451,1,0,1,0.033596847180628185
1040,APOA1,Platelet degranulation ,0.03523976432533112,0,0,1,0.037089687704199244
1041,APOA1,Platelet degranulation ,0.03192113630510451,1,0,1,0.033596847180628185
1042,APOA1,Chylomicron assembly,0.03523976432533112,0,0,1,0.037089687704199244
1043,APOA1,Chylomicron assembly,0.03192113630510451,1,0,1,0.033596847180628185
1044,APOA1,HDL assembly,0.03523976432533112,0,0,1,0.037089687704199244
1045,APOA1,HDL assembly,0.03192113630510451,1,0,1,0.033596847180628185
1046,APOA1,Chylomicron remodeling,0.03523976432533112,0,0,1,0.037089687704199244
1047,APOA1,Chylomicron remodeling,0.03192113630510451,1,0,1,0.033596847180628185
1048,APOA1,HDL remodeling,0.03523976432533112,0,0,1,0.037089687704199244
1049,APOA1,HDL remodeling,0.03192113630510451,1,0,1,0.033596847180628185
1050,APOA1,HDL clearance,0.03523976432533112,0,0,1,0.037089687704199244
1051,APOA1,HDL clearance,0.03192113630510451,1,0,1,0.033596847180628185
1052,APOA1,Scavenging of heme from plasma,0.03523976432533112,0,0,1,0.037089687704199244
1053,APOA1,Scavenging of heme from plasma,0.03192113630510451,1,0,1,0.033596847180628185
1054,APOA1,Scavenging by Class B Receptors,0.03523976432533112,0,0,1,0.037089687704199244
1055,APOA1,Scavenging by Class B Receptors,0.03192113630510451,1,0,1,0.033596847180628185
1056,APOA1,Scavenging by Class A Receptors,0.03523976432533112,0,0,1,0.037089687704199244
1057,APOA1,Scavenging by Class A Receptors,0.03192113630510451,1,0,1,0.033596847180628185
1058,APOA1,Retinoid metabolism and transport,0.03523976432533112,0,0,1,0.037089687704199244
1059,APOA1,Retinoid metabolism and transport,0.03192113630510451,1,0,1,0.033596847180628185
1060,APOA1,Heme signaling,0.03523976432533112,0,0,1,0.037089687704199244
1061,APOA1,Heme signaling,0.03192113630510451,1,0,1,0.033596847180628185
1062,APOA1,ABC transporters in lipid homeostasis,0.03523976432533112,0,0,1,0.037089687704199244
1063,APOA1,ABC transporters in lipid homeostasis,0.03192113630510451,1,0,1,0.033596847180628185
1064,APOA1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.03523976432533112,0,0,1,0.037089687704199244
1065,APOA1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.03192113630510451,1,0,1,0.033596847180628185
1066,APOA1,Amyloid fiber formation,0.03523976432533112,0,0,1,0.037089687704199244
1067,APOA1,Amyloid fiber formation,0.03192113630510451,1,0,1,0.033596847180628185
1068,APOA1,Post-translational protein phosphorylation,0.03523976432533112,0,0,1,0.037089687704199244
1069,APOA1,Post-translational protein phosphorylation,0.03192113630510451,1,0,1,0.033596847180628185
1070,APOE,Nuclear signaling by ERBB4,0.05741348607223234,0,0,1,0.0604274264938201
1071,APOE,Nuclear signaling by ERBB4,0.05465097187004795,1,0,1,0.05751989317176031
1072,APOE,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,0.05741348607223234,0,0,1,0.0604274264938201
1073,APOE,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,0.05465097187004795,1,0,1,0.05751989317176031
1074,APOE,Chylomicron assembly,0.05741348607223234,0,0,1,0.0604274264938201
1075,APOE,Chylomicron assembly,0.05465097187004795,1,0,1,0.05751989317176031
1076,APOE,Chylomicron remodeling,0.05741348607223234,0,0,1,0.0604274264938201
1077,APOE,Chylomicron remodeling,0.05465097187004795,1,0,1,0.05751989317176031
1078,APOE,HDL remodeling,0.05741348607223234,0,0,1,0.0604274264938201
1079,APOE,HDL remodeling,0.05465097187004795,1,0,1,0.05751989317176031
1080,APOE,Chylomicron clearance,0.05741348607223234,0,0,1,0.0604274264938201
1081,APOE,Chylomicron clearance,0.05465097187004795,1,0,1,0.05751989317176031
1082,APOE,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.05741348607223234,0,0,1,0.0604274264938201
1083,APOE,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.05465097187004795,1,0,1,0.05751989317176031
1084,APOE,Scavenging by Class A Receptors,0.05741348607223234,0,0,1,0.0604274264938201
1085,APOE,Scavenging by Class A Receptors,0.05465097187004795,1,0,1,0.05751989317176031
1086,APOE,Retinoid metabolism and transport,0.05741348607223234,0,0,1,0.0604274264938201
1087,APOE,Retinoid metabolism and transport,0.05465097187004795,1,0,1,0.05751989317176031
1088,APOE,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.05741348607223234,0,0,1,0.0604274264938201
1089,APOE,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.05465097187004795,1,0,1,0.05751989317176031
1090,APOE,Amyloid fiber formation,0.05741348607223234,0,0,1,0.0604274264938201
1091,APOE,Amyloid fiber formation,0.05465097187004795,1,0,1,0.05751989317176031
1092,APOE,Post-translational protein phosphorylation,0.05741348607223234,0,0,1,0.0604274264938201
1093,APOE,Post-translational protein phosphorylation,0.05465097187004795,1,0,1,0.05751989317176031
1094,FIBA,Antigen processing-Cross presentation,0.25314211781917856,0,0,1,0.26643089914037676
1095,FIBA,Antigen processing-Cross presentation,0.2526101321319415,1,0,1,0.26587098668407966
1096,FIBA,Toll Like Receptor 4 (TLR4) Cascade,0.25314211781917856,0,0,1,0.26643089914037676
1097,FIBA,Toll Like Receptor 4 (TLR4) Cascade,0.2526101321319415,1,0,1,0.26587098668407966
1098,FIBA,Toll Like Receptor 2 (TLR2) Cascade,0.25314211781917856,0,0,1,0.26643089914037676
1099,FIBA,Toll Like Receptor 2 (TLR2) Cascade,0.2526101321319415,1,0,1,0.26587098668407966
1100,FIBA,Regulation of TLR by endogenous ligand,0.25314211781917856,0,0,1,0.26643089914037676
1101,FIBA,Regulation of TLR by endogenous ligand,0.2526101321319415,1,0,1,0.26587098668407966
1102,FIBA,MyD88 deficiency (TLR2/4),0.25314211781917856,0,0,1,0.26643089914037676
1103,FIBA,MyD88 deficiency (TLR2/4),0.2526101321319415,1,0,1,0.26587098668407966
1104,FIBA,IRAK4 deficiency (TLR2/4),0.25314211781917856,0,0,1,0.26643089914037676
1105,FIBA,IRAK4 deficiency (TLR2/4),0.2526101321319415,1,0,1,0.26587098668407966
1106,FIBA,RAF/MAP kinase cascade,0.25314211781917856,0,0,1,0.26643089914037676
1107,FIBA,RAF/MAP kinase cascade,0.2526101321319415,1,0,1,0.26587098668407966
1108,FIBA,Signaling by RAS mutants,0.25314211781917856,0,0,1,0.26643089914037676
1109,FIBA,Signaling by RAS mutants,0.2526101321319415,1,0,1,0.26587098668407966
1110,FIBA,Signaling by moderate kinase activity BRAF mutants,0.25314211781917856,0,0,1,0.26643089914037676
1111,FIBA,Signaling by moderate kinase activity BRAF mutants,0.2526101321319415,1,0,1,0.26587098668407966
1112,FIBA,Signaling by high-kinase activity BRAF mutants,0.25314211781917856,0,0,1,0.26643089914037676
1113,FIBA,Signaling by high-kinase activity BRAF mutants,0.2526101321319415,1,0,1,0.26587098668407966
1114,FIBA,Signaling by BRAF and RAF1 fusions,0.25314211781917856,0,0,1,0.26643089914037676
1115,FIBA,Signaling by BRAF and RAF1 fusions,0.2526101321319415,1,0,1,0.26587098668407966
1116,FIBA,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.25314211781917856,0,0,1,0.26643089914037676
1117,FIBA,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.2526101321319415,1,0,1,0.26587098668407966
1118,FIBA,Signaling by RAF1 mutants,0.25314211781917856,0,0,1,0.26643089914037676
1119,FIBA,Signaling by RAF1 mutants,0.2526101321319415,1,0,1,0.26587098668407966
1120,FIBA,Platelet degranulation ,0.25314211781917856,0,0,1,0.26643089914037676
1121,FIBA,Platelet degranulation ,0.2526101321319415,1,0,1,0.26587098668407966
1122,FIBA,Common Pathway of Fibrin Clot Formation,0.25314211781917856,0,0,1,0.26643089914037676
1123,FIBA,Common Pathway of Fibrin Clot Formation,0.2526101321319415,1,0,1,0.26587098668407966
1124,FIBA,Integrin cell surface interactions,0.25314211781917856,0,0,1,0.26643089914037676
1125,FIBA,Integrin cell surface interactions,0.2526101321319415,1,0,1,0.26587098668407966
1126,FIBA,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.25314211781917856,0,0,1,0.26643089914037676
1127,FIBA,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.2526101321319415,1,0,1,0.26587098668407966
1128,FIBA,p130Cas linkage to MAPK signaling for integrins,0.25314211781917856,0,0,1,0.26643089914037676
1129,FIBA,p130Cas linkage to MAPK signaling for integrins,0.2526101321319415,1,0,1,0.26587098668407966
1130,FIBA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.25314211781917856,0,0,1,0.26643089914037676
1131,FIBA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.2526101321319415,1,0,1,0.26587098668407966
1132,FIBA,Amyloid fiber formation,0.25314211781917856,0,0,1,0.26643089914037676
1133,FIBA,Amyloid fiber formation,0.2526101321319415,1,0,1,0.26587098668407966
1134,FIBA,Post-translational protein phosphorylation,0.25314211781917856,0,0,1,0.26643089914037676
1135,FIBA,Post-translational protein phosphorylation,0.2526101321319415,1,0,1,0.26587098668407966
1136,FIBB,Antigen processing-Cross presentation,0.1994360256985118,0,0,1,0.20990548750087173
1137,FIBB,Antigen processing-Cross presentation,0.21412961909677924,1,0,1,0.22537042606751473
1138,FIBB,Toll Like Receptor 4 (TLR4) Cascade,0.1994360256985118,0,0,1,0.20990548750087173
1139,FIBB,Toll Like Receptor 4 (TLR4) Cascade,0.21412961909677924,1,0,1,0.22537042606751473
1140,FIBB,Toll Like Receptor 2 (TLR2) Cascade,0.1994360256985118,0,0,1,0.20990548750087173
1141,FIBB,Toll Like Receptor 2 (TLR2) Cascade,0.21412961909677924,1,0,1,0.22537042606751473
1142,FIBB,Regulation of TLR by endogenous ligand,0.1994360256985118,0,0,1,0.20990548750087173
1143,FIBB,Regulation of TLR by endogenous ligand,0.21412961909677924,1,0,1,0.22537042606751473
1144,FIBB,MyD88 deficiency (TLR2/4),0.1994360256985118,0,0,1,0.20990548750087173
1145,FIBB,MyD88 deficiency (TLR2/4),0.21412961909677924,1,0,1,0.22537042606751473
1146,FIBB,IRAK4 deficiency (TLR2/4),0.1994360256985118,0,0,1,0.20990548750087173
1147,FIBB,IRAK4 deficiency (TLR2/4),0.21412961909677924,1,0,1,0.22537042606751473
1148,FIBB,RAF/MAP kinase cascade,0.1994360256985118,0,0,1,0.20990548750087173
1149,FIBB,RAF/MAP kinase cascade,0.21412961909677924,1,0,1,0.22537042606751473
1150,FIBB,Signaling by RAS mutants,0.1994360256985118,0,0,1,0.20990548750087173
1151,FIBB,Signaling by RAS mutants,0.21412961909677924,1,0,1,0.22537042606751473
1152,FIBB,Signaling by moderate kinase activity BRAF mutants,0.1994360256985118,0,0,1,0.20990548750087173
1153,FIBB,Signaling by moderate kinase activity BRAF mutants,0.21412961909677924,1,0,1,0.22537042606751473
1154,FIBB,Signaling by high-kinase activity BRAF mutants,0.1994360256985118,0,0,1,0.20990548750087173
1155,FIBB,Signaling by high-kinase activity BRAF mutants,0.21412961909677924,1,0,1,0.22537042606751473
1156,FIBB,Signaling by BRAF and RAF1 fusions,0.1994360256985118,0,0,1,0.20990548750087173
1157,FIBB,Signaling by BRAF and RAF1 fusions,0.21412961909677924,1,0,1,0.22537042606751473
1158,FIBB,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.1994360256985118,0,0,1,0.20990548750087173
1159,FIBB,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.21412961909677924,1,0,1,0.22537042606751473
1160,FIBB,Signaling by RAF1 mutants,0.1994360256985118,0,0,1,0.20990548750087173
1161,FIBB,Signaling by RAF1 mutants,0.21412961909677924,1,0,1,0.22537042606751473
1162,FIBB,Platelet degranulation ,0.1994360256985118,0,0,1,0.20990548750087173
1163,FIBB,Platelet degranulation ,0.21412961909677924,1,0,1,0.22537042606751473
1164,FIBB,Common Pathway of Fibrin Clot Formation,0.1994360256985118,0,0,1,0.20990548750087173
1165,FIBB,Common Pathway of Fibrin Clot Formation,0.21412961909677924,1,0,1,0.22537042606751473
1166,FIBB,Integrin cell surface interactions,0.1994360256985118,0,0,1,0.20990548750087173
1167,FIBB,Integrin cell surface interactions,0.21412961909677924,1,0,1,0.22537042606751473
1168,FIBB,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.1994360256985118,0,0,1,0.20990548750087173
1169,FIBB,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.21412961909677924,1,0,1,0.22537042606751473
1170,FIBB,p130Cas linkage to MAPK signaling for integrins,0.1994360256985118,0,0,1,0.20990548750087173
1171,FIBB,p130Cas linkage to MAPK signaling for integrins,0.21412961909677924,1,0,1,0.22537042606751473
1172,CRP,Initial triggering of complement,0.0036503486569812956,0,0,1,0.0038419749476462264
1173,CRP,Initial triggering of complement,0.0034875390560274544,1,0,1,0.0036706186014778546
1174,SAMP,Amyloid fiber formation,0.06255289590619459,0,0,1,0.06583663138990759
1175,SAMP,Amyloid fiber formation,0.05450954450382109,1,0,1,0.057371041527982114
1176,C1QA,Initial triggering of complement,0.03429188719479753,0,0,1,0.036092051442251485
1177,C1QA,Initial triggering of complement,0.03274649626396218,1,0,1,0.03446553469042452
1178,C1QA,Regulation of Complement cascade,0.03429188719479753,0,0,1,0.036092051442251485
1179,C1QA,Regulation of Complement cascade,0.03274649626396218,1,0,1,0.03446553469042452
1180,C1QC,Initial triggering of complement,0.019391144433710716,0,0,1,0.020409089136738827
1181,C1QC,Initial triggering of complement,0.018506692287455252,1,0,1,0.01947820737512774
1182,C1QC,Regulation of Complement cascade,0.019391144433710716,0,0,1,0.020409089136738827
1183,C1QC,Regulation of Complement cascade,0.018506692287455252,1,0,1,0.01947820737512774
1184,CO9,Terminal pathway of complement,0.136608781036021,0,0,1,0.14378010532366825
1185,CO9,Terminal pathway of complement,0.13917326018695633,1,0,1,0.14647920767730543
1186,CO9,Regulation of Complement cascade,0.136608781036021,0,0,1,0.14378010532366825
1187,CO9,Regulation of Complement cascade,0.13917326018695633,1,0,1,0.14647920767730543
1188,APOH,Platelet degranulation ,0.021437047791517914,0,0,1,0.022562392885126726
1189,APOH,Platelet degranulation ,0.027382994371340397,1,0,1,0.028820473947063434
1190,A2GL,Neutrophil degranulation,0.032852375642343085,0,0,1,0.03457697224267966
1191,A2GL,Neutrophil degranulation,0.03168732385578647,1,0,1,0.033350760667492055
1192,AMBP,Scavenging of heme from plasma,0.027718892739235102,0,0,1,0.02917400541369159
1193,AMBP,Scavenging of heme from plasma,0.025778449635144376,1,0,1,0.027131698090802996
1194,A1AG1,Platelet degranulation ,0.03149214061525434,0,0,1,0.03314533121655709
1195,A1AG1,Platelet degranulation ,0.03320201078199518,1,0,1,0.03494496159755706
1196,A1AG1,Neutrophil degranulation,0.03149214061525434,0,0,1,0.03314533121655709
1197,A1AG1,Neutrophil degranulation,0.03320201078199518,1,0,1,0.03494496159755706
1198,FETUA,Platelet degranulation ,0.027272065091796065,0,0,1,0.02870372139737077
1199,FETUA,Platelet degranulation ,0.02481751952020582,1,0,1,0.02612032362360736
1200,FETUA,Neutrophil degranulation,0.027272065091796065,0,0,1,0.02870372139737077
1201,FETUA,Neutrophil degranulation,0.02481751952020582,1,0,1,0.02612032362360736
1202,FETUA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.027272065091796065,0,0,1,0.02870372139737077
1203,FETUA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.02481751952020582,1,0,1,0.02612032362360736
1204,FETUA,Post-translational protein phosphorylation,0.027272065091796065,0,0,1,0.02870372139737077
1205,FETUA,Post-translational protein phosphorylation,0.02481751952020582,1,0,1,0.02612032362360736
1206,CXCL7,Class A/1 (Rhodopsin-like receptors),0.0951746152899836,0,0,1,0.10017083899551957
1207,CXCL7,Class A/1 (Rhodopsin-like receptors),0.09612582160743709,1,0,1,0.10117197921118358
1208,CXCL7,G alpha (i) signalling events,0.0951746152899836,0,0,1,0.10017083899551957
1209,CXCL7,G alpha (i) signalling events,0.09612582160743709,1,0,1,0.10117197921118358
1210,CXCL7,Platelet degranulation ,0.0951746152899836,0,0,1,0.10017083899551957
1211,CXCL7,Platelet degranulation ,0.09612582160743709,1,0,1,0.10117197921118358
1212,CXCL7,Neutrophil degranulation,0.0951746152899836,0,0,1,0.10017083899551957
1213,CXCL7,Neutrophil degranulation,0.09612582160743709,1,0,1,0.10117197921118358
1214,PLF4,Transcriptional regulation by RUNX1,0.07771360813887511,0,0,1,0.08179321035258685
1215,PLF4,Transcriptional regulation by RUNX1,0.08861594780343743,1,0,1,0.09326787203507304
1216,PLF4,Class A/1 (Rhodopsin-like receptors),0.07771360813887511,0,0,1,0.08179321035258685
1217,PLF4,Class A/1 (Rhodopsin-like receptors),0.08861594780343743,1,0,1,0.09326787203507304
1218,PLF4,G alpha (i) signalling events,0.07771360813887511,0,0,1,0.08179321035258685
1219,PLF4,G alpha (i) signalling events,0.08861594780343743,1,0,1,0.09326787203507304
1220,PLF4,Platelet degranulation ,0.07771360813887511,0,0,1,0.08179321035258685
1221,PLF4,Platelet degranulation ,0.08861594780343743,1,0,1,0.09326787203507304
1222,PLF4,Cell surface interactions at the vascular wall,0.07771360813887511,0,0,1,0.08179321035258685
1223,PLF4,Cell surface interactions at the vascular wall,0.08861594780343743,1,0,1,0.09326787203507304
1224,PLF4,Common Pathway of Fibrin Clot Formation,0.07771360813887511,0,0,1,0.08179321035258685
1225,PLF4,Common Pathway of Fibrin Clot Formation,0.08861594780343743,1,0,1,0.09326787203507304
1226,TRFE,Platelet degranulation ,0.011171161337701883,0,0,1,0.01175759524052079
1227,TRFE,Platelet degranulation ,0.014580042289273242,1,0,1,0.015345426553674364
1228,TRFE,Cargo recognition for clathrin-mediated endocytosis,0.011171161337701883,0,0,1,0.01175759524052079
1229,TRFE,Cargo recognition for clathrin-mediated endocytosis,0.014580042289273242,1,0,1,0.015345426553674364
1230,TRFE,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.011171161337701883,0,0,1,0.01175759524052079
1231,TRFE,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.014580042289273242,1,0,1,0.015345426553674364
1232,TRFE,Post-translational protein phosphorylation,0.011171161337701883,0,0,1,0.01175759524052079
1233,TRFE,Post-translational protein phosphorylation,0.014580042289273242,1,0,1,0.015345426553674364
1234,TRFE,Transferrin endocytosis and recycling,0.011171161337701883,0,0,1,0.01175759524052079
1235,TRFE,Transferrin endocytosis and recycling,0.014580042289273242,1,0,1,0.015345426553674364
1236,HEMO,Scavenging of heme from plasma,0.013355590472412481,0,0,1,0.014056696723447889
1237,HEMO,Scavenging of heme from plasma,0.012437899415055065,1,0,1,0.013090831162824473
1238,ANGI,Adherens junctions interactions,0.010602016820783777,0,0,1,0.011158573289177147
1239,ANGI,Adherens junctions interactions,0.006690380238851415,1,0,1,0.007041594018350839
1240,ANGI,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",0.010602016820783777,0,0,1,0.011158573289177147
1241,ANGI,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",0.006690380238851415,1,0,1,0.007041594018350839
1242,C4BPA,Regulation of Complement cascade,0.09610731323566828,0,0,1,0.10115249923616217
1243,C4BPA,Regulation of Complement cascade,0.09175257030174312,1,0,1,0.0965691525951277
1244,VTNC,Regulation of Complement cascade,0.2212848804001404,0,0,1,0.23290130523950855
1245,VTNC,Regulation of Complement cascade,0.23023818503696344,1,0,1,0.24232461663951194
1246,VTNC,Integrin cell surface interactions,0.2212848804001404,0,0,1,0.23290130523950855
1247,VTNC,Integrin cell surface interactions,0.23023818503696344,1,0,1,0.24232461663951194
1248,VTNC,ECM proteoglycans,0.2212848804001404,0,0,1,0.23290130523950855
1249,VTNC,ECM proteoglycans,0.23023818503696344,1,0,1,0.24232461663951194
1250,VTNC,Molecules associated with elastic fibres,0.2212848804001404,0,0,1,0.23290130523950855
1251,VTNC,Molecules associated with elastic fibres,0.23023818503696344,1,0,1,0.24232461663951194
1252,VTNC,Syndecan interactions,0.2212848804001404,0,0,1,0.23290130523950855
1253,VTNC,Syndecan interactions,0.23023818503696344,1,0,1,0.24232461663951194
1254,CATA,FOXO-mediated transcription,0.0033752182636360506,0,0,1,0.003552401490999315
1255,CATA,FOXO-mediated transcription,0.003307264839503734,1,0,1,0.0034808808288226125
1256,CATA,Detoxification of Reactive Oxygen Species,0.0033752182636360506,0,0,1,0.003552401490999315
1257,CATA,Detoxification of Reactive Oxygen Species,0.003307264839503734,1,0,1,0.0034808808288226125
1258,CATA,Neutrophil degranulation,0.0033752182636360506,0,0,1,0.003552401490999315
1259,CATA,Neutrophil degranulation,0.003307264839503734,1,0,1,0.0034808808288226125
1260,CATA,Peroxisomal protein import,0.0033752182636360506,0,0,1,0.003552401490999315
1261,CATA,Peroxisomal protein import,0.003307264839503734,1,0,1,0.0034808808288226125
1262,APOB,Regulation of TLR by endogenous ligand,0.01832496248813265,0,0,1,0.019286937608360966
1263,APOB,Regulation of TLR by endogenous ligand,0.017349401398495532,1,0,1,0.018260164108488273
1264,APOB,Cargo recognition for clathrin-mediated endocytosis,0.01832496248813265,0,0,1,0.019286937608360966
1265,APOB,Cargo recognition for clathrin-mediated endocytosis,0.017349401398495532,1,0,1,0.018260164108488273
1266,APOB,VLDL assembly,0.01832496248813265,0,0,1,0.019286937608360966
1267,APOB,VLDL assembly,0.017349401398495532,1,0,1,0.018260164108488273
1268,APOB,Chylomicron assembly,0.01832496248813265,0,0,1,0.019286937608360966
1269,APOB,Chylomicron assembly,0.017349401398495532,1,0,1,0.018260164108488273
1270,APOB,Chylomicron remodeling,0.01832496248813265,0,0,1,0.019286937608360966
1271,APOB,Chylomicron remodeling,0.017349401398495532,1,0,1,0.018260164108488273
1272,APOB,LDL remodeling,0.01832496248813265,0,0,1,0.019286937608360966
1273,APOB,LDL remodeling,0.017349401398495532,1,0,1,0.018260164108488273
1274,APOB,Chylomicron clearance,0.01832496248813265,0,0,1,0.019286937608360966
1275,APOB,Chylomicron clearance,0.017349401398495532,1,0,1,0.018260164108488273
1276,APOB,LDL clearance,0.01832496248813265,0,0,1,0.019286937608360966
1277,APOB,LDL clearance,0.017349401398495532,1,0,1,0.018260164108488273
1278,APOB,VLDL clearance,0.01832496248813265,0,0,1,0.019286937608360966
1279,APOB,VLDL clearance,0.017349401398495532,1,0,1,0.018260164108488273
1280,APOB,Cell surface interactions at the vascular wall,0.01832496248813265,0,0,1,0.019286937608360966
1281,APOB,Cell surface interactions at the vascular wall,0.017349401398495532,1,0,1,0.018260164108488273
1282,APOB,Scavenging by Class B Receptors,0.01832496248813265,0,0,1,0.019286937608360966
1283,APOB,Scavenging by Class B Receptors,0.017349401398495532,1,0,1,0.018260164108488273
1284,APOB,Scavenging by Class A Receptors,0.01832496248813265,0,0,1,0.019286937608360966
1285,APOB,Scavenging by Class A Receptors,0.017349401398495532,1,0,1,0.018260164108488273
1286,APOB,Scavenging by Class F Receptors,0.01832496248813265,0,0,1,0.019286937608360966
1287,APOB,Scavenging by Class F Receptors,0.017349401398495532,1,0,1,0.018260164108488273
1288,APOB,Scavenging by Class H Receptors,0.01832496248813265,0,0,1,0.019286937608360966
1289,APOB,Scavenging by Class H Receptors,0.017349401398495532,1,0,1,0.018260164108488273
1290,APOB,Retinoid metabolism and transport,0.01832496248813265,0,0,1,0.019286937608360966
1291,APOB,Retinoid metabolism and transport,0.017349401398495532,1,0,1,0.018260164108488273
1292,APOB,Heme signaling,0.01832496248813265,0,0,1,0.019286937608360966
1293,APOB,Heme signaling,0.017349401398495532,1,0,1,0.018260164108488273
1294,APOB,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.01832496248813265,0,0,1,0.019286937608360966
1295,APOB,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.017349401398495532,1,0,1,0.018260164108488273
1296,APOB,Platelet sensitization by LDL,0.01832496248813265,0,0,1,0.019286937608360966
1297,APOB,Platelet sensitization by LDL,0.017349401398495532,1,0,1,0.018260164108488273
1298,APOB,Post-translational protein phosphorylation,0.01832496248813265,0,0,1,0.019286937608360966
1299,APOB,Post-translational protein phosphorylation,0.017349401398495532,1,0,1,0.018260164108488273
1300,LCAT,HDL remodeling,0.025114382230618362,0,0,1,0.026432770242675947
1301,LCAT,HDL remodeling,0.022405422632932576,1,0,1,0.0235816028922395
1302,HRG,Platelet degranulation ,0.08307269356336675,0,0,1,0.08743362278382559
1303,HRG,Platelet degranulation ,0.0970186541525994,1,0,1,0.10211168130358413
1304,HRG,Dissolution of Fibrin Clot,0.08307269356336675,0,0,1,0.08743362278382559
1305,HRG,Dissolution of Fibrin Clot,0.0970186541525994,1,0,1,0.10211168130358413
1306,LV743,Initial triggering of complement,0.11070526456055434,0,0,1,0.1165167749663472
1307,LV743,Initial triggering of complement,0.10981659841350311,1,0,1,0.11558145798853951
1308,LV743,Regulation of Complement cascade,0.11070526456055434,0,0,1,0.1165167749663472
1309,LV743,Regulation of Complement cascade,0.10981659841350311,1,0,1,0.11558145798853951
1310,LV743,FCGR activation,0.11070526456055434,0,0,1,0.1165167749663472
1311,LV743,FCGR activation,0.10981659841350311,1,0,1,0.11558145798853951
1312,LV743,Regulation of actin dynamics for phagocytic cup formation,0.11070526456055434,0,0,1,0.1165167749663472
1313,LV743,Regulation of actin dynamics for phagocytic cup formation,0.10981659841350311,1,0,1,0.11558145798853951
1314,LV743,Role of phospholipids in phagocytosis,0.11070526456055434,0,0,1,0.1165167749663472
1315,LV743,Role of phospholipids in phagocytosis,0.10981659841350311,1,0,1,0.11558145798853951
1316,LV743,Role of LAT2/NTAL/LAB on calcium mobilization,0.11070526456055434,0,0,1,0.1165167749663472
1317,LV743,Role of LAT2/NTAL/LAB on calcium mobilization,0.10981659841350311,1,0,1,0.11558145798853951
1318,LV743,FCERI mediated MAPK activation,0.11070526456055434,0,0,1,0.1165167749663472
1319,LV743,FCERI mediated MAPK activation,0.10981659841350311,1,0,1,0.11558145798853951
1320,LV743,FCERI mediated Ca+2 mobilization,0.11070526456055434,0,0,1,0.1165167749663472
1321,LV743,FCERI mediated Ca+2 mobilization,0.10981659841350311,1,0,1,0.11558145798853951
1322,LV743,FCERI mediated NF-kB activation,0.11070526456055434,0,0,1,0.1165167749663472
1323,LV743,FCERI mediated NF-kB activation,0.10981659841350311,1,0,1,0.11558145798853951
1324,LV743,Parasite infection,0.11070526456055434,0,0,1,0.1165167749663472
1325,LV743,Parasite infection,0.10981659841350311,1,0,1,0.11558145798853951
1326,LV743,Leishmania parasite growth and survival,0.11070526456055434,0,0,1,0.1165167749663472
1327,LV743,Leishmania parasite growth and survival,0.10981659841350311,1,0,1,0.11558145798853951
1328,LV743,Potential therapeutics for SARS,0.11070526456055434,0,0,1,0.1165167749663472
1329,LV743,Potential therapeutics for SARS,0.10981659841350311,1,0,1,0.11558145798853951
1330,LV743,CD22 mediated BCR regulation,0.11070526456055434,0,0,1,0.1165167749663472
1331,LV743,CD22 mediated BCR regulation,0.10981659841350311,1,0,1,0.11558145798853951
1332,LV743,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.11070526456055434,0,0,1,0.1165167749663472
1333,LV743,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.10981659841350311,1,0,1,0.11558145798853951
1334,LV743,Cell surface interactions at the vascular wall,0.11070526456055434,0,0,1,0.1165167749663472
1335,LV743,Cell surface interactions at the vascular wall,0.10981659841350311,1,0,1,0.11558145798853951
1336,LV743,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.11070526456055434,0,0,1,0.1165167749663472
1337,LV743,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.10981659841350311,1,0,1,0.11558145798853951
1338,LV743,Scavenging of heme from plasma,0.11070526456055434,0,0,1,0.1165167749663472
1339,LV743,Scavenging of heme from plasma,0.10981659841350311,1,0,1,0.11558145798853951
1340,K2C1,Neutrophil degranulation,0.0005539889794106231,0,0,1,0.000583070818755114
1341,K2C1,Neutrophil degranulation,0.0005046068946605971,1,0,1,0.0005310964047195414
1342,K2C1,Formation of the cornified envelope,0.0005539889794106231,0,0,1,0.000583070818755114
1343,K2C1,Formation of the cornified envelope,0.0005046068946605971,1,0,1,0.0005310964047195414
1344,VWF,RAF/MAP kinase cascade,0.04097212547144475,0,0,1,0.04312297109265285
1345,VWF,RAF/MAP kinase cascade,0.0397740565172896,1,0,1,0.04186200910245675
1346,VWF,Signaling by RAS mutants,0.04097212547144475,0,0,1,0.04312297109265285
1347,VWF,Signaling by RAS mutants,0.0397740565172896,1,0,1,0.04186200910245675
1348,VWF,Signaling by moderate kinase activity BRAF mutants,0.04097212547144475,0,0,1,0.04312297109265285
1349,VWF,Signaling by moderate kinase activity BRAF mutants,0.0397740565172896,1,0,1,0.04186200910245675
1350,VWF,Signaling by high-kinase activity BRAF mutants,0.04097212547144475,0,0,1,0.04312297109265285
1351,VWF,Signaling by high-kinase activity BRAF mutants,0.0397740565172896,1,0,1,0.04186200910245675
1352,VWF,Signaling by BRAF and RAF1 fusions,0.04097212547144475,0,0,1,0.04312297109265285
1353,VWF,Signaling by BRAF and RAF1 fusions,0.0397740565172896,1,0,1,0.04186200910245675
1354,VWF,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.04097212547144475,0,0,1,0.04312297109265285
1355,VWF,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0397740565172896,1,0,1,0.04186200910245675
1356,VWF,Signaling by RAF1 mutants,0.04097212547144475,0,0,1,0.04312297109265285
1357,VWF,Signaling by RAF1 mutants,0.0397740565172896,1,0,1,0.04186200910245675
1358,VWF,Platelet degranulation ,0.04097212547144475,0,0,1,0.04312297109265285
1359,VWF,Platelet degranulation ,0.0397740565172896,1,0,1,0.04186200910245675
1360,VWF,Defective factor VIII causes hemophilia A,0.04097212547144475,0,0,1,0.04312297109265285
1361,VWF,Defective factor VIII causes hemophilia A,0.0397740565172896,1,0,1,0.04186200910245675
1362,VWF,Platelet Adhesion to exposed collagen,0.04097212547144475,0,0,1,0.04312297109265285
1363,VWF,Platelet Adhesion to exposed collagen,0.0397740565172896,1,0,1,0.04186200910245675
1364,VWF,Intrinsic Pathway of Fibrin Clot Formation,0.04097212547144475,0,0,1,0.04312297109265285
1365,VWF,Intrinsic Pathway of Fibrin Clot Formation,0.0397740565172896,1,0,1,0.04186200910245675
1366,VWF,Integrin cell surface interactions,0.04097212547144475,0,0,1,0.04312297109265285
1367,VWF,Integrin cell surface interactions,0.0397740565172896,1,0,1,0.04186200910245675
1368,VWF,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.04097212547144475,0,0,1,0.04312297109265285
1369,VWF,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0397740565172896,1,0,1,0.04186200910245675
1370,VWF,p130Cas linkage to MAPK signaling for integrins,0.04097212547144475,0,0,1,0.04312297109265285
1371,VWF,p130Cas linkage to MAPK signaling for integrins,0.0397740565172896,1,0,1,0.04186200910245675
1372,VWF,GP1b-IX-V activation signalling,0.04097212547144475,0,0,1,0.04312297109265285
1373,VWF,GP1b-IX-V activation signalling,0.0397740565172896,1,0,1,0.04186200910245675
1374,KV116,Initial triggering of complement,0.05399008389283422,0,0,1,0.05682431165606052
1375,KV116,Initial triggering of complement,0.05631994664953607,1,0,1,0.05927648134828518
1376,KV116,Regulation of Complement cascade,0.05399008389283422,0,0,1,0.05682431165606052
1377,KV116,Regulation of Complement cascade,0.05631994664953607,1,0,1,0.05927648134828518
1378,KV116,FCGR activation,0.05399008389283422,0,0,1,0.05682431165606052
1379,KV116,FCGR activation,0.05631994664953607,1,0,1,0.05927648134828518
1380,KV116,Regulation of actin dynamics for phagocytic cup formation,0.05399008389283422,0,0,1,0.05682431165606052
1381,KV116,Regulation of actin dynamics for phagocytic cup formation,0.05631994664953607,1,0,1,0.05927648134828518
1382,KV116,Role of phospholipids in phagocytosis,0.05399008389283422,0,0,1,0.05682431165606052
1383,KV116,Role of phospholipids in phagocytosis,0.05631994664953607,1,0,1,0.05927648134828518
1384,KV116,Role of LAT2/NTAL/LAB on calcium mobilization,0.05399008389283422,0,0,1,0.05682431165606052
1385,KV116,Role of LAT2/NTAL/LAB on calcium mobilization,0.05631994664953607,1,0,1,0.05927648134828518
1386,KV116,FCERI mediated MAPK activation,0.05399008389283422,0,0,1,0.05682431165606052
1387,KV116,FCERI mediated MAPK activation,0.05631994664953607,1,0,1,0.05927648134828518
1388,KV116,FCERI mediated Ca+2 mobilization,0.05399008389283422,0,0,1,0.05682431165606052
1389,KV116,FCERI mediated Ca+2 mobilization,0.05631994664953607,1,0,1,0.05927648134828518
1390,KV116,FCERI mediated NF-kB activation,0.05399008389283422,0,0,1,0.05682431165606052
1391,KV116,FCERI mediated NF-kB activation,0.05631994664953607,1,0,1,0.05927648134828518
1392,KV116,Parasite infection,0.05399008389283422,0,0,1,0.05682431165606052
1393,KV116,Parasite infection,0.05631994664953607,1,0,1,0.05927648134828518
1394,KV116,Leishmania parasite growth and survival,0.05399008389283422,0,0,1,0.05682431165606052
1395,KV116,Leishmania parasite growth and survival,0.05631994664953607,1,0,1,0.05927648134828518
1396,KV116,Potential therapeutics for SARS,0.05399008389283422,0,0,1,0.05682431165606052
1397,KV116,Potential therapeutics for SARS,0.05631994664953607,1,0,1,0.05927648134828518
1398,KV116,CD22 mediated BCR regulation,0.05399008389283422,0,0,1,0.05682431165606052
1399,KV116,CD22 mediated BCR regulation,0.05631994664953607,1,0,1,0.05927648134828518
1400,KV116,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.05399008389283422,0,0,1,0.05682431165606052
1401,KV116,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.05631994664953607,1,0,1,0.05927648134828518
1402,KV116,Cell surface interactions at the vascular wall,0.05399008389283422,0,0,1,0.05682431165606052
1403,KV116,Cell surface interactions at the vascular wall,0.05631994664953607,1,0,1,0.05927648134828518
1404,KV116,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.05399008389283422,0,0,1,0.05682431165606052
1405,KV116,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.05631994664953607,1,0,1,0.05927648134828518
1406,KV116,Scavenging of heme from plasma,0.05399008389283422,0,0,1,0.05682431165606052
1407,KV116,Scavenging of heme from plasma,0.05631994664953607,1,0,1,0.05927648134828518
1408,S10A8,Antigen processing-Cross presentation,0.09267973745380109,0,0,1,0.09754499170125654
1409,S10A8,Antigen processing-Cross presentation,0.09107858486077636,1,0,1,0.09585978605987351
1410,S10A8,Toll Like Receptor 4 (TLR4) Cascade,0.09267973745380109,0,0,1,0.09754499170125654
1411,S10A8,Toll Like Receptor 4 (TLR4) Cascade,0.09107858486077636,1,0,1,0.09585978605987351
1412,S10A8,Toll Like Receptor 2 (TLR2) Cascade,0.09267973745380109,0,0,1,0.09754499170125654
1413,S10A8,Toll Like Receptor 2 (TLR2) Cascade,0.09107858486077636,1,0,1,0.09585978605987351
1414,S10A8,Regulation of TLR by endogenous ligand,0.09267973745380109,0,0,1,0.09754499170125654
1415,S10A8,Regulation of TLR by endogenous ligand,0.09107858486077636,1,0,1,0.09585978605987351
1416,S10A8,RHO GTPase Effectors,0.09267973745380109,0,0,1,0.09754499170125654
1417,S10A8,RHO GTPase Effectors,0.09107858486077636,1,0,1,0.09585978605987351
1418,S10A8,MyD88 deficiency (TLR2/4),0.09267973745380109,0,0,1,0.09754499170125654
1419,S10A8,MyD88 deficiency (TLR2/4),0.09107858486077636,1,0,1,0.09585978605987351
1420,S10A8,IRAK4 deficiency (TLR2/4),0.09267973745380109,0,0,1,0.09754499170125654
1421,S10A8,IRAK4 deficiency (TLR2/4),0.09107858486077636,1,0,1,0.09585978605987351
1422,S10A8,Metal sequestration by antimicrobial proteins,0.09267973745380109,0,0,1,0.09754499170125654
1423,S10A8,Metal sequestration by antimicrobial proteins,0.09107858486077636,1,0,1,0.09585978605987351
1424,S10A8,Neutrophil degranulation,0.09267973745380109,0,0,1,0.09754499170125654
1425,S10A8,Neutrophil degranulation,0.09107858486077636,1,0,1,0.09585978605987351
1426,IPSP,Intrinsic Pathway of Fibrin Clot Formation,0.002539149347579652,0,0,1,0.0026724428536644487
1427,IPSP,Intrinsic Pathway of Fibrin Clot Formation,0.0025016269421188476,1,0,1,0.002632950696804274
1428,IPSP,Common Pathway of Fibrin Clot Formation,0.002539149347579652,0,0,1,0.0026724428536644487
1429,IPSP,Common Pathway of Fibrin Clot Formation,0.0025016269421188476,1,0,1,0.002632950696804274
1430,F13B,Common Pathway of Fibrin Clot Formation,0.028506676054836345,0,0,1,0.030003143681600654
1431,F13B,Common Pathway of Fibrin Clot Formation,0.028431370648049865,1,0,1,0.029923885091947135
1432,HEP2,Intrinsic Pathway of Fibrin Clot Formation,0.05890008095752709,0,0,1,0.06199206068175672
1433,HEP2,Intrinsic Pathway of Fibrin Clot Formation,0.05722105557163379,1,0,1,0.060224894288835054
1434,HEP2,Common Pathway of Fibrin Clot Formation,0.05890008095752709,0,0,1,0.06199206068175672
1435,HEP2,Common Pathway of Fibrin Clot Formation,0.05722105557163379,1,0,1,0.060224894288835054
1436,HEP2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.05890008095752709,0,0,1,0.06199206068175672
1437,HEP2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.05722105557163379,1,0,1,0.060224894288835054
1438,HEP2,Post-translational protein phosphorylation,0.05890008095752709,0,0,1,0.06199206068175672
1439,HEP2,Post-translational protein phosphorylation,0.05722105557163379,1,0,1,0.060224894288835054
1440,KV230,Initial triggering of complement,0.06755183300585205,0,0,1,0.07109798938786543
1441,KV230,Initial triggering of complement,0.06506242256376506,1,0,1,0.06847789650040509
1442,KV230,Regulation of Complement cascade,0.06755183300585205,0,0,1,0.07109798938786543
1443,KV230,Regulation of Complement cascade,0.06506242256376506,1,0,1,0.06847789650040509
1444,KV230,FCGR activation,0.06755183300585205,0,0,1,0.07109798938786543
1445,KV230,FCGR activation,0.06506242256376506,1,0,1,0.06847789650040509
1446,KV230,Regulation of actin dynamics for phagocytic cup formation,0.06755183300585205,0,0,1,0.07109798938786543
1447,KV230,Regulation of actin dynamics for phagocytic cup formation,0.06506242256376506,1,0,1,0.06847789650040509
1448,KV230,Role of phospholipids in phagocytosis,0.06755183300585205,0,0,1,0.07109798938786543
1449,KV230,Role of phospholipids in phagocytosis,0.06506242256376506,1,0,1,0.06847789650040509
1450,KV230,Role of LAT2/NTAL/LAB on calcium mobilization,0.06755183300585205,0,0,1,0.07109798938786543
1451,KV230,Role of LAT2/NTAL/LAB on calcium mobilization,0.06506242256376506,1,0,1,0.06847789650040509
1452,KV230,FCERI mediated MAPK activation,0.06755183300585205,0,0,1,0.07109798938786543
1453,KV230,FCERI mediated MAPK activation,0.06506242256376506,1,0,1,0.06847789650040509
1454,KV230,FCERI mediated Ca+2 mobilization,0.06755183300585205,0,0,1,0.07109798938786543
1455,KV230,FCERI mediated Ca+2 mobilization,0.06506242256376506,1,0,1,0.06847789650040509
1456,KV230,FCERI mediated NF-kB activation,0.06755183300585205,0,0,1,0.07109798938786543
1457,KV230,FCERI mediated NF-kB activation,0.06506242256376506,1,0,1,0.06847789650040509
1458,KV230,Parasite infection,0.06755183300585205,0,0,1,0.07109798938786543
1459,KV230,Parasite infection,0.06506242256376506,1,0,1,0.06847789650040509
1460,KV230,Leishmania parasite growth and survival,0.06755183300585205,0,0,1,0.07109798938786543
1461,KV230,Leishmania parasite growth and survival,0.06506242256376506,1,0,1,0.06847789650040509
1462,KV230,Potential therapeutics for SARS,0.06755183300585205,0,0,1,0.07109798938786543
1463,KV230,Potential therapeutics for SARS,0.06506242256376506,1,0,1,0.06847789650040509
1464,KV230,CD22 mediated BCR regulation,0.06755183300585205,0,0,1,0.07109798938786543
1465,KV230,CD22 mediated BCR regulation,0.06506242256376506,1,0,1,0.06847789650040509
1466,KV230,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.06755183300585205,0,0,1,0.07109798938786543
1467,KV230,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.06506242256376506,1,0,1,0.06847789650040509
1468,KV230,Cell surface interactions at the vascular wall,0.06755183300585205,0,0,1,0.07109798938786543
1469,KV230,Cell surface interactions at the vascular wall,0.06506242256376506,1,0,1,0.06847789650040509
1470,KV230,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.06755183300585205,0,0,1,0.07109798938786543
1471,KV230,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.06506242256376506,1,0,1,0.06847789650040509
1472,KV230,Scavenging of heme from plasma,0.06755183300585205,0,0,1,0.07109798938786543
1473,KV230,Scavenging of heme from plasma,0.06506242256376506,1,0,1,0.06847789650040509
1474,KV401,Initial triggering of complement,0.12204055732581764,0,0,1,0.12844711776937998
1475,KV401,Initial triggering of complement,0.1232855014136322,1,0,1,0.12975741561927337
1476,KV401,Regulation of Complement cascade,0.12204055732581764,0,0,1,0.12844711776937998
1477,KV401,Regulation of Complement cascade,0.1232855014136322,1,0,1,0.12975741561927337
1478,KV401,FCGR activation,0.12204055732581764,0,0,1,0.12844711776937998
1479,KV401,FCGR activation,0.1232855014136322,1,0,1,0.12975741561927337
1480,KV401,Regulation of actin dynamics for phagocytic cup formation,0.12204055732581764,0,0,1,0.12844711776937998
1481,KV401,Regulation of actin dynamics for phagocytic cup formation,0.1232855014136322,1,0,1,0.12975741561927337
1482,KV401,Role of phospholipids in phagocytosis,0.12204055732581764,0,0,1,0.12844711776937998
1483,KV401,Role of phospholipids in phagocytosis,0.1232855014136322,1,0,1,0.12975741561927337
1484,KV401,Role of LAT2/NTAL/LAB on calcium mobilization,0.12204055732581764,0,0,1,0.12844711776937998
1485,KV401,Role of LAT2/NTAL/LAB on calcium mobilization,0.1232855014136322,1,0,1,0.12975741561927337
1486,KV401,FCERI mediated MAPK activation,0.12204055732581764,0,0,1,0.12844711776937998
1487,KV401,FCERI mediated MAPK activation,0.1232855014136322,1,0,1,0.12975741561927337
1488,KV401,FCERI mediated Ca+2 mobilization,0.12204055732581764,0,0,1,0.12844711776937998
1489,KV401,FCERI mediated Ca+2 mobilization,0.1232855014136322,1,0,1,0.12975741561927337
1490,KV401,FCERI mediated NF-kB activation,0.12204055732581764,0,0,1,0.12844711776937998
1491,KV401,FCERI mediated NF-kB activation,0.1232855014136322,1,0,1,0.12975741561927337
1492,KV401,Parasite infection,0.12204055732581764,0,0,1,0.12844711776937998
1493,KV401,Parasite infection,0.1232855014136322,1,0,1,0.12975741561927337
1494,KV401,Leishmania parasite growth and survival,0.12204055732581764,0,0,1,0.12844711776937998
1495,KV401,Leishmania parasite growth and survival,0.1232855014136322,1,0,1,0.12975741561927337
1496,KV401,Potential therapeutics for SARS,0.12204055732581764,0,0,1,0.12844711776937998
1497,KV401,Potential therapeutics for SARS,0.1232855014136322,1,0,1,0.12975741561927337
1498,KV401,CD22 mediated BCR regulation,0.12204055732581764,0,0,1,0.12844711776937998
1499,KV401,CD22 mediated BCR regulation,0.1232855014136322,1,0,1,0.12975741561927337
1500,KV401,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.12204055732581764,0,0,1,0.12844711776937998
1501,KV401,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.1232855014136322,1,0,1,0.12975741561927337
1502,KV401,Cell surface interactions at the vascular wall,0.12204055732581764,0,0,1,0.12844711776937998
1503,KV401,Cell surface interactions at the vascular wall,0.1232855014136322,1,0,1,0.12975741561927337
1504,KV401,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.12204055732581764,0,0,1,0.12844711776937998
1505,KV401,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.1232855014136322,1,0,1,0.12975741561927337
1506,KV401,Scavenging of heme from plasma,0.12204055732581764,0,0,1,0.12844711776937998
1507,KV401,Scavenging of heme from plasma,0.1232855014136322,1,0,1,0.12975741561927337
1508,HV434,Initial triggering of complement,0.016511850380721154,0,0,1,0.01737864556600313
1509,HV434,Initial triggering of complement,0.01632001675701372,1,0,1,0.017176741571164004
1510,HV434,Regulation of Complement cascade,0.016511850380721154,0,0,1,0.01737864556600313
1511,HV434,Regulation of Complement cascade,0.01632001675701372,1,0,1,0.017176741571164004
1512,HV434,FCGR activation,0.016511850380721154,0,0,1,0.01737864556600313
1513,HV434,FCGR activation,0.01632001675701372,1,0,1,0.017176741571164004
1514,HV434,Regulation of actin dynamics for phagocytic cup formation,0.016511850380721154,0,0,1,0.01737864556600313
1515,HV434,Regulation of actin dynamics for phagocytic cup formation,0.01632001675701372,1,0,1,0.017176741571164004
1516,HV434,Role of phospholipids in phagocytosis,0.016511850380721154,0,0,1,0.01737864556600313
1517,HV434,Role of phospholipids in phagocytosis,0.01632001675701372,1,0,1,0.017176741571164004
1518,HV434,Role of LAT2/NTAL/LAB on calcium mobilization,0.016511850380721154,0,0,1,0.01737864556600313
1519,HV434,Role of LAT2/NTAL/LAB on calcium mobilization,0.01632001675701372,1,0,1,0.017176741571164004
1520,HV434,FCERI mediated MAPK activation,0.016511850380721154,0,0,1,0.01737864556600313
1521,HV434,FCERI mediated MAPK activation,0.01632001675701372,1,0,1,0.017176741571164004
1522,HV434,FCERI mediated Ca+2 mobilization,0.016511850380721154,0,0,1,0.01737864556600313
1523,HV434,FCERI mediated Ca+2 mobilization,0.01632001675701372,1,0,1,0.017176741571164004
1524,HV434,FCERI mediated NF-kB activation,0.016511850380721154,0,0,1,0.01737864556600313
1525,HV434,FCERI mediated NF-kB activation,0.01632001675701372,1,0,1,0.017176741571164004
1526,HV434,Parasite infection,0.016511850380721154,0,0,1,0.01737864556600313
1527,HV434,Parasite infection,0.01632001675701372,1,0,1,0.017176741571164004
1528,HV434,Leishmania parasite growth and survival,0.016511850380721154,0,0,1,0.01737864556600313
1529,HV434,Leishmania parasite growth and survival,0.01632001675701372,1,0,1,0.017176741571164004
1530,HV434,Potential therapeutics for SARS,0.016511850380721154,0,0,1,0.01737864556600313
1531,HV434,Potential therapeutics for SARS,0.01632001675701372,1,0,1,0.017176741571164004
1532,HV434,CD22 mediated BCR regulation,0.016511850380721154,0,0,1,0.01737864556600313
1533,HV434,CD22 mediated BCR regulation,0.01632001675701372,1,0,1,0.017176741571164004
1534,HV434,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.016511850380721154,0,0,1,0.01737864556600313
1535,HV434,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.01632001675701372,1,0,1,0.017176741571164004
1536,HV434,Cell surface interactions at the vascular wall,0.016511850380721154,0,0,1,0.01737864556600313
1537,HV434,Cell surface interactions at the vascular wall,0.01632001675701372,1,0,1,0.017176741571164004
1538,HV434,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.016511850380721154,0,0,1,0.01737864556600313
1539,HV434,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.01632001675701372,1,0,1,0.017176741571164004
1540,HV434,Scavenging of heme from plasma,0.016511850380721154,0,0,1,0.01737864556600313
1541,HV434,Scavenging of heme from plasma,0.01632001675701372,1,0,1,0.017176741571164004
1542,GELS,Apoptotic cleavage of cellular proteins,0.21614822724233448,0,0,1,0.22749500173222706
1543,GELS,Apoptotic cleavage of cellular proteins,0.21299215849211434,1,0,1,0.22417325408266903
1544,GELS,Neutrophil degranulation,0.21614822724233448,0,0,1,0.22749500173222706
1545,GELS,Neutrophil degranulation,0.21299215849211434,1,0,1,0.22417325408266903
1546,GELS,Amyloid fiber formation,0.21614822724233448,0,0,1,0.22749500173222706
1547,GELS,Amyloid fiber formation,0.21299215849211434,1,0,1,0.22417325408266903
1548,GELS,Sensory processing of sound by outer hair cells of the cochlea,0.21614822724233448,0,0,1,0.22749500173222706
1549,GELS,Sensory processing of sound by outer hair cells of the cochlea,0.21299215849211434,1,0,1,0.22417325408266903
1550,S10A9,Antigen processing-Cross presentation,0.011393715072409723,0,0,1,0.011991832009005176
1551,S10A9,Antigen processing-Cross presentation,0.006326217524474487,1,0,1,0.006658314458786791
1552,S10A9,Toll Like Receptor 4 (TLR4) Cascade,0.011393715072409723,0,0,1,0.011991832009005176
1553,S10A9,Toll Like Receptor 4 (TLR4) Cascade,0.006326217524474487,1,0,1,0.006658314458786791
1554,S10A9,Toll Like Receptor 2 (TLR2) Cascade,0.011393715072409723,0,0,1,0.011991832009005176
1555,S10A9,Toll Like Receptor 2 (TLR2) Cascade,0.006326217524474487,1,0,1,0.006658314458786791
1556,S10A9,Regulation of TLR by endogenous ligand,0.011393715072409723,0,0,1,0.011991832009005176
1557,S10A9,Regulation of TLR by endogenous ligand,0.006326217524474487,1,0,1,0.006658314458786791
1558,S10A9,RHO GTPase Effectors,0.011393715072409723,0,0,1,0.011991832009005176
1559,S10A9,RHO GTPase Effectors,0.006326217524474487,1,0,1,0.006658314458786791
1560,S10A9,MyD88 deficiency (TLR2/4),0.011393715072409723,0,0,1,0.011991832009005176
1561,S10A9,MyD88 deficiency (TLR2/4),0.006326217524474487,1,0,1,0.006658314458786791
1562,S10A9,IRAK4 deficiency (TLR2/4),0.011393715072409723,0,0,1,0.011991832009005176
1563,S10A9,IRAK4 deficiency (TLR2/4),0.006326217524474487,1,0,1,0.006658314458786791
1564,S10A9,Metal sequestration by antimicrobial proteins,0.011393715072409723,0,0,1,0.011991832009005176
1565,S10A9,Metal sequestration by antimicrobial proteins,0.006326217524474487,1,0,1,0.006658314458786791
1566,S10A9,Neutrophil degranulation,0.011393715072409723,0,0,1,0.011991832009005176
1567,S10A9,Neutrophil degranulation,0.006326217524474487,1,0,1,0.006658314458786791
1568,APOA4,Chylomicron assembly,0.09225163324064,0,0,1,0.09709441401224563
1569,APOA4,Chylomicron assembly,0.0854536894887291,1,0,1,0.08993960989774
1570,APOA4,Assembly of active LPL and LIPC lipase complexes,0.09225163324064,0,0,1,0.09709441401224563
1571,APOA4,Assembly of active LPL and LIPC lipase complexes,0.0854536894887291,1,0,1,0.08993960989774
1572,APOA4,Chylomicron remodeling,0.09225163324064,0,0,1,0.09709441401224563
1573,APOA4,Chylomicron remodeling,0.0854536894887291,1,0,1,0.08993960989774
1574,APOA4,Retinoid metabolism and transport,0.09225163324064,0,0,1,0.09709441401224563
1575,APOA4,Retinoid metabolism and transport,0.0854536894887291,1,0,1,0.08993960989774
1576,APOA4,Amyloid fiber formation,0.09225163324064,0,0,1,0.09709441401224563
1577,APOA4,Amyloid fiber formation,0.0854536894887291,1,0,1,0.08993960989774
1578,LDHB,Pyruvate metabolism,0.0005067668854909081,0,0,1,0.0005333697850009917
1579,LDHB,Pyruvate metabolism,0.00029768492158441603,1,0,1,0.00031331199249475363
1580,CO8A,Terminal pathway of complement,0.015069812205385662,0,0,1,0.01586090710762528
1581,CO8A,Terminal pathway of complement,0.012997832416122608,1,0,1,0.013680158036669141
1582,CO8A,Regulation of Complement cascade,0.015069812205385662,0,0,1,0.01586090710762528
1583,CO8A,Regulation of Complement cascade,0.012997832416122608,1,0,1,0.013680158036669141
1584,CO8G,Terminal pathway of complement,0.09025781273286214,0,0,1,0.09499592722076185
1585,CO8G,Terminal pathway of complement,0.09143548062158938,1,0,1,0.09623541718468193
1586,CO8G,Regulation of Complement cascade,0.09025781273286214,0,0,1,0.09499592722076185
1587,CO8G,Regulation of Complement cascade,0.09143548062158938,1,0,1,0.09623541718468193
1588,TSP1,Transcriptional regulation by RUNX1,0.012188951166581977,0,0,1,0.012828814291623747
1589,TSP1,Transcriptional regulation by RUNX1,0.007721382513831275,1,0,1,0.008126719107392212
1590,TSP1,Diseases associated with O-glycosylation of proteins,0.012188951166581977,0,0,1,0.012828814291623747
1591,TSP1,Diseases associated with O-glycosylation of proteins,0.007721382513831275,1,0,1,0.008126719107392212
1592,TSP1,O-glycosylation of TSR domain-containing proteins,0.012188951166581977,0,0,1,0.012828814291623747
1593,TSP1,O-glycosylation of TSR domain-containing proteins,0.007721382513831275,1,0,1,0.008126719107392212
1594,TSP1,Platelet degranulation ,0.012188951166581977,0,0,1,0.012828814291623747
1595,TSP1,Platelet degranulation ,0.007721382513831275,1,0,1,0.008126719107392212
1596,TSP1,Integrin cell surface interactions,0.012188951166581977,0,0,1,0.012828814291623747
1597,TSP1,Integrin cell surface interactions,0.007721382513831275,1,0,1,0.008126719107392212
1598,TSP1,Syndecan interactions,0.012188951166581977,0,0,1,0.012828814291623747
1599,TSP1,Syndecan interactions,0.007721382513831275,1,0,1,0.008126719107392212
1600,TSP1,Signaling by PDGF,0.012188951166581977,0,0,1,0.012828814291623747
1601,TSP1,Signaling by PDGF,0.007721382513831275,1,0,1,0.008126719107392212
1602,RNAS1,Chaperone Mediated Autophagy,0.017936623644574146,0,0,1,0.018878212785515276
1603,RNAS1,Chaperone Mediated Autophagy,0.01939207858716448,1,0,1,0.02041007232889494
1604,RNAS1,Late endosomal microautophagy,0.017936623644574146,0,0,1,0.018878212785515276
1605,RNAS1,Late endosomal microautophagy,0.01939207858716448,1,0,1,0.02041007232889494
1606,CBG,Metabolism of steroid hormones,0.00692589314958724,0,0,1,0.007289470259203555
1607,CBG,Metabolism of steroid hormones,0.009633129446009164,1,0,1,0.010138823843091877
1608,APOA,LDL remodeling,0.001622200410302089,0,0,1,0.001707358370966149
1609,APOA,LDL remodeling,0.0014736623924746063,1,0,1,0.0015510227995201744
1610,CD14,Antigen processing-Cross presentation,0.10458432649012547,0,0,1,0.11007451617616112
1611,CD14,Antigen processing-Cross presentation,0.11277274960952312,1,0,1,0.11869279334409305
1612,CD14,Toll Like Receptor 4 (TLR4) Cascade,0.10458432649012547,0,0,1,0.11007451617616112
1613,CD14,Toll Like Receptor 4 (TLR4) Cascade,0.11277274960952312,1,0,1,0.11869279334409305
1614,CD14,Toll Like Receptor 9 (TLR9) Cascade,0.10458432649012547,0,0,1,0.11007451617616112
1615,CD14,Toll Like Receptor 9 (TLR9) Cascade,0.11277274960952312,1,0,1,0.11869279334409305
1616,CD14,Toll Like Receptor 7/8 (TLR7/8) Cascade,0.10458432649012547,0,0,1,0.11007451617616112
1617,CD14,Toll Like Receptor 7/8 (TLR7/8) Cascade,0.11277274960952312,1,0,1,0.11869279334409305
1618,CD14,Toll Like Receptor 2 (TLR2) Cascade,0.10458432649012547,0,0,1,0.11007451617616112
1619,CD14,Toll Like Receptor 2 (TLR2) Cascade,0.11277274960952312,1,0,1,0.11869279334409305
1620,CD14,Regulation of TLR by endogenous ligand,0.10458432649012547,0,0,1,0.11007451617616112
1621,CD14,Regulation of TLR by endogenous ligand,0.11277274960952312,1,0,1,0.11869279334409305
1622,CD14,Caspase activation via Death Receptors in the presence of ligand,0.10458432649012547,0,0,1,0.11007451617616112
1623,CD14,Caspase activation via Death Receptors in the presence of ligand,0.11277274960952312,1,0,1,0.11869279334409305
1624,CD14,MyD88 deficiency (TLR2/4),0.10458432649012547,0,0,1,0.11007451617616112
1625,CD14,MyD88 deficiency (TLR2/4),0.11277274960952312,1,0,1,0.11869279334409305
1626,CD14,IRAK4 deficiency (TLR2/4),0.10458432649012547,0,0,1,0.11007451617616112
1627,CD14,IRAK4 deficiency (TLR2/4),0.11277274960952312,1,0,1,0.11869279334409305
1628,CD14,Neutrophil degranulation,0.10458432649012547,0,0,1,0.11007451617616112
1629,CD14,Neutrophil degranulation,0.11277274960952312,1,0,1,0.11869279334409305
1630,CFAH,Regulation of Complement cascade,0.15564157389405808,0,0,1,0.16381203109724324
1631,CFAH,Regulation of Complement cascade,0.14851510535322743,1,0,1,0.15631145617361322
1632,SAA1,Toll Like Receptor 4 (TLR4) Cascade,0.11529150431759763,0,0,1,0.12134377093473526
1633,SAA1,Toll Like Receptor 4 (TLR4) Cascade,0.10785586772376057,1,0,1,0.11351779807631034
1634,SAA1,Toll Like Receptor 9 (TLR9) Cascade,0.11529150431759763,0,0,1,0.12134377093473526
1635,SAA1,Toll Like Receptor 9 (TLR9) Cascade,0.10785586772376057,1,0,1,0.11351779807631034
1636,SAA1,Toll Like Receptor 10 (TLR10) Cascade,0.11529150431759763,0,0,1,0.12134377093473526
1637,SAA1,Toll Like Receptor 10 (TLR10) Cascade,0.10785586772376057,1,0,1,0.11351779807631034
1638,SAA1,Toll Like Receptor 3 (TLR3) Cascade,0.11529150431759763,0,0,1,0.12134377093473526
1639,SAA1,Toll Like Receptor 3 (TLR3) Cascade,0.10785586772376057,1,0,1,0.11351779807631034
1640,SAA1,Toll Like Receptor 5 (TLR5) Cascade,0.11529150431759763,0,0,1,0.12134377093473526
1641,SAA1,Toll Like Receptor 5 (TLR5) Cascade,0.10785586772376057,1,0,1,0.11351779807631034
1642,SAA1,Toll Like Receptor 7/8 (TLR7/8) Cascade,0.11529150431759763,0,0,1,0.12134377093473526
1643,SAA1,Toll Like Receptor 7/8 (TLR7/8) Cascade,0.10785586772376057,1,0,1,0.11351779807631034
1644,SAA1,Toll Like Receptor 2 (TLR2) Cascade,0.11529150431759763,0,0,1,0.12134377093473526
1645,SAA1,Toll Like Receptor 2 (TLR2) Cascade,0.10785586772376057,1,0,1,0.11351779807631034
1646,SAA1,TRAF6 mediated NF-kB activation,0.11529150431759763,0,0,1,0.12134377093473526
1647,SAA1,TRAF6 mediated NF-kB activation,0.10785586772376057,1,0,1,0.11351779807631034
1648,SAA1,Class A/1 (Rhodopsin-like receptors),0.11529150431759763,0,0,1,0.12134377093473526
1649,SAA1,Class A/1 (Rhodopsin-like receptors),0.10785586772376057,1,0,1,0.11351779807631034
1650,SAA1,G alpha (q) signalling events,0.11529150431759763,0,0,1,0.12134377093473526
1651,SAA1,G alpha (q) signalling events,0.10785586772376057,1,0,1,0.11351779807631034
1652,SAA1,G alpha (i) signalling events,0.11529150431759763,0,0,1,0.12134377093473526
1653,SAA1,G alpha (i) signalling events,0.10785586772376057,1,0,1,0.11351779807631034
1654,SAA1,Interleukin-1 family signaling,0.11529150431759763,0,0,1,0.12134377093473526
1655,SAA1,Interleukin-1 family signaling,0.10785586772376057,1,0,1,0.11351779807631034
1656,SAA1,Interleukin-4 and Interleukin-13 signaling,0.11529150431759763,0,0,1,0.12134377093473526
1657,SAA1,Interleukin-4 and Interleukin-13 signaling,0.10785586772376057,1,0,1,0.11351779807631034
1658,SAA1,Advanced glycosylation endproduct receptor signaling,0.11529150431759763,0,0,1,0.12134377093473526
1659,SAA1,Advanced glycosylation endproduct receptor signaling,0.10785586772376057,1,0,1,0.11351779807631034
1660,SAA1,Scavenging by Class B Receptors,0.11529150431759763,0,0,1,0.12134377093473526
1661,SAA1,Scavenging by Class B Receptors,0.10785586772376057,1,0,1,0.11351779807631034
1662,SAA1,Amyloid fiber formation,0.11529150431759763,0,0,1,0.12134377093473526
1663,SAA1,Amyloid fiber formation,0.10785586772376057,1,0,1,0.11351779807631034
1664,CO7,Terminal pathway of complement,0.056482656987087015,0,0,1,0.05944773322018465
1665,CO7,Terminal pathway of complement,0.05538433086316007,1,0,1,0.05829175009391466
1666,CO7,Regulation of Complement cascade,0.056482656987087015,0,0,1,0.05944773322018465
1667,CO7,Regulation of Complement cascade,0.05538433086316007,1,0,1,0.05829175009391466
1668,MBL2,Initial triggering of complement,0.01444414372029705,0,0,1,0.015202393943233455
1669,MBL2,Initial triggering of complement,0.014875023222608117,1,0,1,0.015655892611139432
1670,MBL2,SARS-CoV-2 Infection,0.01444414372029705,0,0,1,0.015202393943233455
1671,MBL2,SARS-CoV-2 Infection,0.014875023222608117,1,0,1,0.015655892611139432
1672,CO6,Terminal pathway of complement,0.004964556233629253,0,0,1,0.005225172296708158
1673,CO6,Terminal pathway of complement,0.0060661101781632806,1,0,1,0.0063845526891226296
1674,CO6,Regulation of Complement cascade,0.004964556233629253,0,0,1,0.005225172296708158
1675,CO6,Regulation of Complement cascade,0.0060661101781632806,1,0,1,0.0063845526891226296
1676,CBPN,Regulation of Complement cascade,0.0361404570036372,0,0,1,0.03803766255009848
1677,CBPN,Regulation of Complement cascade,0.03450001743023176,1,0,1,0.03631110754497655
1678,LBP,Toll Like Receptor 4 (TLR4) Cascade,0.11195128382991208,0,0,1,0.11782820443980352
1679,LBP,Toll Like Receptor 4 (TLR4) Cascade,0.10815602579746836,1,0,1,0.11383371304988786
1680,LBP,Regulation of TLR by endogenous ligand,0.11195128382991208,0,0,1,0.11782820443980352
1681,LBP,Regulation of TLR by endogenous ligand,0.10815602579746836,1,0,1,0.11383371304988786
1682,LBP,Interleukin-4 and Interleukin-13 signaling,0.11195128382991208,0,0,1,0.11782820443980352
1683,LBP,Interleukin-4 and Interleukin-13 signaling,0.10815602579746836,1,0,1,0.11383371304988786
1684,A1AG2,Platelet degranulation ,0.059127865258518805,0,0,1,0.06223180259687586
1685,A1AG2,Platelet degranulation ,0.06851797770137408,1,0,1,0.07211485217682066
1686,A1AG2,Neutrophil degranulation,0.059127865258518805,0,0,1,0.06223180259687586
1687,A1AG2,Neutrophil degranulation,0.06851797770137408,1,0,1,0.07211485217682066
1688,CPN2,Regulation of Complement cascade,0.04173324006308176,0,0,1,0.043924040652889206
1689,CPN2,Regulation of Complement cascade,0.039842136706600126,1,0,1,0.04193366318439267
1690,HV102,Initial triggering of complement,0.11181127966622313,0,0,1,0.1176808507100631
1691,HV102,Initial triggering of complement,0.10848582681473165,1,0,1,0.11418082708339547
1692,HV102,Regulation of Complement cascade,0.11181127966622313,0,0,1,0.1176808507100631
1693,HV102,Regulation of Complement cascade,0.10848582681473165,1,0,1,0.11418082708339547
1694,HV102,FCGR activation,0.11181127966622313,0,0,1,0.1176808507100631
1695,HV102,FCGR activation,0.10848582681473165,1,0,1,0.11418082708339547
1696,HV102,Regulation of actin dynamics for phagocytic cup formation,0.11181127966622313,0,0,1,0.1176808507100631
1697,HV102,Regulation of actin dynamics for phagocytic cup formation,0.10848582681473165,1,0,1,0.11418082708339547
1698,HV102,Role of phospholipids in phagocytosis,0.11181127966622313,0,0,1,0.1176808507100631
1699,HV102,Role of phospholipids in phagocytosis,0.10848582681473165,1,0,1,0.11418082708339547
1700,HV102,Role of LAT2/NTAL/LAB on calcium mobilization,0.11181127966622313,0,0,1,0.1176808507100631
1701,HV102,Role of LAT2/NTAL/LAB on calcium mobilization,0.10848582681473165,1,0,1,0.11418082708339547
1702,HV102,FCERI mediated MAPK activation,0.11181127966622313,0,0,1,0.1176808507100631
1703,HV102,FCERI mediated MAPK activation,0.10848582681473165,1,0,1,0.11418082708339547
1704,HV102,FCERI mediated Ca+2 mobilization,0.11181127966622313,0,0,1,0.1176808507100631
1705,HV102,FCERI mediated Ca+2 mobilization,0.10848582681473165,1,0,1,0.11418082708339547
1706,HV102,FCERI mediated NF-kB activation,0.11181127966622313,0,0,1,0.1176808507100631
1707,HV102,FCERI mediated NF-kB activation,0.10848582681473165,1,0,1,0.11418082708339547
1708,HV102,Parasite infection,0.11181127966622313,0,0,1,0.1176808507100631
1709,HV102,Parasite infection,0.10848582681473165,1,0,1,0.11418082708339547
1710,HV102,Leishmania parasite growth and survival,0.11181127966622313,0,0,1,0.1176808507100631
1711,HV102,Leishmania parasite growth and survival,0.10848582681473165,1,0,1,0.11418082708339547
1712,HV102,Potential therapeutics for SARS,0.11181127966622313,0,0,1,0.1176808507100631
1713,HV102,Potential therapeutics for SARS,0.10848582681473165,1,0,1,0.11418082708339547
1714,HV102,CD22 mediated BCR regulation,0.11181127966622313,0,0,1,0.1176808507100631
1715,HV102,CD22 mediated BCR regulation,0.10848582681473165,1,0,1,0.11418082708339547
1716,HV102,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.11181127966622313,0,0,1,0.1176808507100631
1717,HV102,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.10848582681473165,1,0,1,0.11418082708339547
1718,HV102,Cell surface interactions at the vascular wall,0.11181127966622313,0,0,1,0.1176808507100631
1719,HV102,Cell surface interactions at the vascular wall,0.10848582681473165,1,0,1,0.11418082708339547
1720,HV102,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.11181127966622313,0,0,1,0.1176808507100631
1721,HV102,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.10848582681473165,1,0,1,0.11418082708339547
1722,HV102,Scavenging of heme from plasma,0.11181127966622313,0,0,1,0.1176808507100631
1723,HV102,Scavenging of heme from plasma,0.10848582681473165,1,0,1,0.11418082708339547
1724,FBLN1,Molecules associated with elastic fibres,0.0019359288834085169,0,0,1,0.0020375561266607976
1725,FBLN1,Molecules associated with elastic fibres,0.0025191543865669126,1,0,1,0.0026513982503925974
1726,ZA2G,Miscellaneous transport and binding events,0.12798497646626372,0,0,1,0.1347035912084922
1727,ZA2G,Miscellaneous transport and binding events,0.1222671522815984,1,0,1,0.12868560790420797
1728,PON1,Arachidonic acid metabolism,0.00025165206220015025,0,0,1,0.0002648626225463156
1729,PON1,Arachidonic acid metabolism,0.0010710698187599277,1,0,1,0.0011272959921199963
1730,PON1,Atorvastatin ADME,0.00025165206220015025,0,0,1,0.0002648626225463156
1731,PON1,Atorvastatin ADME,0.0010710698187599277,1,0,1,0.0011272959921199963
1732,PROP,Initial triggering of complement,0.06585094495901415,0,0,1,0.06930781264619877
1733,PROP,Initial triggering of complement,0.06353504694368384,1,0,1,0.06687034077917971
1734,PROP,Activation of C3 and C5,0.06585094495901415,0,0,1,0.06930781264619877
1735,PROP,Activation of C3 and C5,0.06353504694368384,1,0,1,0.06687034077917971
1736,PROP,Regulation of Complement cascade,0.06585094495901415,0,0,1,0.06930781264619877
1737,PROP,Regulation of Complement cascade,0.06353504694368384,1,0,1,0.06687034077917971
1738,PROP,Diseases associated with O-glycosylation of proteins,0.06585094495901415,0,0,1,0.06930781264619877
1739,PROP,Diseases associated with O-glycosylation of proteins,0.06353504694368384,1,0,1,0.06687034077917971
1740,PROP,O-glycosylation of TSR domain-containing proteins,0.06585094495901415,0,0,1,0.06930781264619877
1741,PROP,O-glycosylation of TSR domain-containing proteins,0.06353504694368384,1,0,1,0.06687034077917971
1742,PROP,Neutrophil degranulation,0.06585094495901415,0,0,1,0.06930781264619877
1743,PROP,Neutrophil degranulation,0.06353504694368384,1,0,1,0.06687034077917971
1744,KAIN,Platelet degranulation ,0.022584637991857944,0,0,1,0.02377022622220768
1745,KAIN,Platelet degranulation ,0.028858953552064148,1,0,1,0.030373914105510783
1746,BLVRB,Cytoprotection by HMOX1,0.0004258922992694835,0,0,1,0.0004482496599494521
1747,BLVRB,Cytoprotection by HMOX1,0.0004263795305022088,1,0,1,0.0004487624685509705
1748,BLVRB,Heme degradation,0.0004258922992694835,0,0,1,0.0004482496599494521
1749,BLVRB,Heme degradation,0.0004263795305022088,1,0,1,0.0004487624685509705
1750,PRDX2,Transcriptional Regulation by TP53,0.005501765201030218,0,0,1,0.005790582231032681
1751,PRDX2,Transcriptional Regulation by TP53,0.005699099931227052,1,0,1,0.005998276114811917
1752,PRDX2,Neurodegenerative Diseases,0.005501765201030218,0,0,1,0.005790582231032681
1753,PRDX2,Neurodegenerative Diseases,0.005699099931227052,1,0,1,0.005998276114811917
1754,PRDX2,Detoxification of Reactive Oxygen Species,0.005501765201030218,0,0,1,0.005790582231032681
1755,PRDX2,Detoxification of Reactive Oxygen Species,0.005699099931227052,1,0,1,0.005998276114811917
1756,MASP1,Initial triggering of complement,0.029456141868219283,0,0,1,0.031002452024842697
1757,MASP1,Initial triggering of complement,0.026837210184422092,1,0,1,0.028246038634164954
1758,MASP1,SARS-CoV-2 Infection,0.029456141868219283,0,0,1,0.031002452024842697
1759,MASP1,SARS-CoV-2 Infection,0.026837210184422092,1,0,1,0.028246038634164954
1760,MASP1,Scavenging by Class A Receptors,0.029456141868219283,0,0,1,0.031002452024842697
1761,MASP1,Scavenging by Class A Receptors,0.026837210184422092,1,0,1,0.028246038634164954
1762,LUM,Keratan sulfate/keratin metabolism,0.023336598358547556,0,0,1,0.02456166100335362
1763,LUM,Keratan sulfate/keratin metabolism,0.021861668527472886,1,0,1,0.023009304230614255
1764,LUM,Diseases associated with glycosaminoglycan metabolism,0.023336598358547556,0,0,1,0.02456166100335362
1765,LUM,Diseases associated with glycosaminoglycan metabolism,0.021861668527472886,1,0,1,0.023009304230614255
1766,LUM,Integrin cell surface interactions,0.023336598358547556,0,0,1,0.02456166100335362
1767,LUM,Integrin cell surface interactions,0.021861668527472886,1,0,1,0.023009304230614255
1768,LUM,ECM proteoglycans,0.023336598358547556,0,0,1,0.02456166100335362
1769,LUM,ECM proteoglycans,0.021861668527472886,1,0,1,0.023009304230614255
1770,APOC4,VLDL assembly,0.0007789084683048678,0,0,1,0.0008197975324942037
1771,APOC4,VLDL assembly,0.0006916927484754538,1,0,1,0.0007280033938754998
1772,APOC4,VLDL clearance,0.0007789084683048678,0,0,1,0.0008197975324942037
1773,APOC4,VLDL clearance,0.0006916927484754538,1,0,1,0.0007280033938754998
1774,APOC4,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.0007789084683048678,0,0,1,0.0008197975324942037
1775,APOC4,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.0006916927484754538,1,0,1,0.0007280033938754998
1776,TYB4,Platelet degranulation ,0.009433005763226806,0,0,1,0.009928194599715343
1777,TYB4,Platelet degranulation ,0.012058170255867468,1,0,1,0.012691167992650484
1778,HBB,Cytoprotection by HMOX1,0.026019223025172684,0,0,1,0.0273851109615926
1779,HBB,Cytoprotection by HMOX1,0.027828830000741975,1,0,1,0.029289713869023504
1780,HBB,Factors involved in megakaryocyte development and platelet production,0.026019223025172684,0,0,1,0.0273851109615926
1781,HBB,Factors involved in megakaryocyte development and platelet production,0.027828830000741975,1,0,1,0.029289713869023504
1782,HBB,Erythrocytes take up carbon dioxide and release oxygen,0.026019223025172684,0,0,1,0.0273851109615926
1783,HBB,Erythrocytes take up carbon dioxide and release oxygen,0.027828830000741975,1,0,1,0.029289713869023504
1784,HBB,Erythrocytes take up oxygen and release carbon dioxide,0.026019223025172684,0,0,1,0.0273851109615926
1785,HBB,Erythrocytes take up oxygen and release carbon dioxide,0.027828830000741975,1,0,1,0.029289713869023504
1786,HBB,Neutrophil degranulation,0.026019223025172684,0,0,1,0.0273851109615926
1787,HBB,Neutrophil degranulation,0.027828830000741975,1,0,1,0.029289713869023504
1788,HBB,Scavenging of heme from plasma,0.026019223025172684,0,0,1,0.0273851109615926
1789,HBB,Scavenging of heme from plasma,0.027828830000741975,1,0,1,0.029289713869023504
1790,HBB,Heme signaling,0.026019223025172684,0,0,1,0.0273851109615926
1791,HBB,Heme signaling,0.027828830000741975,1,0,1,0.029289713869023504
1792,HBB,Chaperone Mediated Autophagy,0.026019223025172684,0,0,1,0.0273851109615926
1793,HBB,Chaperone Mediated Autophagy,0.027828830000741975,1,0,1,0.029289713869023504
1794,HBB,Late endosomal microautophagy,0.026019223025172684,0,0,1,0.0273851109615926
1795,HBB,Late endosomal microautophagy,0.027828830000741975,1,0,1,0.029289713869023504
1796,HBA,Cytoprotection by HMOX1,0.020834269705527982,0,0,1,0.02192797175909692
1797,HBA,Cytoprotection by HMOX1,0.021479452920808082,1,0,1,0.02260702408605953
1798,HBA,Erythrocytes take up carbon dioxide and release oxygen,0.020834269705527982,0,0,1,0.02192797175909692
1799,HBA,Erythrocytes take up carbon dioxide and release oxygen,0.021479452920808082,1,0,1,0.02260702408605953
1800,HBA,Erythrocytes take up oxygen and release carbon dioxide,0.020834269705527982,0,0,1,0.02192797175909692
1801,HBA,Erythrocytes take up oxygen and release carbon dioxide,0.021479452920808082,1,0,1,0.02260702408605953
1802,HBA,Scavenging of heme from plasma,0.020834269705527982,0,0,1,0.02192797175909692
1803,HBA,Scavenging of heme from plasma,0.021479452920808082,1,0,1,0.02260702408605953
1804,HBA,Heme signaling,0.020834269705527982,0,0,1,0.02192797175909692
1805,HBA,Heme signaling,0.021479452920808082,1,0,1,0.02260702408605953
1806,PHLD,Post-translational modification: synthesis of GPI-anchored proteins,0.0009260344494806494,0,0,1,0.0009746469419455923
1807,PHLD,Post-translational modification: synthesis of GPI-anchored proteins,0.0005386305404791761,1,0,1,0.0005669061333635629
1808,LV321,Initial triggering of complement,0.06406888177681372,0,0,1,0.06743219945291035
1809,LV321,Initial triggering of complement,0.0613661400899561,1,0,1,0.06458757642463962
1810,LV321,Regulation of Complement cascade,0.06406888177681372,0,0,1,0.06743219945291035
1811,LV321,Regulation of Complement cascade,0.0613661400899561,1,0,1,0.06458757642463962
1812,LV321,FCGR activation,0.06406888177681372,0,0,1,0.06743219945291035
1813,LV321,FCGR activation,0.0613661400899561,1,0,1,0.06458757642463962
1814,LV321,Regulation of actin dynamics for phagocytic cup formation,0.06406888177681372,0,0,1,0.06743219945291035
1815,LV321,Regulation of actin dynamics for phagocytic cup formation,0.0613661400899561,1,0,1,0.06458757642463962
1816,LV321,Role of phospholipids in phagocytosis,0.06406888177681372,0,0,1,0.06743219945291035
1817,LV321,Role of phospholipids in phagocytosis,0.0613661400899561,1,0,1,0.06458757642463962
1818,LV321,Role of LAT2/NTAL/LAB on calcium mobilization,0.06406888177681372,0,0,1,0.06743219945291035
1819,LV321,Role of LAT2/NTAL/LAB on calcium mobilization,0.0613661400899561,1,0,1,0.06458757642463962
1820,LV321,FCERI mediated MAPK activation,0.06406888177681372,0,0,1,0.06743219945291035
1821,LV321,FCERI mediated MAPK activation,0.0613661400899561,1,0,1,0.06458757642463962
1822,LV321,FCERI mediated Ca+2 mobilization,0.06406888177681372,0,0,1,0.06743219945291035
1823,LV321,FCERI mediated Ca+2 mobilization,0.0613661400899561,1,0,1,0.06458757642463962
1824,LV321,FCERI mediated NF-kB activation,0.06406888177681372,0,0,1,0.06743219945291035
1825,LV321,FCERI mediated NF-kB activation,0.0613661400899561,1,0,1,0.06458757642463962
1826,LV321,Parasite infection,0.06406888177681372,0,0,1,0.06743219945291035
1827,LV321,Parasite infection,0.0613661400899561,1,0,1,0.06458757642463962
1828,LV321,Leishmania parasite growth and survival,0.06406888177681372,0,0,1,0.06743219945291035
1829,LV321,Leishmania parasite growth and survival,0.0613661400899561,1,0,1,0.06458757642463962
1830,LV321,Potential therapeutics for SARS,0.06406888177681372,0,0,1,0.06743219945291035
1831,LV321,Potential therapeutics for SARS,0.0613661400899561,1,0,1,0.06458757642463962
1832,LV321,CD22 mediated BCR regulation,0.06406888177681372,0,0,1,0.06743219945291035
1833,LV321,CD22 mediated BCR regulation,0.0613661400899561,1,0,1,0.06458757642463962
1834,LV321,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.06406888177681372,0,0,1,0.06743219945291035
1835,LV321,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0613661400899561,1,0,1,0.06458757642463962
1836,LV321,Cell surface interactions at the vascular wall,0.06406888177681372,0,0,1,0.06743219945291035
1837,LV321,Cell surface interactions at the vascular wall,0.0613661400899561,1,0,1,0.06458757642463962
1838,LV321,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.06406888177681372,0,0,1,0.06743219945291035
1839,LV321,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0613661400899561,1,0,1,0.06458757642463962
1840,LV321,Scavenging of heme from plasma,0.06406888177681372,0,0,1,0.06743219945291035
1841,LV321,Scavenging of heme from plasma,0.0613661400899561,1,0,1,0.06458757642463962
1842,FHR1,Regulation of Complement cascade,0.021818813506810777,0,0,1,0.022964199521109372
1843,FHR1,Regulation of Complement cascade,0.020825641951861158,1,0,1,0.021918891088575487
1844,LG3BP,Platelet degranulation ,0.009988361618393421,0,0,1,0.010512704048832798
1845,LG3BP,Platelet degranulation ,0.01277192564648079,1,0,1,0.013442392214544826
1846,APOF,LDL remodeling,0.014408981681048897,0,0,1,0.015165386060810719
1847,APOF,LDL remodeling,0.01311801589087916,1,0,1,0.013806650583690004
1848,ITIH4,Platelet degranulation ,0.013045796333112841,0,0,1,0.013730639835747438
1849,ITIH4,Platelet degranulation ,0.01666113610698134,1,0,1,0.01753576809708955
1850,PCOC1,Crosslinking of collagen fibrils,0.013412551052310472,0,0,1,0.01411664746830426
1851,PCOC1,Crosslinking of collagen fibrils,0.013898514949037257,1,0,1,0.014628122204591188
1852,PCOC1,Collagen biosynthesis and modifying enzymes,0.013412551052310472,0,0,1,0.01411664746830426
1853,PCOC1,Collagen biosynthesis and modifying enzymes,0.013898514949037257,1,0,1,0.014628122204591188
1854,PON3,Arachidonic acid metabolism,0.001237516565606052,0,0,1,0.0013024804173877057
1855,PON3,Arachidonic acid metabolism,0.002363506728751756,1,0,1,0.0024875798159967543
1856,PON3,Atorvastatin ADME,0.001237516565606052,0,0,1,0.0013024804173877057
1857,PON3,Atorvastatin ADME,0.002363506728751756,1,0,1,0.0024875798159967543
1858,FCN2,Initial triggering of complement,0.016450161836447492,0,0,1,0.017313718660677827
1859,FCN2,Initial triggering of complement,0.0157180724458562,1,0,1,0.01654319798925919
1860,ADIPO,Transcriptional regulation of white adipocyte differentiation,0.018573495554895215,0,0,1,0.019548517502746478
1861,ADIPO,Transcriptional regulation of white adipocyte differentiation,0.024567356153170843,1,0,1,0.025857027845783767
1862,ADIPO,AMPK inhibits chREBP transcriptional activation activity,0.018573495554895215,0,0,1,0.019548517502746478
1863,ADIPO,AMPK inhibits chREBP transcriptional activation activity,0.024567356153170843,1,0,1,0.025857027845783767
1864,FHR5,Regulation of Complement cascade,0.052054891005948026,0,0,1,0.054787530162309084
1865,FHR5,Regulation of Complement cascade,0.04971264845608387,1,0,1,0.0523223307954818
1866,Apoptotic cleavage of cellular proteins,Apoptotic execution phase,0.033322592275148284,0,1,2,1.250959554050937
1867,Apoptotic cleavage of cellular proteins,Apoptotic execution phase,0.03962582796394481,1,1,2,1.487588590628487
1868,Nuclear signaling by ERBB4,Signaling by ERBB4,2.2410280102952992e-05,0,1,2,0.0008413017142323123
1869,Nuclear signaling by ERBB4,Signaling by ERBB4,1.717576877027742e-06,1,1,2,6.447935341864887e-05
1870,Antigen processing-Cross presentation,Class I MHC mediated antigen processing & presentation,0.0291718715628249,0,1,2,1.0951378314069131
1871,Antigen processing-Cross presentation,Class I MHC mediated antigen processing & presentation,0.03128840237810076,1,1,2,1.1745942681375927
1872,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins","Gamma carboxylation, hypusine formation and arylsulfatase activation",0.0201253950930251,0,1,2,0.7555251122958309
1873,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins","Gamma carboxylation, hypusine formation and arylsulfatase activation",0.020271523490000925,1,1,2,0.7610109014206881
1874,Keratan sulfate/keratin metabolism,Glycosaminoglycan metabolism,0.0011686723422934262,0,1,2,0.043872992235281995
1875,Keratan sulfate/keratin metabolism,Glycosaminoglycan metabolism,0.0010590681242500129,1,1,2,0.039758353056146285
1876,Toll Like Receptor 4 (TLR4) Cascade,Toll-like Receptor Cascades,0.019510008073257926,0,1,2,0.7324229398879895
1877,Toll Like Receptor 4 (TLR4) Cascade,Toll-like Receptor Cascades,0.016905597660025234,1,1,2,0.6346510720152435
1878,Initial triggering of complement,Complement cascade,0.03221395372071164,0,1,2,1.2093402832508062
1879,Initial triggering of complement,Complement cascade,0.030002349944884217,1,1,2,1.1263147235853965
1880,Terminal pathway of complement,Complement cascade,0.020908609512879272,0,1,2,0.7849276735760871
1881,Terminal pathway of complement,Complement cascade,0.01946682038460099,1,1,2,0.7308016359000922
1882,Activation of C3 and C5,Complement cascade,0.00846525112992031,0,1,2,0.3177930063475885
1883,Activation of C3 and C5,Complement cascade,0.007888088234858296,1,1,2,0.2961258013516556
1884,Regulation of Complement cascade,Complement cascade,0.12478010857110541,0,1,2,4.684355517231227
1885,Regulation of Complement cascade,Complement cascade,0.11653801642636968,1,1,2,4.374940096345294
1886,Toll Like Receptor 9 (TLR9) Cascade,Toll-like Receptor Cascades,0.004736299740914652,0,1,2,0.17780487672818052
1887,Toll Like Receptor 9 (TLR9) Cascade,Toll-like Receptor Cascades,0.004098717015453173,1,1,2,0.15386945791898093
1888,Toll Like Receptor 10 (TLR10) Cascade,Toll-like Receptor Cascades,0.0005663361462123596,0,1,2,0.021260759278836357
1889,Toll Like Receptor 10 (TLR10) Cascade,Toll-like Receptor Cascades,0.0004886942442417553,1,1,2,0.018346013683330865
1890,Toll Like Receptor 3 (TLR3) Cascade,Toll-like Receptor Cascades,0.00010547842520861815,0,1,2,0.003959753271037521
1891,Toll Like Receptor 3 (TLR3) Cascade,Toll-like Receptor Cascades,9.101829177098997e-05,1,1,2,0.0034169070864643286
1892,Toll Like Receptor 5 (TLR5) Cascade,Toll-like Receptor Cascades,5.524110244972479e-06,0,1,2,0.0002073799790700177
1893,Toll Like Receptor 5 (TLR5) Cascade,Toll-like Receptor Cascades,4.766802006446341e-06,1,1,2,0.00017894995872456298
1894,Toll Like Receptor 7/8 (TLR7/8) Cascade,Toll-like Receptor Cascades,0.0020703451752045504,0,1,2,0.07772258699803895
1895,Toll Like Receptor 7/8 (TLR7/8) Cascade,Toll-like Receptor Cascades,0.0017921289050666046,1,1,2,0.06727810241689659
1896,Toll Like Receptor 2 (TLR2) Cascade,Toll-like Receptor Cascades,0.01123577614111268,0,1,2,0.42180096298765307
1897,Toll Like Receptor 2 (TLR2) Cascade,Toll-like Receptor Cascades,0.009730606033648972,1,1,2,0.3652955473568332
1898,Regulation of TLR by endogenous ligand,Toll-like Receptor Cascades,0.033928820419356964,0,1,2,1.2737178941785747
1899,Regulation of TLR by endogenous ligand,Toll-like Receptor Cascades,0.02935075252637456,1,1,2,1.1018531808173841
1900,TRAF6 mediated NF-kB activation,DDX58/IFIH1-mediated induction of interferon-alpha/beta,0.011206522956621449,0,1,2,0.42070277259707495
1901,TRAF6 mediated NF-kB activation,DDX58/IFIH1-mediated induction of interferon-alpha/beta,0.011462752672425426,1,1,2,0.4303218625037084
1902,RHO GTPase Effectors,Signaling by Rho GTPases,0.020930177943693777,0,1,2,0.785737371524269
1903,RHO GTPase Effectors,Signaling by Rho GTPases,0.019760271254357496,1,1,2,0.74181804081047
1904,Metabolism of steroid hormones,Metabolism of steroids,0.000750730787603531,0,1,2,0.028183097026734626
1905,Metabolism of steroid hormones,Metabolism of steroids,0.0012760688823882315,1,1,2,0.047904753233774515
1906,Crosslinking of collagen fibrils,Assembly of collagen fibrils and other multimeric structures,0.00306566446515673,0,1,2,0.11508775249344558
1907,Crosslinking of collagen fibrils,Assembly of collagen fibrils and other multimeric structures,0.003039662838139648,1,1,2,0.11411162844315233
1908,FCGR activation,Fcgamma receptor (FCGR) dependent phagocytosis,0.04000896999112202,0,1,2,1.5019720808293149
1909,FCGR activation,Fcgamma receptor (FCGR) dependent phagocytosis,0.044446856067611513,1,1,2,1.668574244950697
1910,Regulation of actin dynamics for phagocytic cup formation,Fcgamma receptor (FCGR) dependent phagocytosis,0.024737121319259935,0,1,2,0.9286533892239819
1911,Regulation of actin dynamics for phagocytic cup formation,Fcgamma receptor (FCGR) dependent phagocytosis,0.027534510931947746,1,1,2,1.0336698667386832
1912,Role of phospholipids in phagocytosis,Fcgamma receptor (FCGR) dependent phagocytosis,0.00019683701084105177,0,1,2,0.007389435289705288
1913,Role of phospholipids in phagocytosis,Fcgamma receptor (FCGR) dependent phagocytosis,0.00021961215321913947,1,1,2,0.008244434256096849
1914,Transcriptional Regulation by TP53,Generic Transcription Pathway,0.00026723851234250554,0,1,2,0.010032369854806829
1915,Transcriptional Regulation by TP53,Generic Transcription Pathway,0.0003122761475112388,1,1,2,0.011723122469158668
1916,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,Generic Transcription Pathway,0.00047708265703097025,0,1,2,0.017910104440763918
1917,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,Generic Transcription Pathway,0.0005586278935453629,1,1,2,0.020971384663584423
1918,Transcriptional regulation by RUNX1,Generic Transcription Pathway,0.006217722180366948,0,1,2,0.2334187839211211
1919,Transcriptional regulation by RUNX1,Generic Transcription Pathway,0.007248266704677456,1,1,2,0.2721063358353388
1920,FOXO-mediated transcription,Generic Transcription Pathway,9.098457351481354e-07,0,1,2,3.4156412733378605e-05
1921,FOXO-mediated transcription,Generic Transcription Pathway,1.064767426546254e-06,1,1,2,3.997230989960065e-05
1922,Arachidonic acid metabolism,Fatty acid metabolism,9.815873597459349e-05,0,1,2,0.003684965670349688
1923,Arachidonic acid metabolism,Fatty acid metabolism,0.0005370449452072715,1,1,2,0.020161141714740996
1924,Role of LAT2/NTAL/LAB on calcium mobilization,Fc epsilon receptor (FCERI) signaling,0.009595962323647404,0,1,2,0.3602409035275492
1925,Role of LAT2/NTAL/LAB on calcium mobilization,Fc epsilon receptor (FCERI) signaling,0.009457193079351387,1,1,2,0.35503138349600005
1926,FCERI mediated MAPK activation,Fc epsilon receptor (FCERI) signaling,0.009540131599653364,0,1,2,0.35814496882315305
1927,FCERI mediated MAPK activation,Fc epsilon receptor (FCERI) signaling,0.009397608857244374,1,1,2,0.3527945391562801
1928,FCERI mediated Ca+2 mobilization,Fc epsilon receptor (FCERI) signaling,0.045226170031431444,0,1,2,1.69783037966543
1929,FCERI mediated Ca+2 mobilization,Fc epsilon receptor (FCERI) signaling,0.04453117930209984,1,1,2,1.6717398136717814
1930,FCERI mediated NF-kB activation,Fc epsilon receptor (FCERI) signaling,0.0025494106438411356,0,1,2,0.09570712793826383
1931,FCERI mediated NF-kB activation,Fc epsilon receptor (FCERI) signaling,0.0025130101050378738,1,1,2,0.09434061955222503
1932,Diseases associated with glycosaminoglycan metabolism,Diseases of glycosylation,0.012521789881841118,0,1,2,0.47007905498966146
1933,Diseases associated with glycosaminoglycan metabolism,Diseases of glycosylation,0.013313093626616378,1,1,2,0.4997852966742602
1934,Class A/1 (Rhodopsin-like receptors),GPCR ligand binding,0.021252399414811076,0,1,2,0.7978338502281529
1935,Class A/1 (Rhodopsin-like receptors),GPCR ligand binding,0.017649245728271257,1,1,2,0.6625682774998143
1936,Diseases associated with O-glycosylation of proteins,Diseases of glycosylation,0.0017385700375905947,0,1,2,0.06526745521334062
1937,Diseases associated with O-glycosylation of proteins,Diseases of glycosylation,0.0018474364626937848,1,1,2,0.06935439699367066
1938,G alpha (q) signalling events,GPCR downstream signalling,0.001820402567766681,0,1,2,0.06833952069404102
1939,G alpha (q) signalling events,GPCR downstream signalling,0.0012167123636023585,1,1,2,0.045676457077902854
1940,G alpha (i) signalling events,GPCR downstream signalling,0.02308861339635048,0,1,2,0.8667669453643837
1941,G alpha (i) signalling events,GPCR downstream signalling,0.015451004014576556,1,1,2,0.5800443414520611
1942,PPARA activates gene expression,Regulation of lipid metabolism by PPARalpha,0.007445746719368153,0,1,2,0.2795199100576446
1943,PPARA activates gene expression,Regulation of lipid metabolism by PPARalpha,0.008917344758325877,1,1,2,0.3347650005762992
1944,Adherens junctions interactions,Cell-cell junction organization,0.0023860176479677865,0,1,2,0.08957321051776321
1945,Adherens junctions interactions,Cell-cell junction organization,0.0006065440897330426,1,1,2,0.022770201001755707
1946,Metal ion SLC transporters,"Transport of bile salts and organic acids, metal ions and amine compounds",0.009550794826728031,0,1,2,0.3585452757883473
1947,Metal ion SLC transporters,"Transport of bile salts and organic acids, metal ions and amine compounds",0.008985302437988297,1,1,2,0.33731619191048123
1948,Interleukin-1 family signaling,Signaling by Interleukins,0.004767325093349946,0,1,2,0.17896959586906422
1949,Interleukin-1 family signaling,Signaling by Interleukins,0.004896781697491373,1,1,2,0.18382951116162344
1950,Interleukin-4 and Interleukin-13 signaling,Signaling by Interleukins,0.03450379960502133,0,1,2,1.2953031207944434
1951,Interleukin-4 and Interleukin-13 signaling,Signaling by Interleukins,0.035430073933248464,1,1,2,1.3300762774264385
1952,O-glycosylation of TSR domain-containing proteins,O-linked glycosylation,0.0010964001966240703,0,1,2,0.041159832035429576
1953,O-glycosylation of TSR domain-containing proteins,O-linked glycosylation,0.00016610439111584287,1,1,2,0.006235705593383417
1954,Caspase activation via Death Receptors in the presence of ligand,Caspase activation via extrinsic apoptotic signalling pathway,0.012339222737029672,0,1,2,0.4632253230779336
1955,Caspase activation via Death Receptors in the presence of ligand,Caspase activation via extrinsic apoptotic signalling pathway,0.013408202137039894,1,1,2,0.503355754182591
1956,MyD88 deficiency (TLR2/4),Diseases associated with the TLR signaling cascade,0.0008665005484369215,0,1,2,0.032529196129376464
1957,MyD88 deficiency (TLR2/4),Diseases associated with the TLR signaling cascade,0.0014195119618456602,1,1,2,0.053289733166550765
1958,IRAK4 deficiency (TLR2/4),Diseases associated with the TLR signaling cascade,0.0005463328641783589,0,1,2,0.020509818398661474
1959,IRAK4 deficiency (TLR2/4),Diseases associated with the TLR signaling cascade,0.0008958077001249397,1,1,2,0.03362941249620122
1960,Defective ABCA1 causes TGD,ABC transporter disorders,1.4067215721744602e-05,0,1,2,0.0005280957063816443
1961,Defective ABCA1 causes TGD,ABC transporter disorders,1.318089821154719e-05,1,1,2,0.0004948225639997719
1962,Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages),SLC transporter disorders,0.009697350136837151,0,1,2,0.3640470916094001
1963,Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages),SLC transporter disorders,0.008754859161256713,1,1,2,0.3286651477085818
1964,Defective CP causes aceruloplasminemia (ACERULOP),SLC transporter disorders,0.013066534455800947,0,1,2,0.49052924757028726
1965,Defective CP causes aceruloplasminemia (ACERULOP),SLC transporter disorders,0.01179371882935284,1,1,2,0.4427466244387109
1966,RAF/MAP kinase cascade,MAPK1/MAPK3 signaling,0.016124482903027114,0,1,2,0.6053273339336261
1967,RAF/MAP kinase cascade,MAPK1/MAPK3 signaling,0.01231509766399839,1,1,2,0.46231964652217644
1968,Signaling by RAS mutants,Oncogenic MAPK signaling,8.499330179134359e-05,0,1,2,0.003190723639634448
1969,Signaling by RAS mutants,Oncogenic MAPK signaling,0.00012878089193706644,1,1,2,0.00483454845942527
1970,Signaling by moderate kinase activity BRAF mutants,Oncogenic MAPK signaling,0.002197956599214717,0,1,2,0.08251323259827993
1971,Signaling by moderate kinase activity BRAF mutants,Oncogenic MAPK signaling,0.0033321550206558506,1,1,2,0.12509204338754237
1972,Signaling by high-kinase activity BRAF mutants,Oncogenic MAPK signaling,0.0017198981475222016,0,1,2,0.06456649596382075
1973,Signaling by high-kinase activity BRAF mutants,Oncogenic MAPK signaling,0.002608226583800647,1,1,2,0.09791513028740009
1974,Signaling by BRAF and RAF1 fusions,Oncogenic MAPK signaling,0.0024702915017795917,0,1,2,0.09273692544462361
1975,Signaling by BRAF and RAF1 fusions,Oncogenic MAPK signaling,0.0037319923578366435,1,1,2,0.14010229027597637
1976,Paradoxical activation of RAF signaling by kinase inactive BRAF,Oncogenic MAPK signaling,0.00010836911643520474,0,1,2,0.004068272373568648
1977,Paradoxical activation of RAF signaling by kinase inactive BRAF,Oncogenic MAPK signaling,0.00016377785925999268,1,1,2,0.00614836553205661
1978,Signaling by RAF1 mutants,Oncogenic MAPK signaling,0.007469113163501283,0,1,2,0.28039710701432724
1979,Signaling by RAF1 mutants,Oncogenic MAPK signaling,0.01128517414203756,1,1,2,0.42365540758481257
1980,Metal sequestration by antimicrobial proteins,Antimicrobial peptides,0.009501757031401669,0,1,2,0.35670435362759284
1981,Metal sequestration by antimicrobial proteins,Antimicrobial peptides,0.010880633654870917,1,1,2,0.4084686002907428
1982,Pyruvate metabolism,Pyruvate metabolism and Citric Acid (TCA) cycle,0.0006523340145251961,0,1,2,0.024489195233208052
1983,Pyruvate metabolism,Pyruvate metabolism and Citric Acid (TCA) cycle,0.0004200942265735894,1,1,2,0.015770708412916598
1984,Platelet degranulation ,Response to elevated platelet cytosolic Ca2+,0.07027987248715063,0,1,2,2.638368504447076
1985,Platelet degranulation ,Response to elevated platelet cytosolic Ca2+,0.09146866581196321,1,1,2,3.4338145258615986
1986,Cargo recognition for clathrin-mediated endocytosis,Clathrin-mediated endocytosis,3.464996919919928e-07,0,1,2,1.3007904564986653e-05
1987,Cargo recognition for clathrin-mediated endocytosis,Clathrin-mediated endocytosis,8.12687577931314e-07,1,1,2,3.050900967359295e-05
1988,Neurodegenerative Diseases,Defective Intrinsic Pathway for Apoptosis,2.572362626634076e-05,0,1,2,0.0009656876565006499
1989,Neurodegenerative Diseases,Defective Intrinsic Pathway for Apoptosis,5.331708476388015e-05,1,1,2,0.002001570466930989
1990,VLDL assembly,Plasma lipoprotein assembly,4.9623727536587855e-05,0,1,2,0.0018629185735892422
1991,VLDL assembly,Plasma lipoprotein assembly,4.9086193698728136e-05,1,1,2,0.0018427390784123987
1992,Chylomicron assembly,Plasma lipoprotein assembly,0.0063962051360561415,0,1,2,0.24011919176487592
1993,Chylomicron assembly,Plasma lipoprotein assembly,0.006323844844204456,1,1,2,0.23740272247946292
1994,HDL assembly,Plasma lipoprotein assembly,0.016931814968007827,0,1,2,0.635635292919533
1995,HDL assembly,Plasma lipoprotein assembly,0.016707009669117166,1,1,2,0.6271959033868562
1996,Assembly of active LPL and LIPC lipase complexes,Plasma lipoprotein remodeling,0.0037508298644638124,0,1,2,0.1408094669174326
1997,Assembly of active LPL and LIPC lipase complexes,Plasma lipoprotein remodeling,0.0033150245344498565,1,1,2,0.1244489498008256
1998,Chylomicron remodeling,Plasma lipoprotein remodeling,0.0022919725407993374,0,1,2,0.08604267410712942
1999,Chylomicron remodeling,Plasma lipoprotein remodeling,0.002024739377614771,1,1,2,0.07601050506443752
2000,LDL remodeling,Plasma lipoprotein remodeling,0.011455265901487738,0,1,2,0.4300408025082507
2001,LDL remodeling,Plasma lipoprotein remodeling,0.01011934192837618,1,1,2,0.3798890362875913
2002,HDL remodeling,Plasma lipoprotein remodeling,0.013821724472693414,0,1,2,0.518879748004195
2003,HDL remodeling,Plasma lipoprotein remodeling,0.012194199044541974,1,1,2,0.4577810055355517
2004,HDL clearance,Plasma lipoprotein clearance,0.0002007331987236236,0,1,2,0.007535701625044262
2005,HDL clearance,Plasma lipoprotein clearance,9.05747101410847e-05,1,1,2,0.00340025464017955
2006,Chylomicron clearance,Plasma lipoprotein clearance,4.190966769154852e-05,0,1,2,0.0015733259517430266
2007,Chylomicron clearance,Plasma lipoprotein clearance,1.9266622501982936e-05,1,1,2,0.0007232860305145954
2008,LDL clearance,Plasma lipoprotein clearance,0.0008139294845339306,0,1,2,0.0305556319446622
2009,LDL clearance,Plasma lipoprotein clearance,0.0003734024721812813,1,1,2,0.014017858701520678
2010,VLDL clearance,Plasma lipoprotein clearance,0.00032089252088367986,0,1,2,0.012046588738004863
2011,VLDL clearance,Plasma lipoprotein clearance,0.00014731329598463263,1,1,2,0.005530271280489376
2012,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,NR1H2 and NR1H3-mediated signaling,1.9863659792296745e-05,0,1,2,0.0007456993378670294
2013,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,NR1H2 and NR1H3-mediated signaling,1.7436902051953028e-05,1,1,2,0.0006545967082881748
2014,Defective factor XII causes hereditary angioedema,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.0046143473437107296,0,1,2,0.17322667599391658
2015,Defective factor XII causes hereditary angioedema,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.005287356455786115,1,1,2,0.19849203265531679
2016,Defective SERPING1 causes hereditary angioedema,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.002001621965402574,0,1,2,0.07514265698608293
2017,Defective SERPING1 causes hereditary angioedema,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.002293404851665277,1,1,2,0.08609644432246331
2018,Defective factor VIII causes hemophilia A,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.009566793824163049,0,1,2,0.3591458922869472
2019,Defective factor VIII causes hemophilia A,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.010938105123918414,1,1,2,0.41062613001402093
2020,Defective factor IX causes hemophilia B,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.009660806498928379,0,1,2,0.3626752111565144
2021,Defective factor IX causes hemophilia B,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.011047291608164138,1,1,2,0.4147250870973294
2022,Defective factor IX causes thrombophilia,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.0005548227662615777,0,1,2,0.020828536823574658
2023,Defective factor IX causes thrombophilia,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.0006342403358683327,1,1,2,0.02380994255091864
2024,Parasite infection,Leishmania infection,0.015524891579193558,0,1,2,0.5828181459064081
2025,Parasite infection,Leishmania infection,0.021309323644095126,1,1,2,0.7999708360872324
2026,Cell recruitment (pro-inflammatory response),Leishmania infection,0.009299881096741895,0,1,2,0.34912575268591434
2027,Cell recruitment (pro-inflammatory response),Leishmania infection,0.012776030071038535,1,1,2,0.4796234563097659
2028,Leishmania parasite growth and survival,Leishmania infection,0.0044026138673756935,0,1,2,0.16527801422874927
2029,Leishmania parasite growth and survival,Leishmania infection,0.006044695838800576,1,1,2,0.2269232221923789
2030,Potential therapeutics for SARS,SARS-CoV Infections,0.03638324925323368,0,1,2,1.3658593210556802
2031,Potential therapeutics for SARS,SARS-CoV Infections,0.03662813141065254,1,1,2,1.3750524135951283
2032,SARS-CoV-2 Infection,SARS-CoV Infections,0.006175758180521757,0,1,2,0.23184341829232866
2033,SARS-CoV-2 Infection,SARS-CoV Infections,0.006207887193591307,1,1,2,0.23304956982849098
2034,Detoxification of Reactive Oxygen Species,Cellular response to chemical stress,0.0006860280943552767,0,1,2,0.025754100758275177
2035,Detoxification of Reactive Oxygen Species,Cellular response to chemical stress,0.0019296258936831862,1,1,2,0.07243986084621976
2036,Cytoprotection by HMOX1,Cellular response to chemical stress,0.00019719490278596687,0,1,2,0.007402870869509904
2037,Cytoprotection by HMOX1,Cellular response to chemical stress,0.0005546688264146082,1,1,2,0.020822757785715733
2038,CD22 mediated BCR regulation,Signaling by the B Cell Receptor (BCR),0.009375563139159663,0,1,2,0.351966923422298
2039,CD22 mediated BCR regulation,Signaling by the B Cell Receptor (BCR),0.008206963670618015,1,1,2,0.30809666693204074
2040,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,Signaling by the B Cell Receptor (BCR),0.05387577255355455,0,1,2,2.022544100148175
2041,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,Signaling by the B Cell Receptor (BCR),0.04725697489088662,1,1,2,1.774068588276924
2042,Cell surface interactions at the vascular wall,Cell surface interactions at the vascular wall,0.05479697803831727,0,1,2,2.057126967918264
2043,Cell surface interactions at the vascular wall,Cell surface interactions at the vascular wall,0.05054910784330813,1,1,2,1.8976581678640143
2044,Dissolution of Fibrin Clot,Dissolution of Fibrin Clot,0.0421917705103791,0,1,2,1.5839163407958012
2045,Dissolution of Fibrin Clot,Dissolution of Fibrin Clot,0.04258332022883061,1,1,2,1.5986154631551435
2046,Platelet Adhesion to exposed collagen,Platelet Adhesion to exposed collagen,7.578252738611769e-05,0,1,2,0.0028449430308725536
2047,Platelet Adhesion to exposed collagen,Platelet Adhesion to exposed collagen,0.000549618041560644,1,1,2,0.020633146860000492
2048,Factors involved in megakaryocyte development and platelet production,Factors involved in megakaryocyte development and platelet production,0.0011772021641114178,0,1,2,0.04419320928230708
2049,Factors involved in megakaryocyte development and platelet production,Factors involved in megakaryocyte development and platelet production,0.00022397006586033792,1,1,2,0.008408034146802
2050,Transcriptional regulation of white adipocyte differentiation,Transcriptional regulation of white adipocyte differentiation,0.008220595222164468,0,1,2,0.3086084074203787
2051,Transcriptional regulation of white adipocyte differentiation,Transcriptional regulation of white adipocyte differentiation,0.0073250263821387634,1,1,2,0.2749879619433323
2052,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.056773461654258145,0,1,2,2.1313259090561765
2053,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.05963313781444303,1,1,2,2.238680678593207
2054,Extrinsic Pathway of Fibrin Clot Formation,Extrinsic Pathway of Fibrin Clot Formation,0.01557988273900071,0,1,2,0.5848825626294852
2055,Extrinsic Pathway of Fibrin Clot Formation,Extrinsic Pathway of Fibrin Clot Formation,0.016451565696563877,1,1,2,0.6176063109760466
2056,Intrinsic Pathway of Fibrin Clot Formation,Intrinsic Pathway of Fibrin Clot Formation,0.04731735097894508,0,1,2,1.7763351599640635
2057,Intrinsic Pathway of Fibrin Clot Formation,Intrinsic Pathway of Fibrin Clot Formation,0.04864791433826305,1,1,2,1.8262856840068848
2058,Common Pathway of Fibrin Clot Formation,Common Pathway of Fibrin Clot Formation,0.044543427007852736,0,1,2,1.6721996033664208
2059,Common Pathway of Fibrin Clot Formation,Common Pathway of Fibrin Clot Formation,0.040337491985335934,1,1,2,1.5143050867366692
2060,Reversible hydration of carbon dioxide,Reversible hydration of carbon dioxide,0.009335400064246378,0,1,2,0.3504591661065411
2061,Reversible hydration of carbon dioxide,Reversible hydration of carbon dioxide,0.010477667152521691,1,1,2,0.39334088177731236
2062,Activation of Matrix Metalloproteinases,Activation of Matrix Metalloproteinases,0.0018337725872135382,0,1,2,0.06884144303630028
2063,Activation of Matrix Metalloproteinases,Activation of Matrix Metalloproteinases,0.0015585213164841763,1,1,2,0.058508267152491474
2064,Integrin cell surface interactions,Integrin cell surface interactions,0.015277071367840424,0,1,2,0.5735147562265382
2065,Integrin cell surface interactions,Integrin cell surface interactions,0.014315398499523718,1,1,2,0.5374127071254678
2066,ECM proteoglycans,ECM proteoglycans,0.02550873967494415,0,1,2,0.9576206240103382
2067,ECM proteoglycans,ECM proteoglycans,0.028865192411411195,1,1,2,1.0836248251161233
2068,Collagen biosynthesis and modifying enzymes,Collagen biosynthesis and modifying enzymes,0.0005029585847410639,0,1,2,0.018881509628019235
2069,Collagen biosynthesis and modifying enzymes,Collagen biosynthesis and modifying enzymes,0.0005567397893876611,1,1,2,0.020900503565390815
2070,Erythrocytes take up carbon dioxide and release oxygen,Erythrocytes take up carbon dioxide and release oxygen,0.005888237224823662,0,1,2,0.22104962759469937
2071,Erythrocytes take up carbon dioxide and release oxygen,Erythrocytes take up carbon dioxide and release oxygen,0.006064412867595416,1,1,2,0.22766341687305497
2072,Erythrocytes take up oxygen and release carbon dioxide,Erythrocytes take up oxygen and release carbon dioxide,0.00387419330318724,0,1,2,0.14544063939697408
2073,Erythrocytes take up oxygen and release carbon dioxide,Erythrocytes take up oxygen and release carbon dioxide,0.004579481344129035,1,1,2,0.17191777556599924
2074,Molecules associated with elastic fibres,Molecules associated with elastic fibres,0.009340487704725496,0,1,2,0.3506501606249861
2075,Molecules associated with elastic fibres,Molecules associated with elastic fibres,0.014712260458531232,1,1,2,0.5523112556885722
2076,AMPK inhibits chREBP transcriptional activation activity,AMPK inhibits chREBP transcriptional activation activity,0.005012355308421856,0,1,2,0.18816824662361445
2077,AMPK inhibits chREBP transcriptional activation activity,AMPK inhibits chREBP transcriptional activation activity,0.008340023444506569,1,1,2,0.31309184840025683
2078,Neutrophil degranulation,Neutrophil degranulation,0.06464383783449355,0,1,2,2.4267867842289372
2079,Neutrophil degranulation,Neutrophil degranulation,0.06477776396589957,1,1,2,2.431814489523774
2080,Advanced glycosylation endproduct receptor signaling,Advanced glycosylation endproduct receptor signaling,0.0024288424577818203,0,1,2,0.09118089171329954
2081,Advanced glycosylation endproduct receptor signaling,Advanced glycosylation endproduct receptor signaling,0.004361294680056041,1,1,2,0.16372685543184834
2082,Heme degradation,Heme degradation,0.00020233490928931044,0,1,2,0.007595831254768916
2083,Heme degradation,Heme degradation,0.00013209917015398308,1,1,2,0.004959119555340482
2084,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis","tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",0.003843368767819183,0,1,2,0.1442834591062135
2085,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis","tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",0.002443962249059032,1,1,2,0.09174850203596914
2086,Scavenging of heme from plasma,Scavenging of heme from plasma,0.02436831081426671,0,1,2,0.9148079170276394
2087,Scavenging of heme from plasma,Scavenging of heme from plasma,0.018977138663446396,1,1,2,0.7124185514610315
2088,Scavenging by Class B Receptors,Scavenging by Class B Receptors,0.0011480933132637019,0,1,2,0.04310043730422327
2089,Scavenging by Class B Receptors,Scavenging by Class B Receptors,0.0005662712418365082,1,1,2,0.021258322711224794
2090,Scavenging by Class A Receptors,Scavenging by Class A Receptors,0.014787017335302022,0,1,2,0.5551176948891974
2091,Scavenging by Class A Receptors,Scavenging by Class A Receptors,0.008121967128845163,1,1,2,0.3049058216606379
2092,Scavenging by Class F Receptors,Scavenging by Class F Receptors,0.00010009327072846618,0,1,2,0.003757589814144331
2093,Scavenging by Class F Receptors,Scavenging by Class F Receptors,0.0004579071912461507,1,1,2,0.017190240513947314
2094,Scavenging by Class H Receptors,Scavenging by Class H Receptors,0.0022252478187080277,0,1,2,0.08353776908946761
2095,Scavenging by Class H Receptors,Scavenging by Class H Receptors,0.0010852069565503656,1,1,2,0.040739627913992445
2096,Retinoid metabolism and transport,Retinoid metabolism and transport,0.010862400442595788,0,1,2,0.4077841093931477
2097,Retinoid metabolism and transport,Retinoid metabolism and transport,0.01410420006418748,1,1,2,0.5294841312720966
2098,Retinoid metabolism and transport,Metabolism of fat-soluble vitamins,0.010862400442595788,0,1,2,0.4077841093931477
2099,Retinoid metabolism and transport,Metabolism of fat-soluble vitamins,0.01410420006418748,1,1,2,0.5294841312720966
2100,Heme signaling,Heme signaling,0.002919796471193354,0,1,2,0.10961173912773818
2101,Heme signaling,Heme signaling,0.002227584956393042,1,1,2,0.08362550730299133
2102,Metabolism of Angiotensinogen to Angiotensins,Metabolism of Angiotensinogen to Angiotensins,0.008163610350937163,0,1,2,0.30646914500917294
2103,Metabolism of Angiotensinogen to Angiotensins,Metabolism of Angiotensinogen to Angiotensins,0.007156169694191202,1,1,2,0.2686489326952706
2104,Syndecan interactions,Syndecan interactions,0.038467948534188494,0,1,2,1.4441207738652346
2105,Syndecan interactions,Syndecan interactions,0.04624135211303578,1,1,2,1.7359412119079556
2106,GRB2:SOS provides linkage to MAPK signaling for Integrins ,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.024757125695260774,0,1,2,0.9294043711726384
2107,GRB2:SOS provides linkage to MAPK signaling for Integrins ,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.019580889857938773,1,1,2,0.7350839047079689
2108,p130Cas linkage to MAPK signaling for integrins,p130Cas linkage to MAPK signaling for integrins,0.00036942820372971895,0,1,2,0.013868661152638715
2109,p130Cas linkage to MAPK signaling for integrins,p130Cas linkage to MAPK signaling for integrins,0.00037423136487085276,1,1,2,0.01404897606540223
2110,Miscellaneous transport and binding events,Miscellaneous transport and binding events,0.08228203374470679,0,1,2,3.088940241796495
2111,Miscellaneous transport and binding events,Miscellaneous transport and binding events,0.07316276392334811,1,1,2,2.7465947959559895
2112,ABC transporters in lipid homeostasis,ABC transporters in lipid homeostasis,0.004396195137705242,0,1,2,0.16503704944606304
2113,ABC transporters in lipid homeostasis,ABC transporters in lipid homeostasis,0.007066578752102396,1,1,2,0.2652856095769189
2114,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.013827550113347934,0,1,2,0.5190984477012373
2115,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.005912520803682075,1,1,2,0.2219612545992448
2116,Amyloid fiber formation,Amyloid fiber formation,0.0725286000809359,0,1,2,2.7227877250369943
2117,Amyloid fiber formation,Amyloid fiber formation,0.05416292004351356,1,1,2,2.0333238706120067
2118,Platelet sensitization by LDL,Platelet sensitization by LDL,0.0027605265392598843,0,1,2,0.10363260517020968
2119,Platelet sensitization by LDL,Platelet sensitization by LDL,0.0032174516235085947,1,1,2,0.12078597651979536
2120,Post-translational modification: synthesis of GPI-anchored proteins,Post-translational modification: synthesis of GPI-anchored proteins,0.0006053958366485261,0,1,2,0.022727094566497495
2121,Post-translational modification: synthesis of GPI-anchored proteins,Post-translational modification: synthesis of GPI-anchored proteins,0.00037985405931977956,1,1,2,0.01426005698258645
2122,Post-translational protein phosphorylation,Post-translational protein phosphorylation,0.030354865330542487,0,1,2,1.139548462605396
2123,Post-translational protein phosphorylation,Post-translational protein phosphorylation,0.036420251539197486,1,1,2,1.3672484195617611
2124,Formation of the cornified envelope,Formation of the cornified envelope,2.746368373984894e-05,0,1,2,0.0010310109513724654
2125,Formation of the cornified envelope,Formation of the cornified envelope,5.656399517704633e-06,1,1,2,0.00021234623524409566
2126,GP1b-IX-V activation signalling,GP1b-IX-V activation signalling,2.79482762869371e-07,0,1,2,1.0492029837208585e-05
2127,GP1b-IX-V activation signalling,GP1b-IX-V activation signalling,2.309337357288766e-06,1,1,2,8.669456465971385e-05
2128,Thrombin signalling through proteinase activated receptors (PARs),Thrombin signalling through proteinase activated receptors (PARs),0.004108110312638353,0,1,2,0.15422209059415862
2129,Thrombin signalling through proteinase activated receptors (PARs),Thrombin signalling through proteinase activated receptors (PARs),0.0039685123663088856,1,1,2,0.1489814603561271
2130,Signaling by PDGF,Signaling by PDGF,0.015602611108197774,0,1,2,0.5857358056893378
2131,Signaling by PDGF,Signaling by PDGF,0.009468986875916473,1,1,2,0.35547413303870684
2132,Transferrin endocytosis and recycling,Transferrin endocytosis and recycling,3.134632207583316e-08,0,1,2,1.1767686247617058e-06
2133,Transferrin endocytosis and recycling,Transferrin endocytosis and recycling,2.807652698282969e-07,1,1,2,1.0540176281523533e-05
2134,Peroxisomal protein import,Peroxisomal protein import,3.60306923346288e-05,0,1,2,0.0013526240228521713
2135,Peroxisomal protein import,Peroxisomal protein import,3.5462875284309665e-05,1,1,2,0.0013313076691248086
2136,Chaperone Mediated Autophagy,Chaperone Mediated Autophagy,0.010281137030055423,0,1,2,0.3859629673483281
2137,Chaperone Mediated Autophagy,Chaperone Mediated Autophagy,0.01476935393701123,1,1,2,0.5544545953119969
2138,Late endosomal microautophagy,Late endosomal microautophagy,0.00279029648973025,0,1,2,0.10475019541219999
2139,Late endosomal microautophagy,Late endosomal microautophagy,0.0009633173288680177,1,1,2,0.036163783603024406
2140,Sensory processing of sound by outer hair cells of the cochlea,Sensory processing of sound by outer hair cells of the cochlea,0.025488793913354863,0,1,2,0.9568718424984763
2141,Sensory processing of sound by outer hair cells of the cochlea,Sensory processing of sound by outer hair cells of the cochlea,0.021630048692639205,1,1,2,0.8120111377656491
2142,Atorvastatin ADME,Atorvastatin ADME,0.0001205263947382255,0,1,2,0.004524667341848536
2143,Atorvastatin ADME,Atorvastatin ADME,0.000695421909732752,1,1,2,0.02610675288684944
2144,Diseases of glycosylation,Diseases of metabolism,0.011539611829389089,0,2,3,0.7822526304011266
2145,Diseases of glycosylation,Diseases of metabolism,0.010614782961530855,1,2,3,0.7195598964297363
2146,Transcriptional regulation of white adipocyte differentiation,Transcriptional regulation of white adipocyte differentiation,0.005370681649883804,0,2,3,0.36407029194595386
2147,Transcriptional regulation of white adipocyte differentiation,Transcriptional regulation of white adipocyte differentiation,0.004521979836765047,1,2,3,0.306538094541572
2148,Neutrophil degranulation,Innate Immune System,0.028248675452948593,0,2,3,1.914934488709455
2149,Neutrophil degranulation,Innate Immune System,0.027087020973103,1,2,3,1.8361877088427208
2150,Clathrin-mediated endocytosis,Membrane Trafficking,3.213458532935217e-07,0,2,3,2.1783543738200398e-05
2151,Clathrin-mediated endocytosis,Membrane Trafficking,4.195771809882156e-07,1,2,3,2.844249514948347e-05
2152,Regulation of lipid metabolism by PPARalpha,Metabolism of lipids,6.226309440484184e-06,0,2,3,0.0004220719907671252
2153,Regulation of lipid metabolism by PPARalpha,Metabolism of lipids,3.4106114684196317e-06,1,2,3,0.000231200133236089
2154,Defective Intrinsic Pathway for Apoptosis,Diseases of programmed cell death,1.2762085644534974e-05,0,2,3,0.0008651222599547748
2155,Defective Intrinsic Pathway for Apoptosis,Diseases of programmed cell death,5.9834128109471656e-05,1,2,3,0.004056063998806976
2156,Late endosomal microautophagy,Late endosomal microautophagy,7.030711375754203e-05,0,2,3,0.0047660116723059745
2157,Late endosomal microautophagy,Late endosomal microautophagy,0.0020790713654732914,1,2,3,0.14093706690298996
2158,Common Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.012929181231240346,0,2,3,0.87644941412263
2159,Common Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.012469188256075623,1,2,3,0.8452671941217608
2160,Cellular response to chemical stress,Cellular responses to stress,1.5573105613884325e-05,0,2,3,0.001055677002839054
2161,Cellular response to chemical stress,Cellular responses to stress,3.373955858594872e-05,1,2,3,0.0022871530552885633
2162,Antimicrobial peptides,Innate Immune System,0.004233781730954214,0,2,3,0.2870015858894364
2163,Antimicrobial peptides,Innate Immune System,0.004058641233498655,1,2,3,0.27512907953047466
2164,Signaling by ERBB4,Signaling by Receptor Tyrosine Kinases,2.1267079056477215e-06,0,2,3,0.00014416627507789177
2165,Signaling by ERBB4,Signaling by Receptor Tyrosine Kinases,8.178827815630714e-07,1,2,3,5.5443022408091995e-05
2166,SARS-CoV Infections,Infectious disease,0.023826249433649874,0,2,3,1.6151449951373866
2167,SARS-CoV Infections,Infectious disease,0.027123630105895732,1,2,3,1.8386693859430616
2168,Scavenging by Class F Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.00034759736215661904,0,2,3,0.023563093359432633
2169,Scavenging by Class F Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.00013307079487898205,1,2,3,0.009020665587601772
2170,Plasma lipoprotein clearance,"Plasma lipoprotein assembly, remodeling, and clearance",0.0022334794326604383,0,2,3,0.15140415353450742
2171,Plasma lipoprotein clearance,"Plasma lipoprotein assembly, remodeling, and clearance",0.0019025862240710561,1,2,3,0.12897340918817737
2172,Platelet Aggregation (Plug Formation),"Platelet activation, signaling and aggregation",0.0,0,2,3,0.0
2173,Platelet Aggregation (Plug Formation),"Platelet activation, signaling and aggregation",0.0,1,2,3,0.0
2174,Toll-like Receptor Cascades,Innate Immune System,0.03224883647691818,0,2,3,2.186099284310204
2175,Toll-like Receptor Cascades,Innate Immune System,0.030905297987167565,1,2,3,2.0950228656930783
2176,Heme signaling,Cellular responses to stress,4.944824691344753e-06,0,2,3,0.00033520210028430836
2177,Heme signaling,Cellular responses to stress,1.0672495186767949e-05,1,2,3,0.0007234721198793191
2178,Leishmania infection,Infectious disease,0.008290656263729702,0,2,3,0.5620109034809253
2179,Leishmania infection,Infectious disease,0.00945597511262336,1,2,3,0.6410060853189731
2180,Signaling by Interleukins,Cytokine Signaling in Immune system,0.02379356121093514,0,2,3,1.612929110532272
2181,Signaling by Interleukins,Cytokine Signaling in Immune system,0.024305349101866346,1,2,3,1.6476224286271475
2182,Syndecan interactions,Non-integrin membrane-ECM interactions,0.029091070147859978,0,2,3,1.9720391362203993
2183,Syndecan interactions,Non-integrin membrane-ECM interactions,0.034935865548421326,1,2,3,2.3682488739345637
2184,Erythrocytes take up carbon dioxide and release oxygen,O2/CO2 exchange in erythrocytes,0.0013086345209443967,0,2,3,0.08871033197454327
2185,Erythrocytes take up carbon dioxide and release oxygen,O2/CO2 exchange in erythrocytes,0.0007386136311660868,1,2,3,0.05006948798384209
2186,Reversible hydration of carbon dioxide,Reversible hydration of carbon dioxide,5.1691200602310374e-05,0,2,3,0.0035040674017100164
2187,Reversible hydration of carbon dioxide,Reversible hydration of carbon dioxide,9.057764668686311e-05,1,2,3,0.006140120085832526
2188,"Gamma carboxylation, hypusine formation and arylsulfatase activation",Post-translational protein modification,0.0059285932330536695,0,2,3,0.40189026456881016
2189,"Gamma carboxylation, hypusine formation and arylsulfatase activation",Post-translational protein modification,0.006897276873370056,1,2,3,0.46755584646769005
2190,MAPK1/MAPK3 signaling,MAPK family signaling cascades,0.016232227103566824,0,2,3,1.10035784017406
2191,MAPK1/MAPK3 signaling,MAPK family signaling cascades,0.01192062689218634,1,2,3,0.8080810585581749
2192,Post-translational modification: synthesis of GPI-anchored proteins,Post-translational protein modification,0.00020914972491732772,0,2,3,0.014177939854751
2193,Post-translational modification: synthesis of GPI-anchored proteins,Post-translational protein modification,0.0002437107387620285,1,2,3,0.016520778105210434
2194,NR1H2 and NR1H3-mediated signaling,Signaling by Nuclear Receptors,2.07142951697502e-06,0,2,3,0.0001404190376852588
2195,NR1H2 and NR1H3-mediated signaling,Signaling by Nuclear Receptors,8.738224386263276e-07,1,2,3,5.923508617318535e-05
2196,Plasma lipoprotein assembly,"Plasma lipoprotein assembly, remodeling, and clearance",0.004740933125899376,0,2,3,0.32138060301521926
2197,Plasma lipoprotein assembly,"Plasma lipoprotein assembly, remodeling, and clearance",0.004041506096246599,1,2,3,0.2739675147927797
2198,Integrin cell surface interactions,Integrin cell surface interactions,0.010657520775830431,0,2,3,0.7224570274725929
2199,Integrin cell surface interactions,Integrin cell surface interactions,0.009497354357489787,1,2,3,0.6438111210185568
2200,Scavenging by Class B Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.0010214992101673444,0,2,3,0.0692458685716798
2201,Scavenging by Class B Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.0003909667285471288,1,2,3,0.026503036352264007
2202,Apoptotic execution phase,Apoptosis,0.018595988195420653,0,2,3,1.260593588055398
2203,Apoptotic execution phase,Apoptosis,0.02152920105387142,1,2,3,1.4594315999377259
2204,Formation of the cornified envelope,Keratinization,2.1389895844611266e-05,0,2,3,0.0014499883129378284
2205,Formation of the cornified envelope,Keratinization,4.878465480645066e-07,1,2,3,3.307037109200345e-05
2206,Oncogenic MAPK signaling,Diseases of signal transduction by growth factor receptors and second messengers,0.008892150217434391,0,2,3,0.6027852583216615
2207,Oncogenic MAPK signaling,Diseases of signal transduction by growth factor receptors and second messengers,0.011802122533542963,1,2,3,0.8000478293964547
2208,SLC transporter disorders,Disorders of transmembrane transporters,0.014077674621298003,0,2,3,0.9543040238490017
2209,SLC transporter disorders,Disorders of transmembrane transporters,0.014654585578700174,1,2,3,0.9934119349821765
2210,Signaling by PDGF,Signaling by Receptor Tyrosine Kinases,0.004642885024267067,0,2,3,0.31473407221837085
2211,Signaling by PDGF,Signaling by Receptor Tyrosine Kinases,0.001790105921634167,1,2,3,0.12134854157993748
2212,Post-translational protein phosphorylation,Post-translational protein modification,0.01698785787122275,0,2,3,1.1515808938044663
2213,Post-translational protein phosphorylation,Post-translational protein modification,0.019636193583860383,1,2,3,1.3311075198318607
2214,Platelet Adhesion to exposed collagen,Platelet Adhesion to exposed collagen,6.398244304660773e-05,0,2,3,0.004337271921506987
2215,Platelet Adhesion to exposed collagen,Platelet Adhesion to exposed collagen,0.0005978721304628832,1,2,3,0.040528836984534466
2216,Dissolution of Fibrin Clot,Dissolution of Fibrin Clot,0.0335844145167691,0,2,3,2.276636076208053
2217,Dissolution of Fibrin Clot,Dissolution of Fibrin Clot,0.03366009618356995,1,2,3,2.2817664206081423
2218,"Transport of bile salts and organic acids, metal ions and amine compounds",SLC-mediated transmembrane transport,0.005089384307875178,0,2,3,0.34500157551385685
2219,"Transport of bile salts and organic acids, metal ions and amine compounds",SLC-mediated transmembrane transport,0.006001736655533656,1,2,3,0.4068485452698811
2220,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",Gene Silencing by RNA,0.0008435909447073487,0,2,3,0.057185739454359986
2221,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",Gene Silencing by RNA,0.0009333941134217011,1,2,3,0.06327335886338108
2222,Metabolism of steroids,Metabolism of lipids,1.3388045002724152e-05,0,2,3,0.0009075550871336425
2223,Metabolism of steroids,Metabolism of lipids,7.347498149019357e-06,1,2,3,0.0004980756579090305
2224,Class I MHC mediated antigen processing & presentation,Adaptive Immune System,0.016748352907176224,0,2,3,1.1353452187324182
2225,Class I MHC mediated antigen processing & presentation,Adaptive Immune System,0.015551802429628158,1,2,3,1.0542328925720286
2226,ABC transporter disorders,Disorders of transmembrane transporters,1.5927240363827727e-05,0,2,3,0.0010796832557144018
2227,ABC transporter disorders,Disorders of transmembrane transporters,1.659334909266842e-05,1,2,3,0.0011248377473015222
2228,Factors involved in megakaryocyte development and platelet production,Factors involved in megakaryocyte development and platelet production,3.0326793164455213e-06,0,2,3,0.00020558069088691275
2229,Factors involved in megakaryocyte development and platelet production,Factors involved in megakaryocyte development and platelet production,4.481033728370426e-06,1,2,3,0.0003037624205007167
2230,Extrinsic Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.003959247425715535,0,2,3,0.26839132537258226
2231,Extrinsic Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.003823019583270924,1,2,3,0.25915664836076385
2232,Miscellaneous transport and binding events,Miscellaneous transport and binding events,0.0510133768604497,0,2,3,3.458118767314147
2233,Miscellaneous transport and binding events,Miscellaneous transport and binding events,0.046606572903355285,1,2,3,3.159388269437279
2234,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.01135835751926567,0,2,3,0.7699656780354948
2235,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0045253881201808,1,2,3,0.30676913685967977
2236,GPCR downstream signalling,Signaling by GPCR,0.014551798602218002,0,2,3,0.9864441631096962
2237,GPCR downstream signalling,Signaling by GPCR,0.010762331531539724,1,2,3,0.7295619882425137
2238,Scavenging by Class A Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.008796773078998468,0,2,3,0.596319788033344
2239,Scavenging by Class A Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.0033651342787577405,1,2,3,0.2281173041286433
2240,p130Cas linkage to MAPK signaling for integrins,Integrin signaling,0.0005199130081880709,0,2,3,0.03524410736235414
2241,p130Cas linkage to MAPK signaling for integrins,Integrin signaling,0.0004231359522985869,1,2,3,0.028683738811722096
2242,Diseases associated with the TLR signaling cascade,Diseases of Immune System,0.0011054180853016034,0,2,3,0.07493460072182814
2243,Diseases associated with the TLR signaling cascade,Diseases of Immune System,0.0019980720165810764,1,2,3,0.13544624496993815
2244,Activation of Matrix Metalloproteinases,Degradation of the extracellular matrix,0.0008732078638617176,0,2,3,0.05919342509018689
2245,Activation of Matrix Metalloproteinases,Degradation of the extracellular matrix,0.00144754646513487,1,2,3,0.09812696013705963
2246,Pyruvate metabolism and Citric Acid (TCA) cycle,The citric acid (TCA) cycle and respiratory electron transport,0.00042834765742339446,0,2,3,0.029037032328265936
2247,Pyruvate metabolism and Citric Acid (TCA) cycle,The citric acid (TCA) cycle and respiratory electron transport,8.593555579916911e-05,1,2,3,0.00582543984691742
2248,Erythrocytes take up oxygen and release carbon dioxide,O2/CO2 exchange in erythrocytes,0.001948276174683061,0,2,3,0.13207066103490875
2249,Erythrocytes take up oxygen and release carbon dioxide,O2/CO2 exchange in erythrocytes,0.0010983438510765624,1,2,3,0.074455049207234
2250,Transferrin endocytosis and recycling,Iron uptake and transport,2.6438062337603482e-08,0,2,3,1.792195795843694e-06
2251,Transferrin endocytosis and recycling,Iron uptake and transport,3.3505694232926613e-08,1,2,3,2.2712997486077717e-06
2252,Advanced glycosylation endproduct receptor signaling,Innate Immune System,0.002823368205376344,0,2,3,0.19139181091184737
2253,Advanced glycosylation endproduct receptor signaling,Innate Immune System,0.0027058103566300795,1,2,3,0.18342274420789986
2254,Metabolism of Angiotensinogen to Angiotensins,Peptide hormone metabolism,0.00215310727558304,0,2,3,0.14595584797498362
2255,Metabolism of Angiotensinogen to Angiotensins,Peptide hormone metabolism,0.0012598413071924625,1,2,3,0.08540271466752371
2256,ECM proteoglycans,ECM proteoglycans,0.01816408640107788,0,2,3,1.2313156262231681
2257,ECM proteoglycans,ECM proteoglycans,0.01889980189976899,1,2,3,1.281188654240651
2258,Peroxisomal protein import,Peroxisomal protein import,1.3694977075130632e-05,0,2,3,0.000928361542718479
2259,Peroxisomal protein import,Peroxisomal protein import,6.170032510352839e-05,1,2,3,0.004182570637767712
2260,Scavenging by Class H Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.0008901523068906267,0,2,3,0.06034206295825527
2261,Scavenging by Class H Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.000340778460247238,1,2,3,0.023100850431860696
2262,Metabolism of fat-soluble vitamins,Metabolism of vitamins and cofactors,0.0018776805124664988,0,2,3,0.12728508910404257
2263,Metabolism of fat-soluble vitamins,Metabolism of vitamins and cofactors,0.0027773302159548093,1,2,3,0.18827096604671453
2264,Molecules associated with elastic fibres,Elastic fibre formation,0.004606438771500854,0,2,3,0.31226343650582244
2265,Molecules associated with elastic fibres,Elastic fibre formation,0.01000148508334337,1,2,3,0.6779853716082208
2266,Generic Transcription Pathway,RNA Polymerase II Transcription,0.0035004350300518357,0,2,3,0.23728913504981025
2267,Generic Transcription Pathway,RNA Polymerase II Transcription,0.0024006731638342932,1,2,3,0.16273796076572095
2268,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,Adaptive Immune System,0.041832085453569416,0,2,3,2.8357330701436396
2269,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,Adaptive Immune System,0.03885102260372827,1,2,3,2.633651380555059
2270,Plasma lipoprotein remodeling,"Plasma lipoprotein assembly, remodeling, and clearance",0.01703591004423437,0,2,3,1.1548382770934864
2271,Plasma lipoprotein remodeling,"Plasma lipoprotein assembly, remodeling, and clearance",0.014496441835277166,1,2,3,0.9826916125741845
2272,DDX58/IFIH1-mediated induction of interferon-alpha/beta,Innate Immune System,0.011886754147691105,0,2,3,0.8057848770338693
2273,DDX58/IFIH1-mediated induction of interferon-alpha/beta,Innate Immune System,0.01139195154715655,1,2,3,0.7722429657876254
2274,Intrinsic Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.03259143589968807,0,2,3,2.209323575005417
2275,Intrinsic Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.03139235725027963,1,2,3,2.1280398679426953
2276,Cell-cell junction organization,Cell junction organization,0.002045366764046108,0,2,3,0.1386522835400099
2277,Cell-cell junction organization,Cell junction organization,0.00022965221257221206,1,2,3,0.015567772124234623
2278,Fc epsilon receptor (FCERI) signaling,Innate Immune System,0.04585746356810821,0,2,3,3.1086072937321294
2279,Fc epsilon receptor (FCERI) signaling,Innate Immune System,0.04395107083989524,1,2,3,2.979375847452092
2280,Scavenging of heme from plasma,Binding and Uptake of Ligands by Scavenger Receptors,0.00912231690527175,0,2,3,0.6183879059369773
2281,Scavenging of heme from plasma,Binding and Uptake of Ligands by Scavenger Receptors,0.0034891304158492314,1,2,3,0.23652281254898438
2282,Platelet sensitization by LDL,Platelet homeostasis,0.002673852193379279,0,2,3,0.18125634921686049
2283,Platelet sensitization by LDL,Platelet homeostasis,0.0032051436115627654,1,2,3,0.21727178158392818
2284,Response to elevated platelet cytosolic Ca2+,"Platelet activation, signaling and aggregation",0.04562277185695768,0,2,3,3.0926979017096627
2285,Response to elevated platelet cytosolic Ca2+,"Platelet activation, signaling and aggregation",0.05769042000140076,1,2,3,3.9107453060169903
2286,Cell surface interactions at the vascular wall,Cell surface interactions at the vascular wall,0.039044769316886954,0,2,3,2.646785173809176
2287,Cell surface interactions at the vascular wall,Cell surface interactions at the vascular wall,0.03584880919498279,1,2,3,2.4301359269385387
2288,O-linked glycosylation,Post-translational protein modification,7.095555422696467e-05,0,2,3,0.004809968459619439
2289,O-linked glycosylation,Post-translational protein modification,8.250149973122096e-05,1,2,3,0.005592650440149342
2290,GPCR ligand binding,Signaling by GPCR,0.015197420160605005,0,2,3,1.0302098607569665
2291,GPCR ligand binding,Signaling by GPCR,0.011248256381084256,1,2,3,0.7625020903320313
2292,Complement cascade,Innate Immune System,0.07414858948533842,0,2,3,5.026419434466367
2293,Complement cascade,Innate Immune System,0.07112662158490289,1,2,3,4.821564854082391
2294,AMPK inhibits chREBP transcriptional activation activity,Integration of energy metabolism,0.0034130313377467476,0,2,3,0.23136417247539362
2295,AMPK inhibits chREBP transcriptional activation activity,Integration of energy metabolism,0.005988920813849294,1,2,3,0.40597977897023285
2296,Glycosaminoglycan metabolism,Metabolism of carbohydrates,0.0011969832101474663,0,2,3,0.08114166044122564
2297,Glycosaminoglycan metabolism,Metabolism of carbohydrates,0.0013178355629713185,1,2,3,0.0893340565360281
2298,Assembly of collagen fibrils and other multimeric structures,Collagen formation,0.001364289052111821,0,2,3,0.09248306749139852
2299,Assembly of collagen fibrils and other multimeric structures,Collagen formation,0.0017709617257221704,1,2,3,0.1200507858295288
2300,ABC transporters in lipid homeostasis,ABC-family proteins mediated transport,0.0031818412082807715,0,2,3,0.21569214731793115
2301,ABC transporters in lipid homeostasis,ABC-family proteins mediated transport,0.0037042207854125334,1,2,3,0.2511034596151475
2302,Collagen biosynthesis and modifying enzymes,Collagen formation,0.00023012211075157225,0,2,3,0.01559962580287302
2303,Collagen biosynthesis and modifying enzymes,Collagen formation,0.0002987182917492914,1,2,3,0.020249655961103948
2304,Retinoid metabolism and transport,Visual phototransduction,0.004609517954970549,0,2,3,0.31247216964210717
2305,Retinoid metabolism and transport,Visual phototransduction,0.00566038703546631,1,2,3,0.3837089767876853
2306,Signaling by Rho GTPases,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",0.00936019084095801,0,2,3,0.6345130160919432
2307,Signaling by Rho GTPases,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",0.008022563050059288,1,2,3,0.5438372747066658
2308,Signaling by the B Cell Receptor (BCR),Adaptive Immune System,0.03844502220053455,0,2,3,2.606129234399904
2309,Signaling by the B Cell Receptor (BCR),Adaptive Immune System,0.035702481573579185,1,2,3,2.4202166013636712
2310,Thrombin signalling through proteinase activated receptors (PARs),"Platelet activation, signaling and aggregation",0.0024788354183434367,0,2,3,0.16803646041127587
2311,Thrombin signalling through proteinase activated receptors (PARs),"Platelet activation, signaling and aggregation",0.0032137286651638844,1,2,3,0.21785374923248518
2312,Fcgamma receptor (FCGR) dependent phagocytosis,Innate Immune System,0.03412616603586267,0,2,3,2.313360582811946
2313,Fcgamma receptor (FCGR) dependent phagocytosis,Innate Immune System,0.03270101481870071,1,2,3,2.2167517622704205
2314,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),Diseases of hemostasis,0.014370234396660788,0,2,3,0.9741362034067449
2315,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),Diseases of hemostasis,0.01536839425862478,1,2,3,1.0417999332727341
2316,Sensory processing of sound by outer hair cells of the cochlea,Sensory processing of sound,0.01718268433498873,0,2,3,1.164787881700242
2317,Sensory processing of sound by outer hair cells of the cochlea,Sensory processing of sound,0.015548406537818488,1,2,3,1.0540026902619384
2318,Amyloid fiber formation,Amyloid fiber formation,0.05263733507864006,0,2,3,3.568204410282277
2319,Amyloid fiber formation,Amyloid fiber formation,0.03897623035243818,1,2,3,2.6421390222732573
2320,Chaperone Mediated Autophagy,Chaperone Mediated Autophagy,0.007909035429657676,0,2,3,0.5361414110159853
2321,Chaperone Mediated Autophagy,Chaperone Mediated Autophagy,0.013662757773086167,1,2,3,0.9261774455281574
2322,GRB2:SOS provides linkage to MAPK signaling for Integrins ,Integrin signaling,0.016326356103592034,0,2,3,1.106738701069157
2323,GRB2:SOS provides linkage to MAPK signaling for Integrins ,Integrin signaling,0.01315449865491035,1,2,3,0.8917233375393762
2324,Caspase activation via extrinsic apoptotic signalling pathway,Apoptosis,0.0071161753139632935,0,2,3,0.48239463684265455
2325,Caspase activation via extrinsic apoptotic signalling pathway,Apoptosis,0.00825095586487849,1,2,3,0.5593196741840923
2326,Fatty acid metabolism,Metabolism of lipids,6.633597685550929e-05,0,2,3,0.004496814377524651
2327,Fatty acid metabolism,Metabolism of lipids,3.640662182635165e-05,1,2,3,0.0024679491917702005
2328,Atorvastatin ADME,Atorvastatin ADME,0.00010926430081528139,0,2,3,0.007406859778767686
2329,Atorvastatin ADME,Atorvastatin ADME,0.0009588563394651788,1,2,3,0.06499940420986765
2330,GP1b-IX-V activation signalling,"Platelet activation, signaling and aggregation",3.6161802594548725e-07,0,2,3,2.451353270617733e-05
2331,GP1b-IX-V activation signalling,"Platelet activation, signaling and aggregation",4.6744544995466963e-07,1,2,3,3.16874118646534e-05
2332,Heme degradation,Metabolism of porphyrins,6.6646543005397e-05,0,2,3,0.0045178671816618315
2333,Heme degradation,Metabolism of porphyrins,0.00010265829407155586,1,2,3,0.0069590486887476455
2334,Cell surface interactions at the vascular wall,Hemostasis,0.019400318872503,0,3,4,3.008736311288923
2335,Cell surface interactions at the vascular wall,Hemostasis,0.01793903460265542,1,3,4,2.7821101886617705
2336,Adaptive Immune System,Immune System,0.037885255418050864,0,3,4,5.875508768069988
2337,Adaptive Immune System,Immune System,0.03524121494765803,1,3,4,5.465452591979827
2338,Collagen formation,Extracellular matrix organization,0.0004865769044510741,0,3,4,0.07546172876217405
2339,Collagen formation,Extracellular matrix organization,0.0005565348956092814,1,3,4,0.08631130034116795
2340,Platelet homeostasis,Hemostasis,0.0020676146640947694,0,3,4,0.32066005504850603
2341,Platelet homeostasis,Hemostasis,0.0019137538842328094,1,3,4,0.2967982557504523
2342,"Plasma lipoprotein assembly, remodeling, and clearance",Transport of small molecules,0.0077138069125707795,0,3,4,1.1963107982218872
2343,"Plasma lipoprotein assembly, remodeling, and clearance",Transport of small molecules,0.006648473434421503,1,3,4,1.0310914768074082
2344,Dissolution of Fibrin Clot,Hemostasis,0.02625137587569447,0,3,4,4.071245856192758
2345,Dissolution of Fibrin Clot,Hemostasis,0.024244941097564976,1,3,4,3.760074003149279
2346,Binding and Uptake of Ligands by Scavenger Receptors,Vesicle-mediated transport,0.010063173539242269,0,3,4,1.5606669062142962
2347,Binding and Uptake of Ligands by Scavenger Receptors,Vesicle-mediated transport,0.003663408399103246,1,3,4,0.5681468405699812
2348,Keratinization,Developmental Biology,1.1871060754250115e-05,0,3,4,0.0018410466229734218
2349,Keratinization,Developmental Biology,1.06620172720646e-05,1,3,4,0.0016535397551386546
2350,ABC-family proteins mediated transport,Transport of small molecules,0.002541609009730507,0,3,4,0.39417039312244306
2351,ABC-family proteins mediated transport,Transport of small molecules,0.002187292120775297,1,3,4,0.33922046696357855
2352,Cytokine Signaling in Immune system,Immune System,0.01774387286510881,0,3,4,2.7518431497440243
2353,Cytokine Signaling in Immune system,Immune System,0.016444521895192042,1,3,4,2.5503307689430037
2354,Peptide hormone metabolism,Metabolism of proteins,0.0011857196421541792,0,3,4,0.18388964458796608
2355,Peptide hormone metabolism,Metabolism of proteins,0.0005834657387431478,1,3,4,0.09048792270304751
2356,Post-translational protein modification,Metabolism of proteins,0.004374403672616626,0,3,4,0.6784129300416596
2357,Post-translational protein modification,Metabolism of proteins,0.0021531716175089144,1,3,4,0.33392882212971337
2358,The citric acid (TCA) cycle and respiratory electron transport,Metabolism,0.00010332971313084782,0,3,4,0.016025090204702334
2359,The citric acid (TCA) cycle and respiratory electron transport,Metabolism,7.231953680534411e-05,1,3,4,0.011215816494142055
2360,Integrin signaling,Signal Transduction,0.013875621540251454,0,3,4,2.151927844290686
2361,Integrin signaling,Signal Transduction,0.008187817022848902,1,3,4,1.2698235811861522
2362,Diseases of signal transduction by growth factor receptors and second messengers,Disease,0.0034944982668832013,0,3,4,0.5419510830932643
2363,Diseases of signal transduction by growth factor receptors and second messengers,Disease,0.003402501242219837,1,3,4,0.5276835449948303
2364,Atorvastatin ADME,Drug ADME,0.0009724153327721324,0,3,4,0.15080892951261793
2365,Atorvastatin ADME,Drug ADME,0.0014455300763320821,1,3,4,0.22418285278212308
2366,Apoptosis,Programmed Cell Death,0.014883488365353404,0,3,4,2.3082348376734436
2367,Apoptosis,Programmed Cell Death,0.017828414124194284,1,3,4,2.764954395888183
2368,Signaling by Nuclear Receptors,Signal Transduction,2.0952880161427376e-06,0,3,4,0.0003249518308543055
2369,Signaling by Nuclear Receptors,Signal Transduction,1.2405435779990817e-06,1,3,4,0.0001923921216651921
2370,O2/CO2 exchange in erythrocytes,Transport of small molecules,0.0014882064125508211,0,3,4,0.2308013956657705
2371,O2/CO2 exchange in erythrocytes,Transport of small molecules,0.0012866488880449937,1,3,4,0.19954245364633197
2372,SLC-mediated transmembrane transport,Transport of small molecules,0.0030995974046988525,0,3,4,0.4807071122481573
2373,SLC-mediated transmembrane transport,Transport of small molecules,0.002672588088833014,1,3,4,0.41448353920549263
2374,Iron uptake and transport,Transport of small molecules,1.9459541962392422e-08,0,3,4,3.017921039755917e-06
2375,Iron uptake and transport,Transport of small molecules,1.6789295015644103e-08,1,3,4,2.6038005811392745e-06
2376,RNA Polymerase II Transcription,Gene expression (Transcription),0.00046820603197177303,0,3,4,0.07261264615369833
2377,RNA Polymerase II Transcription,Gene expression (Transcription),0.0006740637257012453,1,3,4,0.10453848830879416
2378,Diseases of Immune System,Disease,0.0008483034670185273,0,3,4,0.13156079861287517
2379,Diseases of Immune System,Disease,0.0008260493133545956,1,3,4,0.128109469763813
2380,Elastic fibre formation,Extracellular matrix organization,0.0008113175381719405,0,3,4,0.12582476366114054
2381,Elastic fibre formation,Extracellular matrix organization,0.0009407595102967001,1,3,4,0.14589952450894333
2382,Late endosomal microautophagy,Autophagy,0.0004274858630034265,0,3,4,0.06629747928546026
2383,Late endosomal microautophagy,Autophagy,0.0007955915027837649,1,3,4,0.12338586077423588
2384,Sensory processing of sound,Sensory Perception,0.007777203411199695,0,3,4,1.2061427679274854
2385,Sensory processing of sound,Sensory Perception,0.009640669106568167,1,3,4,1.4951419817725213
2386,Platelet Adhesion to exposed collagen,Hemostasis,0.0007982805579563165,0,3,4,0.12380289814325474
2387,Platelet Adhesion to exposed collagen,Hemostasis,0.0007394142296001571,1,3,4,0.11467349873485301
2388,Metabolism of carbohydrates,Metabolism,0.00013280117590691237,0,3,4,0.02059572952170986
2389,Metabolism of carbohydrates,Metabolism,9.272081323259127e-05,1,3,4,0.014379788261137135
2390,Integration of energy metabolism,Metabolism,0.0009691758300087771,0,3,4,0.15030652490480284
2391,Integration of energy metabolism,Metabolism,0.0006764735781884604,1,3,4,0.1049122249845047
2392,Metabolism of lipids,Metabolism,0.00010675409612180492,0,3,4,0.01655616732340144
2393,Metabolism of lipids,Metabolism,7.450808909252559e-05,1,3,4,0.0115552323964719
2394,Peroxisomal protein import,Protein localization,2.2905608163371847e-05,0,3,4,0.0035523609413952535
2395,Peroxisomal protein import,Protein localization,5.781433979782685e-05,1,3,4,0.008966249709919095
2396,Non-integrin membrane-ECM interactions,Extracellular matrix organization,0.011941901763823011,0,3,4,1.852033139186433
2397,Non-integrin membrane-ECM interactions,Extracellular matrix organization,0.013874302262246016,1,3,4,2.1517232414866942
2398,Cell junction organization,Cell-Cell communication,0.0019248243016955682,0,3,4,0.2985151330461414
2399,Cell junction organization,Cell-Cell communication,0.00021621354321745597,1,3,4,0.03353189928196609
2400,Innate Immune System,Immune System,0.06690114765801436,0,3,4,10.375495039458588
2401,Innate Immune System,Immune System,0.06268569042654214,1,3,4,9.721732628419435
2402,Reversible hydration of carbon dioxide,Metabolism,6.483273002389899e-05,0,3,4,0.010054710454237474
2403,Reversible hydration of carbon dioxide,Metabolism,4.5258233785277215e-05,1,3,4,0.0070189615062238525
2404,Integrin cell surface interactions,Extracellular matrix organization,0.00413185669795907,0,3,4,0.6407970591561666
2405,Integrin cell surface interactions,Extracellular matrix organization,0.004774729719956404,1,3,4,0.7404982763136282
2406,Degradation of the extracellular matrix,Extracellular matrix organization,0.0005417601338823098,0,3,4,0.08401992758638364
2407,Degradation of the extracellular matrix,Extracellular matrix organization,0.0006227958250942698,1,3,4,0.09658750589590265
2408,Diseases of hemostasis,Disease,0.006267598203236039,0,3,4,0.9720226983162216
2409,Diseases of hemostasis,Disease,0.006086921376701014,1,3,4,0.9440020800894323
2410,Diseases of programmed cell death,Disease,0.00028250739495084366,0,3,4,0.04381321064784024
2411,Diseases of programmed cell death,Disease,0.0002754946513248243,1,3,4,0.04272562561751016
2412,Gene Silencing by RNA,Gene expression (Transcription),0.00024149218584851762,0,3,4,0.03745228690466493
2413,Gene Silencing by RNA,Gene expression (Transcription),0.00034827409916138953,1,3,4,0.05401276831142714
2414,Formation of Fibrin Clot (Clotting Cascade),Hemostasis,0.027388562941541312,0,3,4,4.247608731474719
2415,Formation of Fibrin Clot (Clotting Cascade),Hemostasis,0.025250477463197203,1,3,4,3.9160195726773765
2416,Factors involved in megakaryocyte development and platelet production,Hemostasis,3.830747004989692e-06,0,3,4,0.0005940988748184812
2417,Factors involved in megakaryocyte development and platelet production,Hemostasis,3.5494524323585197e-06,1,3,4,0.0005504737570868614
2418,"Platelet activation, signaling and aggregation",Hemostasis,0.02946246383981082,0,3,4,4.569243699417549
2419,"Platelet activation, signaling and aggregation",Hemostasis,0.02710619758238683,1,3,4,4.203817548725534
2420,Miscellaneous transport and binding events,Transport of small molecules,0.013291252555977582,0,3,4,2.0612998399918583
2421,Miscellaneous transport and binding events,Transport of small molecules,0.011534323099772007,1,3,4,1.7888230066986122
2422,Signaling by Receptor Tyrosine Kinases,Signal Transduction,0.0031463621836921914,0,3,4,0.48795971925793624
2423,Signaling by Receptor Tyrosine Kinases,Signal Transduction,0.0018542348953081488,1,3,4,0.2875676372041436
2424,Amyloid fiber formation,Metabolism of proteins,0.03897458970617584,0,3,4,6.04445030193617
2425,Amyloid fiber formation,Metabolism of proteins,0.019269434924424143,1,3,4,2.9884379187863206
2426,Cellular responses to stress,Cellular responses to stimuli,7.899231303924907e-06,0,3,4,0.00122506770180333
2427,Cellular responses to stress,Cellular responses to stimuli,3.663067492002505e-05,1,3,4,0.0056809397032699625
2428,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Metabolism of proteins,0.007969227967941842,0,3,4,1.2359232710380879
2429,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Metabolism of proteins,0.003920407419678263,1,3,4,0.6080040351991735
2430,Chaperone Mediated Autophagy,Autophagy,0.004371304467996297,0,3,4,0.6779322838451419
2431,Chaperone Mediated Autophagy,Autophagy,0.008135424255696294,1,3,4,1.2616981466498995
2432,Metabolism of porphyrins,Metabolism,5.1464558626338954e-05,0,3,4,0.007981481505594756
2433,Metabolism of porphyrins,Metabolism,3.5903168989332495e-05,1,3,4,0.005568113026309765
2434,Diseases of metabolism,Disease,0.004648648991561911,0,3,4,0.7209448005090666
2435,Diseases of metabolism,Disease,0.0045314450876174014,1,3,4,0.7027680043470989
2436,Disorders of transmembrane transporters,Disease,0.005905342622703985,0,3,4,0.9158415846821228
2437,Disorders of transmembrane transporters,Disease,0.005737979665506525,1,3,4,0.8898857738630338
2438,Visual phototransduction,Sensory Perception,0.003060921987008312,0,3,4,0.47470905962208826
2439,Visual phototransduction,Sensory Perception,0.003793859928429222,1,3,4,0.5883781705664451
2440,Infectious disease,Disease,0.00871581549457528,0,3,4,1.3517092545417497
2441,Infectious disease,Disease,0.008471598442929681,1,3,4,1.3138343765074778
2442,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",Signal Transduction,0.005597944839616288,0,3,4,0.8681681996174813
2443,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",Signal Transduction,0.003309795740146427,1,3,4,0.5133061312946939
2444,Metabolism of vitamins and cofactors,Metabolism,0.0007378077252015842,0,3,4,0.1144243508651712
2445,Metabolism of vitamins and cofactors,Metabolism,0.0005148976094519837,1,3,4,0.07985390056396387
2446,MAPK family signaling cascades,Signal Transduction,0.013089363108596937,0,3,4,2.0299894210656446
2447,MAPK family signaling cascades,Signal Transduction,0.007736531539062591,1,3,4,1.19983509126757
2448,ECM proteoglycans,Extracellular matrix organization,0.006020898601939511,0,3,4,0.9337628092247389
2449,ECM proteoglycans,Extracellular matrix organization,0.006988384892797359,1,3,4,1.0838073086532516
2450,Signaling by GPCR,Signal Transduction,0.024039991492976923,0,3,4,3.7282889937707804
2451,Signaling by GPCR,Signal Transduction,0.014126059377216171,1,3,4,2.1907674849557868
2452,Transcriptional regulation of white adipocyte differentiation,Developmental Biology,0.004312252274889877,0,3,4,0.6687740592392385
2453,Transcriptional regulation of white adipocyte differentiation,Developmental Biology,0.0038957183996152474,1,3,4,0.6041750903430649
2454,Membrane Trafficking,Vesicle-mediated transport,6.923802491986775e-07,0,3,4,0.00010737914209935686
2455,Membrane Trafficking,Vesicle-mediated transport,2.5237712533616127e-07,1,3,4,3.914039898663045e-05
2456,Vesicle-mediated transport,root,0.010368877772661095,0,4,5,5.08369259466719
2457,Vesicle-mediated transport,root,0.0035930430777902393,1,4,5,1.7616107439363358
2458,Metabolism,root,0.0011619773320112054,0,4,5,0.5696986392771879
2459,Metabolism,root,0.0006829049590224815,1,4,5,0.33481722508077255
2460,Transport of small molecules,root,0.0001358722258504458,0,4,5,0.06661594856466206
2461,Transport of small molecules,root,0.001910422077357446,1,4,5,0.9366489585746409
2462,Disease,root,0.01022619215071658,0,4,5,5.013736148506995
2463,Disease,root,0.0038912902711786593,1,4,5,1.9078365054557394
2464,Hemostasis,root,0.011267283227082942,0,4,5,5.524166217347459
2465,Hemostasis,root,0.005682273596169795,1,4,5,2.7859265809734466
2466,Immune System,root,0.05134815929636386,0,4,5,25.17516966522431
2467,Immune System,root,0.061296422114924205,1,4,5,30.052641570029948
2468,Metabolism of proteins,root,0.026380283155721492,0,4,5,12.933824958141717
2469,Metabolism of proteins,root,0.01568984967903324,1,4,5,7.692478817239665
2470,Cell-Cell communication,root,0.0003064518221057861,0,4,5,0.15024835790514163
2471,Cell-Cell communication,root,0.00012653602881481925,1,4,5,0.06203856258587184
2472,Protein localization,root,2.8070929283565833e-05,0,4,5,0.013762721333310315
2473,Protein localization,root,6.319182593958083e-05,1,4,5,0.03098192732289285
2474,Extracellular matrix organization,root,0.010479382212252124,0,4,5,5.137871129079848
2475,Extracellular matrix organization,root,0.02082535310941951,1,4,5,10.210332854228895
2476,Gene expression (Transcription),root,7.907306463243583e-05,0,4,5,0.038768241069388955
2477,Gene expression (Transcription),root,6.33230959768601e-05,1,4,5,0.031046286893045928
2478,Autophagy,root,2.900203734045513e-05,0,4,5,0.014219228511562864
2479,Autophagy,root,3.115381209330304e-05,1,4,5,0.015274208772328088
2480,Programmed Cell Death,root,0.0018292323146663213,0,4,5,0.8968429347787091
2481,Programmed Cell Death,root,0.00044169735507120606,1,4,5,0.21655704911287577
2482,Drug ADME,root,0.002418401309676808,0,4,5,1.1857029370481387
2483,Drug ADME,root,0.0017029905582708982,1,4,5,0.8349486491871367
2484,Developmental Biology,root,0.004540720663217891,0,4,5,2.2262416932829603
2485,Developmental Biology,root,0.004625449487984468,1,4,5,2.267782861812923
2486,Sensory Perception,root,1.5615248533007602e-05,0,4,5,0.007655903085331226
2487,Sensory Perception,root,2.4299196906837087e-05,1,4,5,0.011913502124342683
2488,Cellular responses to stimuli,root,3.022449324206266e-06,0,4,5,0.001481857881258531
2489,Cellular responses to stimuli,root,4.180548238246003e-05,1,4,5,0.020496549951100295
2490,Signal Transduction,root,0.019800475641358464,0,4,5,9.70785205456507
2491,Signal Transduction,root,0.0070264246566434825,1,4,5,3.4449420445620804
